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Abstract 
Mycobacterium bovis Bacille Calmette-Guérin (BCG) strains are live attenuated 
vaccines. These strains are genetically heterogeneous and the accumulation of deletions 
and mutations, particularly those affecting regulatory and antigenic proteins, has been 
proposed to have contributed to overly-attenuated vaccines. To examine this pos~ibility, 
the effects of the two mutations incurred by BCG vaccines was formally studied through 
gene-deletion and complementation studies. First, the effect of deletion of the RD2 
region was examined by over-expressing the antigenic protein MPB64 in a late strain of 
BCG and by creating an RD2-knockout strain in M. tuberculosis. These two approaches 
revealed minimal changes attributable to the RD2 region, but stimulated further 
investigation for other differences contemporaneous with the loss of RD2. Byexamining 
differences in gene expression between RD2+ and RD2- strains of BCG, two regions, in 
addition to the RD2 region itself, that were significantly down-regulated in the latter 
strains were identified. One region contained genes encoding the highly antigenic 
proteins MPB70 and MPB83, and the second region contained the gene encoding the 
extracellular function (ECF) sigma factor, sigK. Sequencing of sigK across all BCG 
strains revealed a start codon single nucleotide polymorphism (SNP) in strains with low 
production of MPB70 and MPB83. Complementation of BCG Pasteur with wild-type 
sigK resulted in up-regulation of mpb70/mpb83 and increased production of MPB70 and 
MPB83 proteins. Further studies revealed that the in vitro growth rate of BCG 
Pasteur::sigK was slower than that of BCG Pasteur::pMV306 and that cytotoxicity to 
macrophage-like THP-l cells was greater following infection with BCG Pasteur::sigK 
than with BCG Pasteur: :pMV306. Infection of C57BL/6J mice demonstrated differences 
between BCG Pasteur::sigK and BCG Pasteur::pMV306 in initial deposition, growth 
rates and persistence. Vaccination of C57BL/6J mice with BCG Pasteur::sigK stimulated 
an MPB70-specific immune response, indicating that restored protein production resulted 
in increased immunogenicity. Finally, in challenge experiments, mice vaccinated with 
BCG Pasteur::sigK demonstrated equal, or slightly greater, protection than vaccination 
with BCG Pasteur::pMV306 against subsequent challenge with M. tuberculosis. 
Together, these findings provide an explanation for the loss of MPB70 and MPB83 
production by BCG vaccines during prolonged in vitro passaging, and provide the basis 
for further studies aimed at understanding the role of the sigK-mpb70 regulon in 
tuberculosis pathogenesis. 
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Resume 
Les souches de Mycobacterium bovis Bacille Calmette-Guerin (BCG) sont des vaccins 
vivants atténués. Ces souches sont génétiquement hétérogènes et il est proposé que 
l'accumulation des délétions et mutations, particulièrement celles qui affectent les 
protéines régulatoires et antigéniques ont contribué à cette forte atténuation. Dans ce 
contexte, nous avons étudié les effets de deux mutations par délétion et complémentation. 
D'abord, l'effet de la délétion de la région RD2 a été examiné par la sur-expression de la 
protéine MPT64 dans une souche de BCG tardive, et par la création d'une souche de M. 
tuberculosis dépourvue de RD2. Ces deux approches ont révélé des changements 
minimes attribuables à la région RD2, mais ont provoqué une investigation approfondie 
sur d'autres modifications génétiques survenues en même temps que la perte de RD2. En 
examinant les différences d'expression génétique entre des souches RD2+ et RD2- , nous 
avons découvert qu'à part la région RD2, deux autres régions étaient fortement sous-
régulées dans les souches RD2-. La première région contient les gènes codant pour les 
protéines antigéniques MPB70 et MPB83, et la deuxième région comprend le gène 
codant pour le facteur sigma de type ECF (fonction extracytoplasmique), SigK. Le 
séquençage de sigK dans toutes les souches de BCG a révélé l'existence d'une mutation 
ponctuelle (SNP) dans le codon d'initiation chez les souches à faible production de 
MPB70 et MPB83. Pour démontrer un lien entre le niveau d'expression et le SNP, BCG 
Pasteur a été complémenté par sigK. Comme prévu, la complémentation s'accompagne 
d'une sur-régulation des gènes de la région mpb70/mpb83 ainsi que les protéines 
correspondantes. Des études additionnelles ont démontré qué le taux de croissance de 
BCG Pasteur::sigK in vitro est plus lent que BCG Pasteur::pMV306. De plus, la 
cytotoxicité des cellules monocytaires THP-l observée après infection avec BCG 
Pasteur::sigK est plus importante que celle obtenue après infection avec BCG 
Pasteur:pMV306. En infectant des souris C57BL/6J, nous avons noté des différences 
importantes entre BCG Pasteur::sigK et BCG Pasteur::pMV306 au niveau de la charge 
bactérienne initiale, du taux de croissance et de la persistance. La vaccination des souris 
C57BL/6J avec BCG Pasteur::sigK a induit une réponse immunitaire spécifique à 
MPB70, indiquant que la protéine restaurée a aussi une immunogénicité accrue. Enfin, 
chez les souris, la protection conférée par BCG Pasteur: :sigK contre une épreuve par la 
souche M. tuberculosis virulente de type sauvage est comparable ou un peu plus élevée 
que celle de BCG Pasteur::pMV306. Ensemble, ces résultats élucident la perte de 
production de MPB70 et MPB83 dans les vaccins BCG durant un passage prolongé in 
vitro et permettent d'étudier de façon approfondie le rôle du régulon de sigK-mpb70 dans 
la pathogenèse de la tuberculose. 
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1. Literature Review 
1.1. Mycobacterium tuberculosis 
Tuberculosis (TB) has killed people indiscriminately for centuries and has been 
weIl documented both as fact and in fiction for equally as long. Although many 
people perceive TB as a disease of the past, nearly two million people died of the 
disease in 2004 and five times as many became newly infected (WHO, 2006a). An 
estimated two billion people are infected with Mycobacterium tuberculosis. Although 
the majority of these people will not develop active tuberculosis, the minority in 
whom this does occur is considerable, giving an indication how difficult control and 
eradication of this disease will be. Acquiring infection with M. tuberculosis, like 
other infectious diseases, is dependent on man y factors. Duration of exposure, 
intensity of exposure and genetic susceptibility are aIl factors that influence whether 
someone in contact with a TB case will become infected with M. tuberculosis. Once 
infected, only a fraction of individuals develop active TB. An estimated 5% of 
infected individuals will develop TB within two years of infection, which is typically 
termed primary TB. Another 5% will develop active disease at a later time, called 
reactivation disease. The remaining 90% of infected individuals are not expected to 
develop disease, unless mitigating factors, such as drugs or other disease, alter the 
natural histo .... y of their infection (Institute of Medicine and Committee on the 
Elimination of Tuberculosis in the United States, 2000;WHO, 2006b). In the majority 
of the individuals who do not develop disease, the infection is not cleared, but 
remains dormant. The ability of M. tuberculosis to remain dormant in infected 
1 
individuals for decades establishes an enormous reservoir for potential disease 
outbreaks. 
The causative agent of tuberculosis was identified by Robert Koch, a man 
recognized as a pioneer in bacteriology. He has been credited with the development 
of numerous techniques that advanced the study of microbiology tremendously, he 
identified the causative agents of important diseases inc1uding anthrax and cholera 
and he demonstrated a set of criteria, now termed Koch's postulates, used to establish 
the etiology of a disease. In 1882, Koch first presented his experiments by which he 
identified Mycobacterium tuberculosis as the causative agent of tuberculosis. He 
meticulously stained the bacteria, isolated bacteria from TB patients and infected 
animaIs, cultured bacteria from both sources and re-infected animaIs with purified 
cultures. From this, he convincingly demonstrated to his colleagues the etiology of 
TB and defined the demonstration of the tuberc1e bacillus as the definite criterion for 
the diagnosis of TB. 
Mycobacterium tuberculosis is a member of the M. tuberculosis complex which, 
in addition to M. tuberculosis, inc1udes M. bovis, M. microti, and M. africanum. 
Identifying characteristics of M. tuberculosis complex organisms inc1ude slow 
growth, dormancy, complex cell envelope, intracellular pathogenesis and genetic 
homogeneity (Cole et al., 1998). The 'members of this complex are known for causing 
TB or TB-like diseases in specific hosts and share greater than 99% sequence 
homology. The species of the M. tuberculosis complex figure among organisms 
2 
classified as slow-growing mycobacteria. In contrast to the fast-growing 
mycobacteria, such as M. smegmatis that has replication time of 3-4 hours, slow-
growing mycobacteria can have a replication time on the order of hours to days. This 
slow replication contributes to the difficulty in treating and eradicating TB as drug 
regimens for treatment are necessarily long. As a means of developing a greater 
understanding of this organism, the sequenced and annotated genome of 
Mycobacterium tuberculosis was determined, first published in 1998 and 
subsequently re-annotated in 2002 (Cole et al., 1998;Camus et al., 2002). From this 
annotation, 4044 predicted genes, known as open reading frames (ORFs) were 
identified in the 4.4Mbp genome. Conserved hypothetical proteins represent a quarter 
of the ORFs, while genes encoding intermediary metabolism and respiration represent 
22.1 % and cell wall and cell processes represent 17.5%. Genes encoding lipid 
metabolism (5.8%), regulatory proteins (4.7%) and the PE and PPE families of 
glycine-rich proteins (4.2%) figure less prominently (Camus et al., 2002). Of note, 
376 putative proteins show no homology to other known proteins and have been 
hypothesized to be unique to M. tuberculosis (Camus et al., 2002). Identification and 
characterization of these proteins may provide insight into the mechanism by which 
M. tuberculosis has become such a successful pathogen. 
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1.1.1. Infection, Host Response and Immune Reaction 
1.1.1.1. CeU Envelope 
The cell envelope of Mycobacterium tuberculosis is a highly complex 
structure, to which the success of the tubercle bacillus as a pathogen has been 
partially attributed. The cell envelope is composed of three layers; the plasma 
membrane, a mycolic acid-arabinogalactan-peptidoglycan complex layer and the outer 
capsule. The innermost plasma membrane is functionally and structurally similar to 
other bacterial plasma membranes and is generally not thought to have significant 
unique properties (Draper and Daffe, 2005). The peptidoglycan layer is highly cross-
linked and covalently bound to arabinogalactan, which is further esterified to mycolic 
acids. This structure makes mycobacteria highly impermeable and contributes to its 
resilience. Lipoarabinomannan (LAM), phthiocerol dimycocerosate (PDIM) and 
phosphatidyl-inositol mannosides (PIM) are among the other important components 
of the cell envelope, and loss of these molecules severely affects the virulence and 
survival of M. tuberculosis (Briken et al., 2004;Onwueme et al., 2005). The capsule 
of M. tuberculosis is largely composed of proteins and polysaccharides, with the main 
components being the polysaccharides glucan, arabinomannan and mannan. The 
relatively few lipids found in the capsule tend to be situated towards the inner portion 
of the capsule. The proposed role of the capsule is to control phagocytosis of the 
bacterium, such that it confers properties on the bacterium that may permit it to enter 
macrophages via preferred pathways (Stokes et al., 2004). 
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1.1.1.2. Uptake Receptors 
Upon entry into the lungs, uptake of M. tuberculosis is primarily mediated by 
alveolar macrophages, with monocyte-derived macrophages and dendritic cells 
playing an increasing role as the y are recruited to the site of infection. Uptake of M. 
tuberculosis is mediated through several different receptors. Complement receptor 1 
(CRI), CR3 and CR4 play an important role in the uptake of M. tuberculosis by 
alveolar macrophages and monocyte-derived macrophages (Schlesinger et al., 
1990;Schlesinger, 1993;Hirsch et al., 1994). Macrophage invasion by mycobacteria 
can proceed by opsonization with C3b via the alternative complement pathway 
(Schlesinger et al., 1990) or alternatively, by binding directly with C2a to form a C3 
convertase, resulting in the generation of C3b and subsequent opsonization (Schorey, 
Carroll, and Brown, 1997). In addition, non-opsonized bacteria can bind directly to 
CR3 and CR4. The mannose receptor provides another significant pathway through 
which phagocytosis of M. tuberculosis occurs (Schlesinger, 1993). Binding of M. 
tuberculosis to the mannose receptor through interactions with the terminal mannose 
residues of LAM has been described (Schlesinger, Hull, and Kaufman, 
1994;Schlesinger et al., 1996). More recently, interactions between the mannose 
residues of a 19kDa antigen and the mannose receptor have also been identified as a 
possible route of entry of M. tuberculosis (Diaz-Silvestre et al., 2005). Specific 
inhibition of the individu al complement receptors or the mannose receptor 
significantly reduced M. tuberculosis uptake by macrophages and concurrent 
inhibition of binding to the complement receptors and the mannose receptor inhibits 
uptake of M. tuberculosis to a greater extent than inhibition of the receptors 
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individually, yet does not fully block phagocytosis. This points to additional 
mechanisms through which phagocytosis may occur, as suggested by noting that 
blocking of c1ass A scavenger receptors in addition to blocking the complement and 
mannose receptors completely abrogates binding (Zimmerli, Edwards, and Ernst, 
1996). Uptake of M. tuberculosis by dendritic cells (DC) has also been identified as 
an important pathway of immune stimulation and is mediated primarily through DC-
specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN) (Tailleux 
et al., 2003). Uptake through DC-SIGN occurs preferentially over either complement 
receptor or mannose receptor-mediated uptake and induces functional activation of 
the infected cells (Jiao et al., 2002;Tailleux et al., 2003). 
1.1.1.3. Granuloma Formation 
Although it is difficult to precisely define its importance, the formation of 
granulomas is considered essential to the control and containment of M. tuberculosis 
infection. Granulomas in human TB patients are most frequently characterized by a 
central core of caseating necrosis surrounded by cellular layers composed largely of 
lymphocytes and macrophages. Examining tissue sections from 20 TB patients, 
UIrichs et al (Ulrichs et al., 2004) provided a comprehensive description of the 
organization of the granulomas. They observed that the inner layer of cells 
surrounding the necrotic core is dominated by macrophages and CD4+ cells, while the 
outer layer consists predominantly of CD4+ and CD8+ cells. B-cell aggregates, 
which inc1uded both naïve and memory cells, were identified largely in proximity to 
lymphatics and blood vessels, as weIl as the central necrotic core. Outside of these 
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large regions surrounding necrotic centers, smaller peripheral foei of macrophages 
and lymphocytes were also observed. Mycobacteria were identified in macrophages 
in the inner eircle surrounding the necrotic core and in the peripheral foei, and to a 
limited extent within the necrotic core. 
Consistent with observations from human TB cases, the development of 
granulomas is also typically observed in animaIs models of M. tuberculosis infection, 
although the speeific characteristics of these granulomas vary between models. In 
guinea pigs, granulomas typically develop as discrete foei of macrophages mixed with 
granulocytes and lymphocytes. They progressively develop necrotic cores surrounded 
by an inner layer of macrophages and neutrophils and an outer layer consisting mainly 
of lymphocytes. There is further extensive coalescence of granulomas surrounded by 
macrophages, scattered lymphocytes and neutrophils. CD4+ and CD8+ cells are 
equally distributed throughout the lymphocyte-rich regions (Turner, Basaraba, and 
Orme, 2003). The distribution of CD4+ and CD8+ cells is one characteristic of 
granuloma formation that varies between the guinea pig and mouse models of 
infection. In mice, the accumulation of lymphocytes surrounding the foei of 
macrophages (Rhoades, Frank, and Orme, 1997;Cardona et al., 2000) is 
predominantly eomposed of CD4+ cells, while CD8+ cells aeeumulate initially at the 
periphery and are later found throughout the lymphocyte-rich regions (Gonzalez-
Juarrero et al., 2001). Additionally, only small foei of necrosis, if any, are observed 
and usually only occur late in the disease process. Although neither the gui ne a pig, 
nor the mouse is a perfeet model of granuloma formation in humans, each has its 
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similarities to humans. The development of central necrotic cores surrounded by 
macrophages and lymphocytes in guinea pigs and the early formation of the 
granuloma and the distribution of lymphocytes in the mouse model closely resemble 
the characteristics of granulomas in humans. In a number of animal models, 
susceptibility to M. tuberculosis infection or virulence of an M. tuberculosis strain, as 
demonstrated by increased bacterial counts, increased dissemination of bacteria 
beyond the site of primary infection and/or decreased time of survival, is often 
associated with poor granuloma formation and organization (Cooper et al., 1993;Bean 
et al., 1999;Saunders, Frank, and Orme, 1999;Shimono et al., 2003). 
1.1.1.4. Innate Immunity 
The initial response to M. tuberculosis is dependent on three main cell types: 
macrophages, dendritic cells and natural killer cells. Each of these cell types is 
important in the initial containment of the bacteria, the innate immune response 
against M. tuberculosis and the initiation of an adaptive immune response. The 
development of an effective innate immune response against M. tuberculosis is 
thought to require the recognition of mycobacterial components. Toll-like receptors 
(TLR) represent a family of membrane receptors that respond to microbial products, 
such as lipopolysaccharide (LPS), lipoproteins and peptidoglycan, and mediate the 
transcription of genes involved in the innate immune response. TLR2 and TLR4 have 
been implicated in M. tuberculosis-induced cellular activation (Means et al., 
1999;Means et al., 2001) and signaling through these TLRs induces secretion of IL-12 
and TNFa by macrophages (Jones et al., 2001;Means et al., 2001;Reiling et al., 
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2002;Drennan et al., 2004). In murine macrophages, expression of a dominant 
negative form of TLR2 or TLR4 substantially blocks M. tuberculosis-induced cellular 
activation, and co-expression of both dominant negative forms blocked virtually aIl 
M. tuberculosis-induced activation (Means et al., 2001). Similarly, primary 
macrophages isolated from TLR2-/- or TLR4-/- mice secrete less IL-12 and TNFa in 
response to M. tuberculosis than wild-type controls (Reiling et al., 2002;Drennan et 
al., 2004). Although M. tuberculosis can activate signaling through both TLR2 and 
TLR4, most individual ligands that have been identified have been TLR2 ligands. 
Means et al. identified a soluble, heat-stable, protease-resistant factor that mediates 
TLR2-dependent activation and a heat-sensitive, cell-associated factor that mediates 
TLR4-dependent activation (Means et al., 1999). The 19kDa lipoprotein secreted 
antigen (Brightbill et al., 1999), PIM (Jones et al., 2001;Gilleron, Quesniaux, and 
Puzo, 2003) and lipomannan (LM) (Quesniaux et al., 2004) have also been identified 
as TLR2-specific ligands, possessing high capacities for induction of IL-12 and TNFa 
production. Through TLR2 signaling, the 19kDa lipoprotein also induces dendritic 
cell maturation (Hertz et al., 2001) and activation of alveolar macrophages, enabling 
killing of intracellular M. tuberculosis independent of nitric oxide (NO) release 
(Thoma-Uszynski et al., 2001). 
To further determine the importance of TLRs in protection against M. 
tuberculosis, a number of groups have challenged TLR knock-out mice with M. 
tuberculosis to look for defects in host responses. Contrary to the findings from in 
vitro studies, there has been liUle evidence indicating the importance of these 
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pathways from in VlVO studies. Infections of TLR4-deficient mIce with M. 
tuberculosis have revealed at most a very mild phenotype. Two studies using aerosol 
infections demonstrated no differences in time to death, bacterial counts, recruitment 
of cells or granuloma formation (Reiling et al., 2002;Shim, Turner, and Orme, 2003). 
Branger et al (Branger et al., 2004) used the intranasal route of infection and 
demonstrated a slightly increased mortality and higher bacterial counts in the TLR4-
defective mice with increased inflammation in the lungs. The deletion of TLR2 may 
lead to a slightly more pronounced phenotype th an that seen in TLR4-deficient mice, 
although it also remains a relatively modest phenotype. With a low-dose aerosol 
infection, survival of the TLR2-deficient mice is comparable to wild-type, while the 
colony forming units (CFU) in the lungs, spleens and livers of infected mice are 
similar or slightly increased in the TLR2-deficient mice (Reiling et al., 
2002;Sugawara et al., 2003a;Drennan et al., 2004). However, infection with a higher 
infectious dose of M. tuberculosis revealed a greater susceptibility of the TLR2 
defective mice compared to controls (Reiling et al., 2002;Drennan et al., 2004) and 
increased inflammation with large coalescing lesions, focal necrosis and few 
organized granulomas (Drennan et al., 2004). Contrary to TLR4 and TLR2, MyD88 
knockout mice have increased susceptibility to M. tuberculosis infection demonstrated 
by decreased survival and increased CFU (Scanga et al., 2004;Fremond et al., 2004). 
In addition, these mice displayed significant inflammation with increased neutrophilic 
infiltration, poor granuloma formation and extensive necrosis (Sugawara et al., 
2003b;Scanga et al., 2004;Fremond et al., 2004). MyD88, a common downstream 
signaling molecule of TLRs, is essential for M. tuberculosis-induced macrophage 
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activation (Underhill et al., 1999). Together this indicates that activation of this 
pathway, regardless of the mechanism through which activation is induced, is 
important in the protective response against M. tuberculosis. 
Activation of macrophages through TLRs and phagocytosis of M. tuberculosis 
trigger the induction of both an innate and an adaptive immune response. The early 
production of TNFa and IL-12 by macrophages plays a crucial role in the 
development of these responses. TNFa, produced by macrophages, monocytes and 
dendritic cells stimulated by M. tuberculosis or mycobacterial products, can act as an 
autocrine regulator to stimulate macrophages to produce IL-l, IL-6 and various 
chemokines, and is important in macrophage activation and granuloma formation. 
TNFa is also later produced by T lymphocytes to further activate macrophages. Mice 
lacking TNFa are less capable of containing an M. tuberculosis infection, showing 
increased proliferation and survival of the bacteria, and have a lower mean survival 
time following infection (Flynn et al., 1995;Bean et al., 1999;Saunders et al., 2005). 
Granuloma formation in these mice is also impaired, indicated by poorly organized 
granulomas with extensive necrosis and neutrophilic infiltration (Flynn et al., 
1995;Bean et al., 1999). IL-12 is produced mainly by phagocytic cells and exerts its 
protective effects largely through the induction of IFNy. IL-12p40 knockout mice are 
highly susceptible to M. tuberculosis infection demonstrated by increased CFU and 
dramatically decreased time to death compared to wild-type mice. The lack of IL-12 
contributes to decreased IFNy and delayed production of TNFa, to which the authors 
attributed the delayed macrophage activation signified by the reduced expression of 
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iNOS in these mice (Cooper et al., 1997). IL-12 is important in the production of 
IFNy and to promote the polarization of naïve T lymphocytes to a Thl phenotype. 
Early stimulation of NK cells by IL-12, as well as direct stimulation by mycobacterial 
products, contribute to the early production of IFNy, which further stimulates 
macrophages (Trinchieri, 1994;Iho et al., 1999). In response to M. tuberculosis 
infection, dendritic cells produce IL-12 and efficiently present M. tuberculosis-
derived antigens (Jiao et al., 2002). M. tuberculosis-infected DC have been identified 
in lymph nodes in both TB patients and experimentally infected animaIs (Jiao et al., 
2002;Tailleux et al., 2003) and are thought to be an important contributor to the 
development of an adaptive immune response against M. tuberculosis. 
Production of IFNy is crucial in the control and containment of M. tuberculosis 
infection in mice. IFNy-knockout mice quickly succumb to infection and are 
burdened by high numbers of bacteria, which are widely disseminated throughout the 
mice (Flynn et al., 1993;Cooper et al., 1993). Granuloma formation initially appears 
similar to wild-type mice, but rapidly progresses to extensive necrosis with 
neutrophilic infiltration not seen in control mice. In wild-type mice, M. tuberculosis 
infection leads to high serum levels of reactive nitrogen intermediates and increased 
expression of inducible nitric oxide synthase (iNOS). Neither of these features were 
present in the M. tuberculosis-infected IFNy-knockout mice, indicating that 
macrophage activation is severely limited in the absence of IFNy (Flynn et al., 1993). 
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1.1.1.5. Adaptive 1mmunity 
1.1.1.5.1. Helper T cells 
CD4+ T cells are one of the most important cell types involved in the control 
of M. tuberculosis infection. This has become increasingly evident in part from the 
high incidence of TB observed in HIV/AIDS patients, in whom the susceptibility to 
both exogenous infection and reactivation of latent infections is increased (WHO, 
2003). Loss of CD4+ ceIls, shown by murine studies of cell depletion (Muller et al., 
1987) and gene knockouts (Caruso et al., 1999;Mogues et al., 2001) impairs the 
ability to control M. tuberculosis infection and substantially decreases time to death. 
Similarly, depletion of CD4+ cells in chronically infected mice led to reactivation of 
the low-grade, persistent infection, indicated by increased bacterial proliferation, 
prominent areas of necrosis in the lungs and decreased survival (Scanga et al., 2000). 
In addition, bacterial counts can be significantly reduced by adaptive transfer of 
CD4+ cells into M. tuberculosis-infected athymic mice, demonstrating the protective 
role of these cells (Tascon et al., 1998). A significant Th1 response develops in 
response to M. tuberculosis infection, with high levels of IFNy and IL-12 being 
produced, and little IL-4 and IL-lO. A lack of either IFNyor IL-12 leads to severe 
disease and rapid death. Consistent with this, in M. tuberculosis-infected CD4-
knockout mice, IFNy production is initially low, and despite sorne compensation by 
CD8+ cells later in infection, these mice succumb to infection significantly earlier 
than their wild-type counterparts (Caruso et al., 1999) In addition to the importance 
of IFNy production, CD4+ cells contribute substantially to infection control by other 
mechanisms, demonstrated by the depletion of these cells in chronically infected mice 
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in which infection worsens despite high levels of NOS2 and IFNy expression being 
maintained (Scanga et al., 2000). 
1.1.1.5.2. Cytotoxic T ceUs 
Although the role of CD8+ T cells in controlling M. tuberculosis infection in 
humans has not been demonstrated through a natural experiment, as has been the case 
for CD4+ T cens, a number of lines of evidence support the role of cytotoxic T cells 
as an important component of the adaptive immune response against M. tuberculosis. 
A functional lack of CD8+ cells, through either cell depletion or gene knockouts, 
leads to an impaired response and increased susceptibility to M. tuberculosis, 
demonstrated by increased bacterial counts, altered histopathology or decreased time 
to death (Muller et al., 1987;Flynn et al., 1992;Sousa et al., 2000;van Pinxteren et al., 
2000;Mogues et al., 2001;Rolph et al., 2001). Additionally, the transfer of CD8+ 
cells to athymic mice reduces the bacillary burden following infection with M. 
tuberculosis. The ability of these mice to control the infection was dependent on the 
production of IFNy (Tascon et al., 1998). In response to mycobacteria, CD8+ T cens 
are recruited to the sites of infection and are capable of producing IFNy (Lewinsohn et 
al., 1998;Serbina and Flynn, 1999;Feng et al., 1999;Smith et al., 1999) and M. 
tuberculosis-infected macrophages and dendritic cells can be directly lysed by 
antigen-specific CD8+ cens (Tan et al., 1997;Stenger et al., 1997;Lalvani et al., 
1998;Serbina et al., 2000). Important aspects of the mechanisms through which 
CD8+ cens respond to M. tuberculosis and help control the infection remain 
incompletely elucidated, but these cens are now being recognized as significant 
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contributors to the control of M. tuberculosis infection and the loss of these cells 
cannot be completely compensated for by CD4+ cells. 
1.1.1.5.3. Humoral Immunity 
Humoral immunity is generally considered to play an insignificant role in 
protection against M. tuberculosis. Johnson et al. (Johnson et al., 1997) reported a 
normal course of infection in B cell deficient mice compared to control mice, as weIl 
as similar pathology between the two groups. Vordermeier et al. however, reported 
increased CFU counts in the lungs and spleen of B cell deficient mice (Vordermeier et 
al., 1996). Despite the increased bacterial load though, the lack of B cells did not 
confer a lethality phenotype, suggesting humoral immunity may play a minor role in 
the control of the infection, but not a necessary role for survival. More recently, 
Bosio et al (Bosio, Gardner, and Elkins, 2000) reported reduced immunopathology 
and delayed bacterial dissemination in B cell knockout mice. Direct comparison of 
these results is difficult due the differences in strains and route of infection used, but 
they do illustrate the confusion surrounding the role humoral immunity in M. 
tuberculosis infection. Several mycobacterial antigens that induce a humoral 
response have been identified and are generally considered for their use as diagnostic 
agents. 
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1.1.2. Mechanisms of Evasion of Host Defenses 
1.1.2.1. Reactive Nitrogen Intermediates and Reactive Oxygen 
Intermediates 
The generation of large amounts of reactive nitrogen intermediates (RNI) and 
reactive oxygen intermediates (ROI) is a major mechanism through which macrophages 
exert their antimicrobial properties. Mutations in these pathways in humans result in a 
disease called chronic granulomatous disease, a condition in which afflicted individuals 
suffer recurrent life-threatening infections due to the inability of phagocytic cells to 
generate sufficient RNI and ROI to contain the infections. Animal models with 
mutations in these pathways are highly susceptible to infections from many organisms, 
inc1uding M. tuberculosis (Bogdan, Rollinghoff, and Diefenbach, 2000). Several 
mechanisms have been identified by which M. tuberculosis can respond to and protect 
itself from the bactericidal challenge posed by RNI and ROI. Although no single 
pathway has been determined to be essential to the ability of M. tuberculosis to respond 
to RNIIROI, there is evidence identifying key pathways through which M. tuberculosis 
can evade this toxicity. 
Alkyl hydroperoxide reductase C (AhpC) is a member of the highly conserved 
peroxiredoxin family of peroxidases. A compensatory up-regulation of ahpC was 
observed in isoniazid resistant strains of M. tuberculosis, whose resistance was due to a 
mutation in katG, the gene encoding the mycobacterial catalase-peroxidase-
peroxynitritase. A mutation in katG is expected to impair the organism's ability to 
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metabolize hydrogen peroxide, however, the up-regulation of ahpC was sufficient to 
compensate for this loss. AhpC has been confirmed to function as both a peroxidase 
(Hillas et al., 2000) and a peroxynitrite reductase (Bryk, Griffin, and Nathan, 2000). 
Chen et al (Chen, Xie, and Nathan, 1998) demonstrated protection of Salmonella 
typhimurium and of human epithelial cells by M. tuberculosis AhpC against 
hydroperoxides and RNI, as weIl as protection of the latter from cytotoxicity and 
apoptosis induced by NOS2. Loss of ahpC in M. tuberculosis increases susceptibility to 
cumene hydroperoxide (Springer et al., 2001) and peroxynitrite (Master et al., 2002) and 
results in decreased survival in resting macrophages (Master et al., 2002). 
Deletion of the katG gene in M. tuberculosis demonstrated the importance of 
KatG in the response to ROI (Ng et al., 2004). The katG-knockout strain was attenuated 
in C56Bl/6 and NOST1- mice, but were indistinguishable from wild-type M. tuberculosis 
in gp91Phox-l- mice that are unable to pro duce an oxidative burst. Interestingly, KatG was 
more important for survival of M. tuberculosis in mice between two and four weeks of 
infection suggesting that either the alternative pathways compensate for the deletion of 
katG or that the activity of phagocyte NADPH oxidase wanes during infection. 
Several pathways for peroxidase and peroxynitrite reductase activity in M. 
tuberculosis have been proposed, two of which involve AhpC. Bryk et al (Bryk et al., 
2002) elucidated a pathway composed of dihydrolipoamide succinyltransferase (SucB), 
dihydrolipoamide dehydrogenase (Lpd) , AhpD and AhpC. This pathway efficiently 
metabolizes hydrogen and alkyl hydroperoxides, as well as peroxynitrite, thereby 
constituting both peroxidase and peroxynitrite reductase systems. AhpC also shows 
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peroxidase activity equivalent to that observed in the AhpC/AhpD system when 
combined with thioredoxin C (TrxC) and thioredoxin reductase (TR). However, a third 
system constituted of TrxC, TR and thiol peroxidase (Tpx) showed peroxynitrite 
reductase activity of one order of magnitude greater than that of the AhpC system (Jaeger 
et al., 2004). AhpC clearly plays a significant role in the protection of M. tuberculosis 
against ROI and RNI, however, it has become clear that it is only one of the several 
important components comprising the systems fulfilling this function. 
Several other pathways have been proposed as protective mechanisms against 
RNIIROI, however the relative importance of these pathways and their mechanisms are 
under investigation. In screening transposon mutants for sensitivity to nitrite, Darwin et 
al (Darwin et al., 2003) identified 12 highly sensitive mutants, five of which had 
mutations in two genes proposed to be proteasome associated genes. Rv2115c has been 
proposed to help unfold and translocate proteins to the proteolytic core of the proteasome 
and Rv2097 chas been proposed to be involved in the recognition of proteins destined for 
degradation. Although these mutants were highly sensitive to nitrosative stress in vitro, 
the contribution of these prote as omal proteins to in vivo adaptation and survival was 
difficult to assess as the deletion strains were highly attenuated not only in C57B1I6-
derived macrophages and C57B1I6 mice, but also in iNOS-/- macrophages and mice. 
A second pathway involving M. tuberculosis' response to protein damage caused 
by RNIIROI involves the enzyme methionine sulfoxide reductase (msrA), which reduces 
oxidized methionine residues in proteins. Oxidation of the methionine residues in 
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proteins may result from exposure to ROI/RNI, such as hydrogen peroxide and 
peroxynitrite. An E. coli strain lacking msrA was found to be more sensitive to hydrogen 
peroxide, GSNO and nitrite, however, this susceptibility could be compensated for by 
complementation of the strain with msrA from either Escherichia coli or M. tuberculosis, 
suggesting that MsrA may play a protective role in the response of M. tuberculosis to 
ROIIRNI (St John et al., 2001). To further investigate the role of msrA, Douglas et al 
(Douglas et al., 2004) created an msrA-disrupted strain in M. smegmatis. Contrary to the 
results in the msrA deficient strain of E. coli, the ~srA strain in M. smegmatis was not 
more susceptible to hydrogen peroxide, S-nitrosoglutathione (GSNO) or nitrite, but did 
show higher susceptibility to hydroperoxides. Survival of the ~srA strain in both 
unactivated and activated J774A.I alveolar macrophages was significantly lower than 
wild-type M. smegmatis. Although the role of msrA in M. tuberculosis has yet to be 
defined, these early results indicate that msrA most likely plays a role not in neutralizing 
RNIIROI, but instead in protecting against some of the deleterious effects of the presence 
ofRNIIROI. 
Superoxide dismutase enzymatically converts superoxide to hydrogen peroxide 
and molecular oxygen, preventing the generation of more toxic molecules such as the 
hydroxyl radical and peroxynitrite. Although not specific to M. tuberculosis , sodC has 
been shown to contribute the resistance of M. tuberculosis to ROI (Piddington et al., 
2001). A sodC knockout strain of M. tuberculosis displayed significantly increased 
sensitivity in vitro to killing by superoxide, nitric oxide and a combination of the two 
compared to wild-type M. tuberculosis, as weIl as lower survival in macrophage 
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infection. Interestingly, in macrophages isolated from phagocyte oxidase-deficient mice, 
but not from iNOS-I- mice, this attenuation was abrogated, suggesting that the 11.sodC 
strain was specifically sensitive to killing by ROI, not RNI. 
Several other genes have been identified in M. tuberculosis as potentially 
protective against RNIIROI. The genes noxRl (Ehrt et al., 1997) and noxR3 (Ruan et al., 
1999), whose function have not been identified, have been suggested to play a role in 
protection of M. tuberculosis against RNIIROI. Expression of noxRl from M. 
tuberculosis in E. coli and M. smegmatis and expression of noxR3 in S. typhimurium, 
conferred resistance in vitro to GSNO, nitrite and hydrogen peroxide. Upon deletion of 
noxRl in M. tuberculosis, however, there was no observed difference in resistance to 
RNI between 11.noxRl and wild-type M. tuberculosis, nor was there a difference in 
proliferation and survival of these strains following infection of Balb/c mice (Stewart et 
al., 2000). Further investigation is required to determine the role of these genes in the 
resistance of M. tuberculosis to RNIIROI. 
1.1.2.2.Inhibition of Phagolysosome Fusion 
One of the most successful strategies employed by mycobacteria, including M. 
tuberculosis, to evade ho st defenses is that of phagosome maturation arrest (Armstrong 
and Hart, 1971;Vergne et al., 2004). Phagosome maturation efficiently enables ho st cells 
to destroy phagocytosed bacteria, however, those containing M. tuberculosis do not 
successfully kill the invading pathogen. The hallmark features of a mycobacterial 
phagosome include decreased vacuolar proton-ATPases, with corresponding limited 
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acidification (Armstrong and Hart, 1971;Sturgillkoszycki et al., 1994;Clemens and 
Horwitz, 1995), absence of mature lysosomal hydrolases (Clemens and Horwitz, 
1995;Malik, Denning, and Kusner, 2000) and failure to acquire markers of phagosome 
maturation, including Rab7 and LAMP (Clemens and Horwitz, 1995;Via et al., 1997). 
Although the complete mechanism used by M. tuberculosis to arrest phagosome 
maturation has yet to be clearly defined, several strategies have been elucidated. Malik et 
al (Malik, Denning, and Kusner, 2000) demonstrated an alteration in calcium signaling in 
M. tuberculosis-infected phagosomes. Upon uptake of heat-killed M. tuberculosis or 
latex beads, a subsequent increase in calcium concentration, due to both a release from 
intracellular stores and an influx of extracellular calcium, is consistently observed. 
However, uptake of live M. tuberculosis does not lead to this same increase and this lack 
of a rise in calcium concentration results in increased survival of the bacteria. A 
pharmacological increase in calcium concentration resulted in a reversaI of the block in 
phagosomal maturation. How this increase in calcium concentration could play a role in 
phagosome maturation was further examined by Malik et al. (Malik, Iyer, and Kusner, 
2001). Phagosomes containing live M. tuberculosis exhibit lower levels of calmodulin 
(CaM), which was linked to the lack of increase in calcium concentration. Furthermore, 
pharmacological increase in calcium increased the percentage of phagosomes containing 
activated calmodulin kinase II (CaMKII). An inhibitor of CaMKII, acting by inhibiting 
the binding of Ca-CaM to CaMKII, blocked the maturation of phagosomes. Two 
conclusions were drawn from these results: 1) phagolysosome fusion requires Ca-CaM 
dependent activation of CaMKII and 2) decreased activation of CaMKII contributes to 
the inhibition of phagosomal maturation. 
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Early-endosomal autoantigen 1 (EEAI) is recruited to the endosome membrane 
via Rab5-GTP and phosphotidylinositol 3-phosphate (Patki et al., I997;Simonsen et al., 
1998) and is crucial for the recruitment of syntaxin 6 (Fratti, Chua, and Deretic, 2003). 
Syntaxin 6 has been demonstrated to be critical for trafficking between the trans-golgi 
network (TGN) and the endosome, which involves molecules such as vacuolar proton-
ATPases and lysosomal hydrolases that are necessary for proper functioning of the 
phagolysosome (Bock et al., I997;Mallard et al., 2002). Levels of both EEAI and 
syntaxin 6 are Iower on phagosomes containing M. tuberculosis compared to those 
containing latex beads, and it is the exclusion of these molecules that has been proposed 
to be the principal factor in M. tuberculosis-induced arrest in phagosome maturation. 
Two converging pathways involved in the recruitment of EEAI and ultimately syntaxin 
6, are disrupted by M. tuberculosis infection, resulting in reduced trafficking between the 
TGN and the endosome. 
The increase in calcium concentration normally induced during phagosome 
maturation is involved in the recruitment of a phosphotidyIinositoI 3-kinase, h VPS34, 
and a serine/threonine kinase that mediates its activity, pI50. p150/hVPS34 binds to 
CaM in a calcium dependent manner and is responsible for the generation of PI3P 
(Vergne, Chua, and Deretic, 2003). PI3P binds EEAI, and thus disruption of the calcium 
signaling pathway decreases recruitment of EEAI. M. tuberculosis mannose-capped 
lipoarabinomannan (ManLAM) inhibits the calcium signaling pathway by inhibiting the 
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initial rise in calcium concentration (Vergne, Chua, and Deretic, 2003), thereby reducing 
EEAI and syntaxin 6 recruitment and thus phagosome maturation. 
M. tuberculasis inhibits phagosome maturation by interfering with a second 
overlapping pathway involved in EEAI recruitment. Infection with M. tuberculasis 
stimulates a MAP kinase, p38, activation of which was previously identified to displace 
EEAI associated with endosome membranes (Cavalli et al., 2001). Specific inhibition of 
p38 increased mycobacterial phagosome co-Iocalization with EEAI, increased the late 
endosomal marker, LBPA, and increased acidification of the phagosome (Fratti, Chua, 
and Deretic, 2003), whereas stress-induced activation of p38 decreased EEAI associated 
with latex bead phagosomes. Although the pathway requires clarification, it has been 
proposed that M. tuberculasis activation of p38 interferes with the cycling of Rab5, 
retaining it in its inactive GDP-bound form and thus interfering with both its activation of 
hVPS34 and its direct binding to EEAI. 
Protein kinase G (pknG) is a serine/threonine kinase that is predicted to be 
localized to the cytoplasm and has been identified by Walburger et al (Walburger et al., 
2004) to contribute to M. tuberculasis' survival in macrophages by blocking lysosomal 
delivery. Growth of M. bavis BCG and M. tuberculasis in macrophages was inhibited in 
a dose-dependent manner by a pknG-specific inhibitor. Immunofluorescent staining 
indicated that deletion of pknG in M. bavis BGC resulted in localization of the mutant 
strain in LAMP-positive vacuoles, whereas the wild-type strain was found in LAMP-
negative vacuoles. This was confirmed by cell fractionation of infected macrophages in 
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which t1.pknG BCG was resolved in the lysosomal fractions and wild-type BCG was 
resolved in the non-Iysosomal fractions. Furthermore, growth in macrophages was 
severely restricted for the t1.pknG mutant strains and not for wild-type BCG. 
1.1.2.3.MHCII Inhibition 
Presentation of antigens is a necessary event in the development of cell-mediated 
immunity against M. tuberculosis, which itself is necessary for the control of M. 
tuberculosis infection. M. tuberculosis however, interferes with the proper presentation 
of antigens, which thereby provides a mechanism by which it can evade immune 
surveillance. M. tuberculosis-infected monocytes have been shown to lack the ability to 
stimulate T-cell proliferation and IFNy secretion (Gercken et al., 1994). Noss et al. 
(Noss, Harding, and Boom, 2000) also reported that infection of bone marrow-derived 
macrophages with M. tuberculosis inhibited antigen processing and presentation. 
Analysis of M. tuberculosis-infected monocytes by F ACS revealed that surface 
expression of MHC-II molecules is decreased in infected cells (Gercken et al., 
1994;Hmama et al., 1998). Expression of MHCII rnRNA is decreased in M. 
tuberculosis-infected cells (Noss, Harding, and Boom, 2000), however, in addition to 
decreased expression, diminished synthesis and processing of MHCII molecules is the 
major factor contributing to defective antigen presentation in infected cells (Hmama et 
al., 1998;Noss, Harding, and Boom, 2000). The M. tuberculosis 19kDa lipoprotein has 
been implicated in the decreased processing and surface expression of MHCII molecules 
via a TLR2-dependent mechanism and the inhibition of IFNy-induced gene expression 
(Noss et al., 2001;Pai et al., 2003;Pai et al., 2004). 
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1.1.3. Response to External Condition - ECF Sigma Factors 
The ability to respond and adapt to changing environmental conditions is crucial 
for the survival and, in many cases, the virulence of an organism. The specificity of those 
responses in bacteria is govemed by a group of altemate sigma factors, termed 
extracytoplasmic function (EeF) sigma factors. First described by Lonetto et al. 
(Lonetto et al., 1994), these sigma factors were identified by their similarities to the 
sigma70 family of sigma factors and by their responsiveness to extracytoplasmic 
changes. These factors associate with the core RNA polymerase and are required for 
promoter-specific DNA binding to initiate transcription of the genes required to respond 
to given extracytoplasmic signals. Three characteristics of EeF sigma factors were 
described by Lonetto et al. (Lonetto et al., 1994): 1) they regulate and respond to 
extracytoplasmic conditions; 2) many are negatively regulated by genes within their own 
operons (now termed anti-sigma factors); and 3) they may control only very small 
regulons. 
Two of the earliest described EeF sigma factors are SigE in Streptomyces 
coelicolor and AIgU in Pseudomonas aeruginosa. SigE was identified as a sigma factor 
recognizing one of four promoters from which the dagA gene in S. coelicolor is 
transcribed. Upon cloning and sequencing of the sigE gene by Lonetto et al., it was 
found to have a high degree of similarity to sigma70-type sigma factors over most of the 
conserved regions. Sorne significant differences were identified however, notably in the 
region involved in the interaction with the -10 promoter region and in the region involved 
in preventing the free sigma factor from binding to the promo ter. Based on their 
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similarity to each other and to the sigma70-type sigma factors and their proposed 
functions, Lonetto et al. (Lonetto et al., 1994) proposed seven other sigma factors to he 
designated as ECF sigma factors, among which they included the P. aeruginosa sigma 
factor, AIgU. P. aeruginosa causes chronic infections in cystic fibrosis patients and 
switching from the nonmucoid to the mucoid form is associated with a worse clinical 
outcome. This switching has been attributed to increased secretion of alginate, the 
production of which is under the control of the alginate biosynthetic cluster. 
Transcription of algD, the first gene in this cluster, is initiated by the ECF sigma factor 
AIgU. 
Mycobacterium tuberculosis has 13 sIgma factors, ten of which have been 
classified as ECF sigma factors. Several of these sigma factors have been described and 
have been found to be involved in response to various stresses. 
A sigC-knockout strain of M. tuberculosis CDC1551 has heen descrihed as an 
immunopathology mutant by Sun et al (Sun et al., 2004). Growth in activated alveolar 
macrophages and in mouse bone marrow derived macrophages was similar between wild-
type and the &igC mutant. The &igC strains also had the capacity to proliferate and 
persist in miee in both aerosol and intravenous infections. A significant differenee 
between wild-type and the &igC mutant was observed in time to death experiments. In 
both aerosol and intravenous infections, all miee infected with wild-type M. tuberculosis 
died within 235 and 107 days respectively, while no death was observed in miee infected 
with the t1sigC mutant. Histopathology revealed that infection with wild-type M. 
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tuberculosis led to considerable inflammation with alveolar consolidation and advanced 
destruction of airspaces. The level of inflammation and destruction of tissue was 
significantly less in the ~sigC-infected mice and it was concluded that this failure to elicit 
the same degree of immunopathology as wild-type M. tuberculosis was the reason for 
delayed lethality. Similarly, Karls et al. (Karls et al., 2006) suggested that SigC is 
important for pathogenesis as a ~sigC mutant strain of M. tuberculosis H37Rv was highly 
attenuated in guinea pigs. 
Inactivation of SigD also seems to result in an immunopathology mutant, 
although the phenotype is less well defined. Raman et al. (Raman et al., 2004) reported 
a sigD-knockout in M. tuberculosis CDC1551 that showed slight attenuation in growth 
in the lungs of mice, while growth in the spleen was similar to wild-type M. tuberculosis, 
and, as is typical with immunopathology mutants, showed prolonged survival compared 
to wild-type in a time to death model and little immunopathology. Infection with wild-
type M. tuberculosis led to extensive lymphocytic infiltration and consolidation of lung 
tissue, whereas the ~sigD mutant showed less lymphocytic infiltration with significant 
areas of healthy lung tissue interspersed with smaller granulomas. From the se 
observations, the ~sigD mutant was characterized as an immunopathology mutant. 
Calamita et al. (Calamita et al., 2005), however, reported that although their sigD-
knockout strain showed comparable growth and survival in activated and resting 
macrophages as wild-type, similar growth in mice deterrnined by CFU following aerosol 
infection and prolonged time to death compared to wild-type, they did not observe a 
decrease in immunopathology. In both the ~sigD mutant and wild-type infected mice, 
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they observed significant consolidation of lung tissue and granulomatous infection. The 
differences observed between the two studies could be due to the different strains in 
which the knockouts were created, as weIl as to the different mouse strains infected. An 
additional and significant finding also reported by Calamita et al. (Calamita et al., 2005) 
was TNF production in macrophages in response to M. tuberculosis infection. Infection 
of mouse alveolar macrophage cellline J774A.l with wild-type M. tuberculosis induces 
TNF production, which was not observed following infection with the ~igD mutant. 
The failure to induce cytokine responses similar to wild-type M. tuberculosis during 
infection has been cited as a possible mechanism of the described phenotype of 
immunopathology mutants (Kaushal et al., 2002), leading the authors to propose that 
although their mutant did not demonstrate reduced immunopathology in their selected 
animal model, the l'1sigD mutant should be c1assified as an immunopathology mutant 
based on the other characteristics observed. Both groups reported approximately 50 
genes that were down-regulated in the ~igD mutant compared to wild-type, however the 
expression profiles were determined under different growth conditions making a direct 
comparison difficult. 
Disruption of sigE in M. tuberculosis created a mutant that was more sensitive to 
exposure to SDS, heat shock and exposure to the oxidative compounds hydrogen 
peroxide, cumene hydroperoxide and plumbagin (Manganelli et al., 2001). The l'1sigE 
mutant also displayed lower survival than wild-type M. tuberculosis in THP-l 
macrophage cell line and in both activated and unactivated J774A.l alveolar 
macrophages (Manganelli et al., 2001). Growth in mice was dependent on the strains of 
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mice and of M. tuberculosis used. The AsigE mutant created in M. tuberculosis 
CDC1551 showed similar growth to wild-type in C3H1HeJ mice, while f1sigE created in 
M. tuberculosis H37Rv showed attenuated growth compared to wild-type in Balb/c mice 
(Ando et al., 2003;Manganelli et al., 2004a). In both cases, however, a delayed time to 
death was observed in SCID mice, and the f1sigE mutant created in CDC1551 also 
resulted in a delayed time to death in immunocompetant C3H1HeJ mice. 
Upon exposure to SDS, there is an increase in expression of sigE and sigB in M. 
tuberculosis, however, in the AsigE mutant, the increase in expression of sigB was 
blunted compared to wild-type, indicating that sigB expression in response to SDS is at 
least in part SigE-dependent. Expression of sigE in the AsigE strain could be detected by 
the use of a molecular beacon that binds to a region of the sigE gene located upstream of 
the disrupted region and after exposure to SDS, was found to be similar to wild-type, 
suggesting that SigE is not required for its own expression. Other genes differentially 
expressed in the f1sigE mutant also include transcriptional regulators, ribosomal proteins, 
and other factors involved in translation. 
Manganelli et al (Manganelli et al., 1999) examined the differential expression of 
the ECF sigma factors in M. tuberculosis under various conditions and the most striking 
response observed was in two conditions: exposure to SDS and heat shock. In both 
cases, expression of sigB and sigE was significantly increased and in the latter, a dramatic 
increase in sigH was also observed. Using selective capture of transcribed sequences 
(SCOTS) and a sigE-GFP fusion plasmid, sigE and sigH were both shown to have 
increased expression in macrophage infection (Graham and Clark-Curtiss, 1999;Jensen-
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Cain and Quinn, 2001). Exposure of M. tuberculosis to diamide results in an increase in 
expression of sigB. In both a I1sigE mutant and a I1sigH mutant, diamide-induced 
expression of sigB was severely blunted. In a I1sigEl1sigH double mutant, this response 
was abolished. Expression of sigB in response to exposure to SDS is also dependent on 
SigE. Expression of sigE and sigB increase upon exposure to SDS in M. tuberculosis, 
however, in the I1sigE mutant, expression of sigE increases as in wild-type and the 
previously observed increase in sigB is significantly lower. This suggests that SigE does 
not control its own expression, but expression of sigB is, at least partiaIly, dependent on 
sigE. Comparison of gene expression in the l1sigH mutant and wild-type M. tuberculosis 
by microarray identified sigH, sigE and sigB aIl to be significantly down-regulated and 
similar promoter sites have been identified upstream of aIl three of these genes. Based on 
this evidence, a model has been established in which, under conditions of heat stress or 
oxidative stress, SigH can induce its own expression and in tum, the expression of sigE 
and sigB. SigE, along with being inducible by sigH, can be induced by heat, surface or 
oxidative stresses and in tum induce sigB. SigB does not appear to be induceable directly 
by environmental stresses, but instead induces expression of response systems to su ch 
stresses upon activation by SigE and SigH. 
The loss of SigH in M. tuberculosis resulted in increased sensitivity to heat shock 
and oxidative stress (Raman et al., 2001;Manganelli et al., 2002), however, unlike the 
I1sigE mutant, no difference was found in survival compared to wild-type M. 
tuberculosis in unactivated or activated macrophages (Manganelli et al., 2002), nor was 
there a difference between the mutant and the wild-type strains in proliferation and 
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survival in mice (Kaushal et al., 2002). In immunocompetant mice, a significantly longer 
time to death was observed for the I1sigH mutant compared to wild-type, but a similar 
difference was not found in immunocompromised SCID mice. Differences in 
immunopathology were only detectable in the lungs of infected immunocompetant 
animaIs, with the I1sigH-infected mice displaying fewer lesions and smaller granulomas 
than wild-type infected mice. No differences in immunopathology were observed in the 
SCID mice (Kaushal et al., 2002). The delay in pathological disease was reported to 
correlate with a decrease in T -cell recruitment to the lungs in the l1sigH infected mice. 
Heat shock proteins and components of the thioredoxin-thioredoxin reductase system 
were reported to be among the genes down-regulated with the loss of SigH. 
The ability of M. tuberculosis to cope with exposure to hydrogen peroxide has 
also been partially attributed to SigJ. Loss of this sigma factor increased the 
susceptibility of cultures to hydrogen peroxide over both long and short exposure times. 
The I1sigJ mutant was not more susceptible to other stresses such as heat shock, low pH 
and exposure to SDS, nor was its survival in mice impaired. Proliferation and survival of 
the I1sigJ mutant and the wild-type M. tuberculosis were similar in Balb/c mice and there 
were no differences in granuloma formation or tissue damage observed, suggesting that 
other pathways for resistance to oxidative stress may compensate for the loss of SigJ (Hu 
et al., 2004). 
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To date, there have been no works published investigating the ECF sigma factor 
SigK in M. tuberculosis. This sigma factor was in fact exc1uded from a study examining 
the differential expression of sigma factors in M. tuberculosis (Manganelli et al., 1999). 
SigL has been proposed by Hahn et al. (Hahn et al., 2005) to be involved in the 
regulation of cell envelope lipid synthesis and the modification of secreted proteins based 
on analysis of gene expression in M. tuberculosis overexpressing sigL. Several genes 
up-regulated in the overexpression mutant are involved in polyketide synthesis, leading to 
the suggestion that the decreased virulence of the I1sigL strain in mice, seen as an 
increase in median survival time of mice following intravenous infection, is at least in 
part due to the disruption of normal expression of these genes. The loss of SigL did not 
lead to increased susceptibility to SDS or to oxidative or nitrosative stresses. The role of 
SigL and the SigL-regulon in pathogenesis or response to stress was further examined by 
Dainese et al (Dainese et al., 2006), who confirmed a SigL-dependent promoter of sigB, 
as weIl as an involvement of SigL in the expression of several polyketide synthases. 
The function of the ECF sigma factor SigM was recently investigated by Agarwal 
et al. (Agarwal et al., 2006) and Raman et al. (Raman et al., 2006). Both groups 
observed that expression of sigM was low relative to expression of sigA. Agarwal et al. 
determined that expression of sigM was increased in stationary phase and following heat 
shock, while Raman et al. did not observe any change in expression throughout various 
growth phases. Up-regulation of expression of a limited number of genes was observed 
upon overexpression of sigM, many of which were identified or putative secreted and 
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cell-surface associated products and among those commonly identified were four esat-6 
homologues. Raman et al. further demonstrated that genes involved in PDIM synthesis 
and mycolic acid synthesis are negatively regulated by SigM. In animaI studies, L1sigM-
mutant strains were not observed to be attenuated compared to wild-type M. tuberculosis 
(Agarwal et al., 2006;Karls et al., 2006). Taken together, these experiments suggest that 
SigM is unlikely involved in virulence of M. tuberculosis, but may play a role in survival 
and adaptation during infection. 
Although not aIl the functions or activating signaIs of the ECF sigma factors and their 
downstream effectors in M. tuberculosis have been clearly established, it is evident that 
the ability of the bacteria to adapt to a variety of environmentaI stresses is dependent on 
these networks. 
1.2. Bacille Calmette-Guérin 
1.2.1. Development of BCG 
Sponsored by the Institut Pasteur, Albert Calmette and Camille Guérin spent 
years examining the peculiar characteristics of the tubercle bacillus. Calmette 
strongly believed that one must understand the "propagation of a disease before even 
thinking of possible means of treating it effectively" (Guerin, 1978) and thus studied 
both the clinical manifestations of the disease and the microbiological properties of 
the disease causing agent in detail. Knowing that many other investigators had been 
unsuccessful in their attempts to attenuate the bacterium, the y began their own studies 
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using a highly virulent bovine strain of the bacillus, now known to actually have been 
M. hovis. In 1908, they observed that the addition of beef bile to a culture of the 
bacilli resulted in the disaggregation of the clumps of bacilli normally seen in 
cultures. Continued passage in the presence of beef bile did not appear to have an 
effect on the virulence of the bacteria and thus they continued to explore new media 
on which they could passage the bacteria, finally settling on a medium containing 
potatoes partially immersed in glycinerated beef bile. It was on this medium that they 
observed a change in the characteristic appearance of the culture from the typical dry, 
granular and rough appearance to a moist, waxy and smooth appearance (Guerin, 
1978). They continued to passage the culture every three weeks on to new media and 
in 1921, they described a culture that was observed to be attenuated, yet retained its 
immunogenic properties in animaIs. Bacille Calmette-Guérin (BCG) was 
administered as a vaccine for the first time in July, 1921. 
1.2.2. Clinical Trials and Efficacy of BCG 
Since the first dose of BCG was administered 85 years ago, numerous studies 
have been initiated in attempt to define how weIl BCG protects against tuberculosis, 
yet the answer to this question remains elusive. One of the earliest studies that 
showed encouraging results was initiated by Heimbeck, in Norway, in 1927. Upon 
observation of a high rate of tuberculosis in nursing students who were tuberculin-
negative prior to entry to nursing school, he began offering BCG vaccination to these 
students. A significantly higher number of cases of TB (6 times greater) and of 
deaths attributable to TB (7 times greater) were observed in the non-vaccinated group 
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of students compared to the vaccinated group. Aiso in 1927, Aronson and 
Dannenberg began a trial in which they vaccinated newborns in Philadelphia. In 
families with a known case of tuberculosis, the y observed 10 deaths out of 84 non-
vaccinated children and only one death out of 41 vaccinated children. Similarly, in 
the families without a known case of TB, two deaths were observed out of the 41 non-
vaccinated children and no deaths were observed in the 15 vaccinated children. 
Several other formaI trials were initiated in the 1930s, two of which took place 
within First Nations communities in Canada and the United States and a third trial of 
interest took place in Chicago. In these trials, vaccination occurred either at birth or 
in childhood and aIl children were considered to be living in a high incidence 
environment. Significant protection against both TB cases and death due to TB was 
observed in aIl three populations, with protection ranging from 75-83% (Guerin, 
1978). 
After World War Il, both the US Public Health Service and the Medical 
Research Council in the UK recommended large-scale trials. Four such trials ta ok 
place beginning in 1949-1950, one of which showed a high level of protection, two a 
moderate/low level and one an insignificant level of protection. The trial 
demonstrating the highest efficacy took place in England, enrolling 54,239 
individuals between 1950-52, who were aged 14 or 15 at the time of entry, and 
following these individuals for 20 years. Over this time period, the overall protective 
efficacy was determined to be 77% and although the efficacy was high over the entire 
35 
time period, when divided into five-year intervals, the efficacy decreased in each 
subsequent interval. However, because the countrywide incidence also decreased 
dramatically in England during this time period and so few cases were observed 
within the last interval (15-20 years after vaccination), the study conc1uded that the 
estimate of low protective efficacy during this interval was not precise and the overall 
protection provided by BCG vaccination against tuberculosis in this population was 
high (Hart and Sutherland, 1977). 
A similar trend of decreasing efficacy over time was observed in Madanapalle 
in southern India (Frimodt-Moller, Acharyulu, and Pillai, 1973). The difference in 
outcome with this trial, however, was the overall protective efficacy for the 21-year 
observation period was determined to be only 20%. The highest efficacy was 
observed in the first ni ne years, during which the protective efficacy was estimated to 
be 83%, however, over the remainder of the follow-up period, several cases arose in 
the vaccinated group, as well as the control group, resulting in a low overall estimate 
of efficacy. 
The US Public Health Service initiated a large-scale trial in Puerto Rico 
(Comstock, Livesay, and Woolpert, 1974), selecting this location because of the high 
mortality rate from tuberculosis in the country during the 1930s and 1940s. 
Vaccinations took place between 1949 and 1951, although enrolment was 
significantly lower than expected. An overall reduction of tuberculosis cases of 
28.7% was observed over the 19-year follow-up. In contrast to the studies in England 
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and India, the protection attributable to vaccination varied insignificantly over the 
five-year intervals of observation. 
A large-scale trial from which questions regarding the use of BCG in the 
United State arose, took place in Georgia and Alabama beginning in 1950. Over a 20-
year follow-up, very little protection due to BCG vaccination was observed. 
However, it was noted by the authors that although protection was seemingly low, the 
numbers of cases that had arisen in both the vaccinated and the control groups was 
considerably lower than expected and thus " ... there was little opportunity for any 
vaccine to contribute much to the control of tuberculosis." (Comstock and Palmer, 
1966). 
Further questions arose from the release of two studies, one in Chingleput, 
India (Baily, 1980) and the other in the Karonga district in Malawi (Ponnighaus et al., 
1992), which demonstrated no benefit from BCG vaccination. The Chingleput region 
was chosen because of its prior lack of BCG vaccination in the population and the 
moderate rate of TB in the region. Vaccinations took place from July, 1968 to March, 
1971. 366,625 people were registered, of whom 77.8% were vaccinated (all ages). In 
the 15-year-followup, there was no indication of protection in BCG vaccinated 
individuals compared to placebo group. In Malawi, routine BCG vaccination of 
school-aged children began in 1974. Between 1979 and 1989, 180 cases of 
tuberculosis were identified in 83,455 individuals in whom BCG scar status could be 
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determined. As in Chingleput, the rate of tuberculosis did not differ between the 
BCG scar negative and the BCG scar positive groups. 
Despite the extensive use of BCG worldwide and the numerous clinical trials 
in which BCG has been evaluated, a subset of which is presented here, its efficacy as 
a vaccine against tuberculosis still remains in question. A meta-analysis by Colditz et 
al (Colditz et al., 1994) reported an overall protective effect of BCG vaccination of 
50%, however, when extrapolating to any given population, this value is considered to 
be misleading since it does not address two important factors: the risk of exposure and 
the environment of that population. From a summary of the estimates of BCG 
efficacy by Fine (Fine, 1995), the overall trend suggests that, albeit low in sorne 
cases, BCG does afford sorne degree of protection against tuberculosis in most 
populations. A recent meta-analysis of the effect of BCG vaccination on tuberculous 
meningitis and miliary tuberculosis in children conc1uded that BCG vaccination is a 
highly co st-effective measure against childhood tuberculosis and supported the 
continued use of BCG, particularly in high-incidence environments (Tronz, Fine, and 
Dye, 2006). 
1.2.3. Failure of BCG 
The variable performance of BCG in clinical trials has raised several questions 
concerning its overall efficacy and what factors contribute to the observed 
discrepancies. The significant protection provided by BCG against TB in children 
demonstrates that BCG can effectively, and consistently, generate a protective 
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Immune response. However, since this protection is not seen as consistently in adults 
or over the long-term, attention has turned to identifying the factors that contribute to 
either the loss or the maintenance of a protective immune response. 
1.2.3.1. Failure of BCG - Environmental Mycobacteria 
In comparing the different levels of protection against M. tuberculosis 
provided by vaccination with BCG, it has been suggested that exposure to 
environmental mycobacteria may influence the immune response that BCG is capable 
of inducing. Crossreactivity of many species of mycobacteria, specifically with BCG, 
has been demonstrated in both animal models and in humans (Lozes et al., 
1997;Oftung et al., 1998), suggesting that exposure to other mycobacteria may 
influence the immune response to BCG. Generally, higher levels of protection have 
been observed in temperate environments and lower levels in more tropical 
environments. Although there are many factors that may influence this trend, 
exposure to non-tuberculous mycobacteria has been proposed to be a major factor. 
Comparison of immune responsiveness to various mycobacterial antigens in similar 
non-vaccinated populations in the UK and Malawi suggested, from positive IFNyand 
DTH responses, that both populations had been exposed to a variety of mycobacteria. 
However, the greater prevalence of responsiveness to PPDs from environmental 
mycobacteria in the Malawian population suggested much higher exposure in this 
population (Weir et al., 2003). Following vaccination, the increase in IFNyand DTH 
responses observed in the UK population were much greater than those observed in 
the Malawian population (Black et al., 2002). Within the Malawian population, 
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individuals with low responsiveness to environ mental mycobacteria pnor to 
vaccination demonstrated a greater increase in IFNy response to M. tuberculosis PPD 
following vaccination th an individuals with initial high responsiveness (Black et al., 
2001). Two hypotheses, regarding the exposure to environmental mycobacteria, 
explaining the apparent failure of BCG have been proposed: the masking hypothesis 
and the blocking hypothesis. 
1.2.3.1.1. Environmental Mycobacteria: Masking Hypothesis 
The masking hypothesis suggests that environmental mycobacteria stimulate a 
baseline level of immunity to M. tuberculosis and any additional protective immunity 
generated by BCG vaccination is limited. Palmer and Long (Palmer and Long, 1966) 
originally suggested this hypothesis based on their observations that vaccinating 
guinea pigs with environmental mycobacteria could protect against an M. tuberculosis 
challenge to a varying degree, but also reduced the protective effects of subsequent 
BCG vaccination. Similar results were observed by Orme and Collins (Orme and 
Collins, 1984) with M. avium infection in mice. Mice pre-sensitized with M. avium 
were protected against an M. tuberculosis challenge, but no further protection was 
observed in mice that were both pre-sensitized and BCG vaccinated. The level of 
protection induced by prior sensitization depended on the species of mycobacteria, 
with M. avium demonstrating the highest level of induced protection (greater than 
BCG), M. kansasii and M. simiae inducing a moderate level and no protection being 
induced by M. scrofulaceum. Regardless of the level of protection afforded by 
sensitization, all groups of mice (unsensitized/vaccinated or sensitized/vaccinated) 
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demonstrated similar levels of protection. The protection induced by the pre-
sensitization with environmental mycobacteria masked the protection that would 
otherwise be induced by BCG, making the protection attributable to BCG apparently 
lower. 
The measured effect will be the difference between the protection afforded by 
sensitization and that provided by BCG, effectively changing the non-vaccinated 
control group from a mycobacteria naïve group to a previously exposed group. This 
hypothesis suggests that the baseline to which vaccination is compared will depend 
upon the degree of sensitization in the population, with a higher degree of 
sensitization providing a higher degree of masking and therefore a lesser apparent 
effect. De Lisle et al. (de Lisle et al., 2005) compared the protective efficacy of BCG 
in guinea pigs, both sensitized and unsensitized with M. avium, against an M. bavis 
challenge. Sensitization alone afforded a low level of protection. BCG vaccination in 
sensitized animaIs showed equal or slightly lower protection than BCG vaccination in 
unsensitized animaIs when each group was compared to control animaIs that were 
both unsensitized and unvaccinated. The reduction in CFU counts in vaccinated-
sensitized animaIs when compared to unvaccinated-sensitized animaIs, however, is 
less than the reduction seen when compared to unvaccinated-unsensitized animaIs 
since sensitization alone provided a base level of protection. The apparent reduction 
in CFU is dependent on the control group to which the vaccinated group is compared, 
while the actual CFU counts were similar in all vaccinated groups regardless of 
sensitization. 
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Based on this hypothesis, BCG vaccination in a previously sensitized 
population will indeed provide less protection than in a population with relatively low 
exposure to mycobacteria because, to sorne extent, a protective immune response has 
already been generated in this population. This apparent failure of BCG in widely 
exposed populations will then reflect a redundancy in immune responses, rather than 
an inability to stimulate a protective response. It does suggest that a vaccine that can 
further boost the immune response above that stimulated by environmental 
mycobacteria would be advantageous. 
1.2.3.1.2. Environmental Mycobacteria: Blocking Hypothesis 
The blocking hypothesis suggests that the immune response generated by 
environmental mycobacteria to common mycobacterial antigens is sufficient to block 
the replication of BCG, which is crucial for the induction of protective immunity. 
This hypothesis, contrary to the masking hypothesis, suggests that BCG cannot induce 
a strong protective immune response in highly sensitized populations. Prior 
sensitization with certain mycobacteria can inhibit BCG growth in animal models 
(Lozes et al., 1997;Brandt et al., 2002;Demangel et al., 2005). Brandt et al. (Brandt 
et al., 2002) originally proposed the blocking hypothesis based on observations that 
BCG vaccinated mice were significantly protected against M. tuberculosis, while 
mice that were first sensitized and subsequently vaccinated were not protected. 
Demangel et al. (Demangel et al., 2005) found that mice pre-sensitized with M. avium 
inhibited BCG growth to a greater extent than M. vaccae or M. scrofulaceum and 
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correspondingly, BCG vaccination in mice pre-sensitized with M. vaccae and M. 
scrofulaceum induced greater protection against M. tuberculosis than in M. avium 
sensitized mice. As a comparison, a recombinant strain of BCG (BCG::RDl), which 
has been shown to persist longer than BCG in mouse infections, was tested in the 
same mode!. Growth of BCG::RDI was not as restricted in pre-sensitized mice as 
BCG and, most interestingly, it induced greater protection in the lungs and similar 
protection in the spleen of pre-sensitized mice compared to unsensitized mice. It was 
concluded that if BCG replication is not inhibited, then a protective immune response 
can be generated in addition to that provided by exposure to environmental 
mycobacteria. Therefore, use of a strain of BCG whose replication is not inhibited by 
prior exposure of the host to environmental mycobacteria or by a vaccine that does 
not depend on replication to induce a protective response may be most beneficial. 
1.2.3.2. F ailure of BCG - Attenuation of BCG 
Among the variables that must be considered when analyzing the protective 
efficacy of BCG, the vaccine itself must be examined. Behr and Small (Behr and 
SmaIl, 1997) demonstrated by plotting vaccine efficacy versus passage number for the 
strains of BCG that had been used in multiple trials, that increased passage number 
correlated with decreased efficacy in four of the five strains analyzed. Behr further 
described the strains used, the passage numbers and the trials in which they were used 
and although acknowledging that aIl the variables between the trials could not be 
controlled for, the analysis revealed a trend of decreasing efficacy to be associated 
with increased passage number (Behr, 2001). Analysis of sorne the genetic changes 
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that have accumulated in the BCG strains over time may elucidate phenotypic 
changes affecting vaccine efficacy and is a focus of this thesis. 
1.2.4. Current Use 
BCG strains are currently the only vaccines used for tuberculosis prevention and 
are widely used throughout the world, with an estimated 2 million doses given per 
week. WHO vaccination policies vary by country, however, the most common 
recommendation is for vaccination at birth (Fine P.E. et al., 1999). Currently, there 
are five substrains (Russia, Tokyo, Danish, Moreau and Pasteur) that account for 
greater than 90% of production (WHO, 2005). 
1.3. Evolution of BCG 
1.3.1. Phylogeny 
As BCG started to be used around the world, aliquots were disseminated at 
various times to several locations and continued passaging occurred at many sites 
worldwide, in addition to the Pasteur Institute. As these aliquots were cultured in 
various laboratories, there were reports of varying morphological characteristics, 
growth characteristics and reactions in animal and human hosts. 
In 1996, Mahairas et al. (Mahairas et al., 1996) analyzed the genetic 
differences between M. hovis and strains of BCG and, through the use of subtractive 
genomic hybridization, three distinct regions of difference (RD) were identified. The 
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10 ORFs comprising RD3 were identified as missing in aIl BCG strains analyzed, but 
present in virulent laboratory strains of M. tuberculasis and M. bavis. Upon 
comparison with clinical strains of M. tuberculasis, this region was only found in a 
minority of these strains and thus determined to not likely be of high importance in 
the virulence of M. tuberculasis. This predicted prophage was possibly absent in the 
M. bavis from which BCG was derived or may have occurred during the multiple 
passages leading to the attenuation of BCG. RD2 was identified as a 1O.8kB, 11 ORF 
region, missing in a subset of BCG strains. Two imperfect direct repeats are located 
at the deletion breakpoints, suggesting a mechanism by which this region may have 
been deleted. The RDI region was found to be present in aIl clinical strains of M. 
tuberculasis, as weIl as the laboratory strains H37Rv and Erdman and in M. bavis, 
while it is lacking in aIl strains of BCG. Based on this distribution and the prediction 
that at least one gene in the RDI region is a virulence factor or involved in the 
regulation of other virulence factors, RD 1 was predicted to be the attenuating 
mutation of BCG. 
By constructing a genealogy based on written records of BCG dissemination 
and using IS61JO and mpt64 molecular typing, Behr and SmaIl (Behr and Small, 
1999) established a preliminary phylogeny of BCG, which was further elaborated 
upon by DNA microarray analysis comparing M. bavis and BCG strains to M. 
tuberculasis H37Rv (Behr et al., 1999). From this, 16 deletions were identified, five 
of which are BCG-specifie deletions (one missing in aIl BCG - RD1, four missing 
from various substrains - RD2, RD8, RDI4, RDI6). In addition to confirming 
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previously identified deletions, Mostowy et al. (Mostowy et al., 2003) identified three 
further deletions, two of which are specific to one strain each (RDRussia, 
RDFrappier) and one that is deleted from both BCG Denmark and BCG Glaxo. 
Figure 1.1 shows the complete phylogeny of BCG. 
1.3.2. RD1 
The attenuation of M. bavis can at least in part be attributed to the loss of the 
RD1 region. Pym et al (Pym et al., 2002) complemented RD1, RD3, RD4, RD5 and 
RD7 into BCG Pasteur to examine what, if any, role these regions played in the 
attenuation of BCG. Only complementation of RD1 led to a significant phenotypic 
change. Colony morphology of BCG Pasteur::RDl appeared more similar to M. 
tuberculasis or M. bavis th an typical BCG, developing a spreading, less rugose 
morphology. Virulence in mice was partially restored, with modest differences in 
persistence also observed. In SCID mice, BCG::RD1 proliferated to a 100-1000-fold 
higher level than BCG, as weIl as inducing severe inflammation and the formation of 
granuloma-like structures not seen in BCG-infected mice. The level of virulence, 
however, was not fully restored to the levels of M. tuberculasis H37Rv. 
Deletion of the RD1 region severely attenuated M. tuberculasis H37Rv (Lewis 
et al., 2003). While M. tuberculosis H37Rv infected and multiplied rapidly in THP-1 
cells, H37Rv~RDl increased only 3-fold over 7 days, appearing much more similar to 
BCG, which did not replicate intracellularly. Similarly, H37Rv infection led to more 
than 80% destruction of the cell monolayer over 7 days, while very little cell death 
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was observed in BCG- or H37Rv~RDl-infected cells. Murine infections with the 
RD1 knockout strain also revealed a BCG-like phenotype. Contrasted to the rapid 
proliferation of H37Rv in the lungs and dissemination to the spleen following aerosol 
infection, growth of H37Rv~RD1 and BCG Russia was slow, with delayed 
dissemination to the spleen. Infection with H37Rv~RD1 and BCG Russia was 
indistinguishable by histopathology, revealing very little inflammation and no 
granuloma formation at 6 weeks, a time after which H37Rv infection led to severe 
inflammation and granuloma formation. Differences in growth and histopathology 
were apparent in a long-term infection model (57-68 weeks) (Sherman et al., 2004), 
indicating that deletion of RD 1 did not fully attenuate M. tuberculosis to the levels of 
BCG. Survival of mice infected with H37Rv~RD1 was significantly prolonged 
compared to H37Rv, yet led to more rapid death than BCG, again indicating that loss 
of RD1 did not fully attenuate M. tuberculosis to BCG levels (Hsu et al., 2003). 
Attenuation of virulence of H37Rv~RD1 strains in murine infection was 
confirmed by Hsu et al. (Hsu et al., 2003), who additionally demonstrated that 
disruption the ESAT-6/CFPlO operon was sufficient to attain similar levels of 
attenuation as those observed with the loss of RD 1. ESAT-6 and CFPlO are secreted 
proteins, which are encoded for by genes in the RD 1 region. Lung histopathology of 
Balb/c mice infected with this strain revealed the bacilli are largely contained in intact 
macrophages located in the alveolar spaces, whereas evidence of macrophage lysis 
and the presence of M. tuberculosis in macrophages located in interalveolar walls was 
apparent in wild-type M. tuberculosis-infected mice. Disruption of other genes in the 
47 
RDl region (Rv3871, Rv3876/3877) resulted in strains defective in the secretion of 
ESAT-6 and CFPlO (both proteins were produced and detected intracellularly) and 
attenuated in SCID mice. It was proposed that ESAT -6 is an effector molecule 
responsible for cytolysis, inducing cell-to-cell spreading and tissue invasiveness. 
Further evidence that other genes in the RD 1 region are required for secretion 
of ESAT-6 and CFP was provided by Gao et al. (Gao et al., 2004) and Guinn et al. 
(Guinn et al., 2004). Disruption of individu al genes in the RDl region, specifically 
Rv3870, Rv3871 and Rv3876, led to the loss of secretion of ESAT-6 and CFP, even 
though these proteins were detectable within the bacilli. Decreased cytolysis and cell-
to-cell spreading have been attributed to the lack of secretion of these proteins. 
During infection of THP-l cells with M. tuberculosis, the percentage of cells infected 
increased over time and the majority of cells were infected with fewer than 10 bacilli. 
With secretion-deficient mutants, the percentage of cells infected remained steady, 
while the proportion infected with greater than 10 bacilli increased, indicating the 
ability of the bacteria to replicate but not to spread to new cells (Guinn et al., 2004). 
Individual mutants were comparably attenuated in animal models to H37Rv~RDl. 
Early suggestions proposed that ESAT-6 and CFPlO activity is mediated through the 
formation of a pore, however recent structural data contradicts this idea suggesting a 
signaling and receptor binding function of the complex (Renshaw et al., 2005). The 
proteins form a stable l: 1 di mer (Renshaw et al., 2002) and the formation of this 
dimer appears to be important for virulence (Brodin et al., 2005). 
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ESAT-6 and CFPlO are both immunogenic proteins, stimulating strong 
cellular immune responses during M. tuberculosis infection. This has been 
demonstrated both in TB patients (Johnson et al., 1999;Dillon et al., 2000), as weIl as 
in several animal models (Brandt et al., 1996; Vordermeier et al., 2001 ;Brusasca et al., 
2001;Kamath et al., 2004), suggesting the importance of these proteins in early 
infection. The strongly induced immune response to these proteins has prompted 
their inclusion in various vaccine formulations (to be discussed in section 1.4). 
Additional gene products encoded for in the RD 1 region have been examined for 
immunogenic properties. Although ESAT-6 and CFPlO induce the strongest 
responses, cellular responses to PPE68 (Rv3873), Rv3878 and Rv3879c have also been 
detected (Okkels et al., 2003;Agger et al., 2003;Liu et al., 2004). There is significant 
interest in identifying immunogenic proteins in the RD 1 region for their potential use 
in diagnostic testing for M. tuberculosis infection. 
1.3.3. RD2 
Several years after the development and continued passaging of BCG, reports 
of an additional loss of virulence of BCG were published (Oettinger et al., 1999). 
From the established timeline of deletions in BCG, it has been noted that this 
secondary loss of virulence coincided with the 10ss of the RD2 region and it has been 
speculated that a function link exists between the observed change in virulence and 
the loss of this region. The genes in the RD2 region include a ribonucleotide 
reductase subunit, lysE-family and lysR-regulatory proteins, a methyltransferase and 
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the antigenic protein MPT64, the most widely described of the RD2 gene products 
(Figure 1.2). 
MPT64 was identified as a culture filtrate protein, abundantly produced and 
secreted, and detectable as early as day 2 in in vitro cultures (Harboe et al., 1986;Fifis 
et al., 1991;Andersen et al., 1991). The highly immunogenic prote in induces a 
prominent cellular immune response in animal models, inc1uding guinea pigs and 
cattle (Haga et al., 1995;Oettinger et al., 1995;Lightbody et al., 1998). Similarly, a 
strong response to MPT64 is detectable in TB patients (Roche et al., 1994;Roche, 
Feng, and Britton, 1996). From the strength of these responses, the potential 
importance of MPT64 in inducing a protective immune response and its inclusion in 
DNA and subunit vaccines has been supported. The absence of mpt64 in several 
substrains of BCG was first noted by Li et al. (Li et al., 1993) and it was subsequently 
confirmed as a constituent of the deleted RD2 region (Mahairas et al., 1996), raising 
the question of the possible effect this loss has had on the protective immunity BCG 
is capable of inducing. 
Several other RD2 products have been identified as inducing immune 
responses in animaIs and TB patients, however, as the levels of induction have been 
relatively low, none have been classified as major antigens (Cockle et al., 2002;Liu 
et al., 2004). 
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M. tuberculosis is known to be intrinsically resistance to macrolides, although 
sensitivity of certain strains of BCG to macrolides has been reported. This phenotype 
has recently been attributed to the loss of the RD2 gene Rv1988 (Buriankova et al., 
2004), whieh encodes a product showing strong similarity to the Erm family of 
methyltransferases. Methylation of the 23S rRNA by these methyltransferases 
reduces binding of macrolides to the ribosome, inhibiting the macrolide-stimulated 
dissociation of the peptidyl-tRNA from the ribosome, thus conferring resistance. 
The role of the ribonuc1eotide reductase subunit R2-1 encoded by nrdF 1 
(Rv1981c) appears to be secondary to that of nrdF2 (Rv3048c). The R2-2 subunit, 
encoded by nrdF2, preferentially associates with the RI subunit to form a functional 
holoenzyme. The R2-1 subunit can form an active holoenzyme with RI only when 
present in high concentrations (Yang et al., 1997). In addition, a knockout of R2-2 in 
M. tuberculosis could only be successfully created when the strain was first 
complemented with a second copy of R2-2, indicating that R2-1 could not compensate 
for the loss of R2-2 and may serve a different, unidentified function (Dawes et al., 
2003). 
1.3.4. Other Deletions 
Several other deletions, sorne of which affect multiple strains and sorne of which 
are strain specifie, have been identified. They range from 21 to 9073 bp in size and 
inc1ude genes annotated as transcriptional regulators, a magne sium transporter 
(Rv1811c), a sigma factor (sig1-Rv1189), mce4 family proteins (Rv3495-3497), and a 
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PE_PGRS family protein (Rv 1768). Three genes annotated as transcription al 
regulators have been deleted from BCG (Rv1773c, Rv1985c, Rv3405c) , making this 
category significantly over-represented in the deletions in BCG compared to their 
frequency in the genome (Behr et al., 1999). In addition to these deletions, several 
significant SNPs that have resulted in functional changes have also been identified. 
In the mmaA3 gene, a G to A mutation was found at position 293 and this point 
mutation resulted in impaired production of methoxymycolic acid in aIl strains 
derived after 1931 (Belley et al., 2004). Two point mutations have also been 
identified in Rv3676, a gene encoding the transcriptional regulator cAMP receptor 
protein (CRP). The first mutation is present in aIl strains of BCG, while the second 
affects those derived after 1931, however, both mutations decrease the DNA binding 
ability of the protein and prevent CRP from binding to the promoter with which it 
normally associates (Spreadbury et al., 2005). 
1.4. Vaccine Development 
1.4.1. Live Vaccines 
The development of a new live vaccine against tuberculosis has been actively 
pursued in recent years and this work has focused on two approaches: modifying BCG 
to enhance immunogenicity and developing attenuated strains of M. tuberculosis. 
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1.4.1.1. Recombinant BCG 
Several strains of recombinant BCG have shown promising results in their 
ability to protect against tuberculosis in animaIs models and have been moved 
forward into clinical trials. Modifying BCG for use as a new vaccine against M. 
tuberculosis has the advantages of the good safety record of BCG and the relatively 
low cost of production of the vaccine. 
Although the RD1 proteins ESAT-6 and CFPlO are often associated with the 
virulence of M. tuberculosis, they induce significant cellular immune responses and 
are thought to be highly important during infection, making them potential candidates 
for improving vaccine-induced protective immunity. A recombinant strain of BCG 
complemented with the RD1 region (BCG::RD1) successfully secretes these proteins 
and induces ESA T -6 and CFP 10-specifie response in splenocytes of vaccinated mice 
(Pym et al., 2003). In vaccinated mice and guinea pigs challenged with M. 
tuberculosis, BCG::RD1 protects as weIl or better than the wild-type BCG. CFU in 
the lungs were similar between the two strains, but fewer CFU were present in the 
spleens of BCG: :RD 1-vaccinated animaIs at most time points. In addition, gross 
pathology of the spleens revealed fewer and smaller tuberc1es on the surface of the 
spleens from BCG::RD1-vaccinated mice compared to wild-type BCG-vaccinated 
mice. However, a safety concern has been raised regarding this potential vaccine. 
This strain is significantly more virulent in SCID mice (time to death) compared to 
the parental strain (Brodin et al., 2004). Pre-clinical studies of this vaccine are 
ongoing (Kamath et al., 2005). 
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A recombinant strain of BCG expressing the M. tuberculosis 30kDa major 
secretory protein Ag85B is currently being evaluated in a Phase 1 clinical trial. This 
protein is expressed and secreted in large amounts by M. tuberculosis both .in vitro 
and in vivo and is considered to be an important protective antigen. Over-expressing 
major antigens in BCG to induce protective immunity is based on the theory that 
extracellular pro teins are potent immunoprotective molecules and the demonstration 
that vaccinating with such proteins induces a protective immune response. 
Recombinant BCG strains expressing this protein (rBCG30) induce a strong DTH 
response in guinea pigs. Vaccination with rBCG30 protected guinea pigs extremely 
weIl against aerosol infection with M. tuberculosis Erdman (Horwitz et al., 2000). M. 
tuberculosis CFU counts were significantly reduced in the lungs and spleens, 
although to a lesser extent in the lungs (significant in only 1 of 2 experiments), 
compared to both unvaccinated and, more interestingly, BCG (parental strains) 
vaccinated animaIs (Horwitz et al., 2000). The median survival of rBCG30 
vaccinated guinea pigs was also significantly increased from 24 to 30 weeks, 
compared to BCG-vaccinated guinea pigs (unvaccinated median survival was 15.5 
weeks) (Horwitz and Harth, 2003). 
A new recombinant BCG showing greater protection than the parental BCG 
has recently been reported (Grode et al., 2005). This strain is urease deficient and 
expresses listeriolysin (Hly) from Listeria monocytogenes (!J..ureChly + rBCG). 
Expression of Hly serves two functions: first, the mycobacterial phagosomal 
membrane is perforated by Hly resulting in translocation of mycobacterial antigens to 
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the cytosol and subsequent presentation on MHCI molecules and second, perforation 
of the phagosomal membrane induces apoptosis which promotes cross-priming of 
mycobacterial antigens. The loss of urease, which is suggested to be involved in the 
M. tuberculosis-induced blocking of phagosomal acidification, allows the phagosome 
to acidify normally and reach a pH at which Hly functions most efficiently (Grode et 
al., 2005). Significant protection against low (30 CFU) and medium (200CFU) dose 
M. tuberculosis H37Rv infections in Balb/c mice was induced by the L1..ureChly+ 
rBCG strain compared to unvaccinated mice at aIl time points examined and 
compared to parental BCG at sorne time points. Interestingly, L1..ureChly+ rBCG also 
protected against a challenge with the highly virulent Beijing strain, against which 
parental BCG did not protect. To address the question of safety raised by the 
introduction of a known virulence factor into BCG, SCID mice were infected with a 
very high dose (l08), at which mice infected with the parental BCG strain had a mean 
survival time of 25 days. The mice infected with the L1..ureChly+ rBCG strain were 
c1early attenuated, surviving for a mean of 80 days. 
1.4.1.2. Attenuated Mycobacterium tuberculosis 
Several strains of attenuated M. tuberculosis are being considered as potential 
vaccine candidates, although for one of these strains to be put into use the question 
about safety would have to be thoroughly addressed. At a meeting in Geneva, in 
November, 2004, on the development of TB vaccines, three attenuated strains were 
presented. Deletion of PhoP, which is part of a two component system thought to 
regulate the expression of virulence genes, severely attenuates M. tuberculosis in a 
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mouse model, however, even though growth of the knockout is limited, it does persist 
as long as wild-type M. tuberculosis in a short-term model. As persistence of BCG is 
important for developing a protective immune response, this may be regarded as an 
advantageous phenotype for a potential vaccine derived from an attenuated M. 
tuberculosis strain. The two other strains discussed used a panCpanD-deleted strain 
as a backbone, upon which either lysA or RD1 was additionally deleted. Both strains 
were highly attenuated and showed protective efficacy similar to that induced by BCG 
vaccination (Sambandamurthy et al., 2002;Sambandamurthy et al., 2005). 
1.4.2. DNA Vaccines 
There have been a multitude of DNA vaccines tested for their ability to induce 
a protective response against M. tuberculosis infection. The most successful of these 
vaccines have demonstrated protection in animal models similar to that of BCG, but 
used alone the y have yet to surpass the protective efficacy of BCG. Several have 
shown success, however, in their ability to act in a prime-boost strategy to enhance 
the protection induced by BCG. Sorne of the genes used in DNA vaccines include 
Rv3875 (ESAT-6), Rv3804c (Ag85A), Rv1886c (Ag85B), hspX, sodA, hsp65, hsp70, 
mpt83, mpt64. 
Although capable of inducing a modest protective response, single antigen 
vaccines have not induced a response as protective as BCG. To improve upon this, 
multi-gene vaccines have been tested. Delogu et al (Delogu et al., 2002) screened a 
series of single antigen vaccines for their ability to induce a protective response in a 
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short-term, low dose aerosol challenge and from these, selected 10 that demonstrated 
significant protection (eight of which encode CFP - including mpt83, one PE and one 
PPE). The antigens were fused with the tissue plasminogen activator signal sequence 
to ensure efficient secretion. Vaccination with either the combination DNA vaccine 
or BCG induced significant protection following aerosol infection demonstrated by a 
decrease in CFU in the lungs and spleen, improved histopathology and increased 
mean survival period. The combination vaccine administered a dose of each 
individual component that was ineffective as a single vaccine. In combination, 
however, this dose induced protection similar to that induced by BCG. This lead the 
authors to suggest that multi-cistronic plasmids, from which several antigens could be 
expressed, may permit an increase in dosage that can be administered and perhaps 
enhance protective immunity. 
This approach was used with two immunodominant proteins, ESA T -6 and 
Ag85B, to create a plasmid from which a fusion protein was expressed and secreted 
(Derrick, Yang, and Morris, 2004). Vaccination with the plasmid DNA induced 
significant protection from an M. tuberculosis challenge, indicated by reduced CFU in 
the lungs and spleen and an increased mean survival time that were comparable to 
BCG and that far exceeded the efficacy of either single antigen. By using a fusion 
gene plasmid, this effectively allowed for the amount of each antigen per vaccination 
to be increased for the same total amount of DNA. 
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Another approach taken to address the limitation on the quantity of DNA that can 
used per vaccination is the use of cationic PLGA (DL-Iactide-co-glycolide) 
microspheres (Cai et al., 2005). The microspheres serve three functions: to act as 
mediators of DNA transfection targeted to phagocytic cells, to protect against 
biological degradation by nucleases and to enhance gene expression. A combination 
of DNA vaccines encoding Ag85B, MPT64 and MPT83 was tested in mice as both 
non-encapsulated and encapsulated DNA. The non-encapsulated DNA was injected 
three times at three-week intervals for a total amount of 900ug (300ug each plasmid), 
while a total dose of only 90ug of encapsulated DNA was administered in one 
injection. Both vaccination strategies resulted in a reduction of CFU in the lungs and 
spleen of M. tuberculosis-infected mice to levels comparable with BCG. The high 
efficacy of the low-dose, single injection vaccination with encapsulated DNA makes 
this formulation an enticing prospect for further studies. 
1.4.3. Subunit Vaccines 
Many individual antigens have been identified for their immunogenic 
properties and assayed for their ability to induce a protective response to M. 
tuberculosis in animal models. Although sorne degree of protection has been 
demonstrated in mouse models following vaccination with subunit vaccines, the level 
of protection has not shown any improvement over that induced by BCG. As with 
DNA vaccines, however, the importance of multiple components in subunit vaccines 
is being raised. 
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Two immunodominant proteins, Ag85B and ESAT -6, have been used to create 
a multi-component subunit vaccine based on a fusion prote in of the two antigens. 
PBMCs from mice vaccinated with the fusion protein can be stimulated to produce 
IFNy in response to both Ag85B and ESAT-6 and vaccination effectively reduced 
CFU in the lungs and spleen following an aerosol challenge with M. tuberculosis to 
levels comparable with BCG (Olsen et al., 2001). Additionally, vaccination of guinea 
pigs with the fusion protein, protected the animaIs against weight loss as weIl as 
BCG, whereas vaccination with the individual components or a mixture of the 
components did not increase the mean survival time (Olsen et al., 2004). This is the 
first reported subunit vaccine to have shown significant protection in the guinea pig 
mode!. 
ESAT -6 is a valuable diagnostic reagent and as such the use of a vaccine 
containing ESAT -6 is not necessarily a favourable approach to a new vaccine. Based 
on this and the promising results of the Ag85B-ESAT6 fusion protein, Dietrich et al 
(Dietrich et al., 2005) pursued candidates to replace ESAT -6 in the fusion protein and 
maintain the effectiveness of the vaccine. TB 10.4 is a member of an ESAT -6 related 
subfamily that is recognized by a high proportion of TB patients (Skjot et al., 2002). 
Vaccination with the Ag85B-TB 10.4 fusion protein induced a strong IFNy response in 
PBMCs stimulated with either antigen, and the response the TB 10.4 was stronger in 
mice vaccinated with the fusion protein than in those vaccinated with TB 10.4 alone. 
Vaccination of mice with the Ag85B-TB 10.4 fusion protein significantly reduced 
CFUs in the lungs following an aerosol challenge with M. tuberculosis to levels 
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comparable to those found in mice vaccinated with either BCG or the Ag85B-ESAT6 
fusion protein. As both proteins are present in BCG and recognized in BCG-
vaccinated individuals, this vaccine is being tested as a BCG-booster vaccine. 
The first subunit vaccine to be tested in humans is a recombinant polyprotein 
Mtb72F, developed as a fusion of two antigens, Mtb32 (Rv0125) and Mtb39 
(Rv1l96), that were identified in PPD-positive individuals and in animal models as 
potential vaccine candidates. Vaccination with rMtb72F in either of two adjuvants 
tested reduced CFU by -0.6 logs in the lungs of aerosol-challenged mice, regardless 
of the qualitative and quantitatively different immune responses generated by the 
different vaccine formulations. More importantly, vaccination extended survival of 
guinea pigs following aerosol challenge with M. tuberculosis to greater than a year, 
which is comparable to BCG and significantly longer than the 30-week survival of the 
control animaIs (Skeiky et al., 2004). 
1.4.4. Prime-Boost Strategies 
As BCG has been and continues to be used so extensively throughout the 
world, developing a new vaccination strategy that incorporates BCG can take 
advantage of the established vaccination programs, as weIl as benefit individuals who 
have been previously vaccinated. Heterologous prime-boost strategies can effectively 
generate CD4+ and CD8+ T cell responses and have been proposed as an effective 
strategy to boost BCG-induced immunity. 
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Boosting BCG with the Mtb72F subunit vaccine, which was shown to be 
highly effective as a subunit vaccine, modestly increased protection. Survival of 
guinea pigs vaccinated with BCG and boosted with Mtb72F was significantly longer 
th an those vaccinated with BCG alone, with three animais surviving the length of the 
experiment compared to one BCG-vaccinated animal. Histopathology of all surviving 
animaIs, including the non-boosted BCG-vaccinated guinea pig, revealed small 
granulomas associated with large airways and blood vessels, whereas all animaIs that 
died before the end of the experiment showed large coalescing lesions, consolidating 
most of the lung tissue. Although the surviving animaIs showed similar pathology 
regardless of the vaccine used, boosting with Mtb72F resulted in a longer mean 
survival time, with more animaIs showing favourable histopathology results. 
Boosting with Mtb72F DNA vaccine, in contrast to the subunit vaccine, did not 
significantly prolong survival time in M. tuberculosis-challenged guinea pigs 
compared to animaIs vaccinated with BCG alone. Non-boosted BCG-vaccinated 
animaIs, however, displayed large coalescing lesions with central regions of necrosis, 
whereas animaIs receiving the booster showed less inflammation and signs of healing 
(Brandt et al., 2004). 
Boosting BCG vaccination with modified vaccinia VIruS Ankara expressing 
Ag85A (MV A85A) has been proposed as an effective combination to enhance BCG-
induced immunity. In BCG-vaccinated Balb/c mice, MV A85A boosting induces 
strong antigen specific CD4+ and CD8+ responses, in spleen, lungs and lung lymph 
nodes, which were significantly greater than those observed in mice vaccinated with 
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BCG alone. CFU in the lungs and spleen of M. tuberculosis-challenged mice were 
significantly reduced in both BCG-vaccinated and the BCG-vaccinated, MVA85A-
boosted mice relative to control mice, with the latter vaccination group also showing 
significantly lower CFU relative to BCG-vaccinated mice. Boosting with BCG 
however, also decreased the CFU to similar levels as the MV A85A boosted levels 
(Goonetilleke et al., 2003). In further studies using the guinea pig model of infection, 
boosting with MV A85A induced significant protection compared to control animaIs 
demonstrated by prolonged survival, decreased CFU and decreased consolidation of 
lung tissue, however, the protection observed was similar to that induced by BCG 
alone (Williams et al., 2005). This vaccination model has been moved forward into 
c1inical trials and to date MV A85A has shown good tolerance and immunogenicity in 
vaccinated individuals (McShane et al., 2004;McShane et al., 2005). Interestingly, 
boosting with MVA85A stimulated a strong response in both BCG-vaccinated 
individuals, as well as individuals determined to have been previously exposed to 
environ mental mycobacteria, suggesting MV A85A, in addition to being a component 
of a new vaccination strategy, may have value as a booster of previously vaccinated 
and exposed individuals. 
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1.5. Research Objectives 
As we now recognize that there are significant genetic differences between strains of 
BCG and as strains of BCG are continuing to be used to vaccinate children worldwide 
against tuberculosis, it could prove to be highly beneficial to understand the phenotypic 
differences between strains arising from the various genetic changes that have occurred. 
To this end, the work in this thesis has been completed in an endeavour to understand 
what impact sorne of these genetic changes have had on the affected strains of BCG. 
More specifically, the first objective of this thesis is to examine if the loss of the RD2 
region contributed to ongoing attenuation of BCG strains. The deletion of this region 
resulted in the loss of both antigenic and regulatory proteins, both of which could affect 
the ability of BCG to induce a protective immune response against M. tuberculosis. To 
further address differences in antigenic proteins between strains of BCG, the second 
objective focuses on identifying the cause of the differential expression of two antigenic 
proteins, MPB70 and MPB83, in various strains of BCG. The third objective of this 
thesis was to evaluate the impact of expression of these proteins in BCG by restoring 
their expression in a low-producing strain of BCG. Taken together, these three objectives 
will hopefully provide sorne insight into how BCG strains have evolved through in vitro 
culturing and what impact these changes have had on the ability of these vaccines to 
protect against tuberculosis. 
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FIGURE 1.1 - Phylogeny of BCG strains. Vertical axis represents the timeline from the 
derivation of BCG from M. havis in 1908 to the lyophilization of BCG in 1961. 
Horizontal axis represents the various strains of BCG. Genetic deletions have been 
labeled. 
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FIGURE 1.2 - RD2 region. Arrows represent genes in the RD2 region. Location of the 
region in the genome is indicated in basepairs. 
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2. Materials and Methods 
Bacterial cultures. Unless otherwise stated, BCG strains and M. tuberculosis H37Rv 
were grown at 37°C in Middlebrook 7H9 medium (Difco Laboratories, Detroit, Mich.) 
containing 0.05% Tween 80 (Sigma-Aldrich, St. Louis, Mo.) and 10% albumin-dextrose-
catalase supplement (Becton Dickinson and Co., Sparks, Md.) on a roller platform 
(Wheaton). Cultures were grown to mid-log phase and stored as 1 ml aliquots in 7H9 
medium containing 15% glycerol, at -80°C. Frozen aliquots were thawed, as needed, and 
diluted in fresh 7H9 medium supplemented with Tween 80 and ADC and grown with 
rotation at 37°C. 
THP-l cell culture. The human monocytic cell line THP-l was acquired from ATCC 
(Ameriean Type Culture Collection, #TIB-202). Cells were maintained in RPMI 1640 
media (Wisent) containing 2mM L-glutamine and supplemented with 10% heat-
inactivated fetal bovine serum (Wisent) and 20 mM HEPES (Wisent), at 37°C with 5% 
CO2 in vented tissue culture treated flasks (Falcon). Cell density was maintained 
between 0.5 - 8.0x105 cells/ml. Aliquots were frozen in complete RPMI medium with 
5% DMSO and stored in liquid nitrogen. As needed, aliquots were quiek thawed, washed 
with complete RPMI and re-suspended in new media. 
AnimaIs. C57BL/6J mice were ordered from Jackson Laboratory (Bar Harbor, Maine). 
Mice were housed in the Conventional Animal Facility in the Montreal General Hospital 
for the BCG experiments and in the Biosafety Level 3 Animal Facility for the M. 
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tuberculosis infections. AlI procedures were approved by the Facility Animal Care 
Committee. 
Deletion of RD2. To knockout the RD2 region, the genomic regions flanking the RD2 
region were amplified by PCR using the primers listed in Table 2.1. PCR products for 
the regions upstream and downstream of RD2 were cloned into the plasmid pKO 
(provided by D.R. Sherman) to flank the kanamycin resistance cassette, creating the 
constructs pKO-RD2. The same PCR products were also cloned into the multiple cloning 
site of p2NIL (Parish and Stoker, 2000). The plasmid pGOAL19 (Parish and Stoker, 
2000) was digested with PacI and the fragment containing the marker genes of interest 
was ligated into the p2NIL vector containing the cloned fragments digested with the same 
enzyme, creating the construct pNIL/pGOAL-RD2. AlI constructs were verified by 
restriction analysis and purified before use. Bacteria for transformation were grown to 
mid-log phase and pelIeted by centrifugation. Bacteria were washed three times in 10% 
glycerol (20ml, lOml, 5ml) and re-suspended at 1/50 of the initial volume in 10% 
gl ycerol (200/-Ù per 10ml culture). BCG strains were mixed with 500-1000ng of plasmid 
DNA (either pKO-RD2 or p2NIL/pGOAL-RD2) and electroporated (BTX Harvard 
Apparatus, Holliston, MA or Bio-Rad Laboratories, Hercules, CA) using the settings 
2500V, 10000 and 25~F in 2-mm gap cuvettes (VWR). 800~1 of warm 7H9 media was 
added immediately after electroporation and bacteria were incubated at 37°C ovemight. 
Bacteria were then plated on 7HlO agar with hygromycin (50~g/ml) or kanamycin 
(25~g/ml) and incubated at 37°C until colonies appeared, after approximately 3 weeks. 
Individual colonies were re-suspended in 7H9 and incubated at 37°C for approximately 
67 
one week. For PCR screening, 100J..lI aliquots were centrifuged and bacteria were re-
suspended in water. Lysates were prepared by boiling samples for 20 minutes and used 
as templates for PCR screening. For detection of site-specific integration, primer pairs 
consisted of a vector-specific primer and a genomic DNA-specific primer (see table 1), 
allowing for amplification only from DNA in which the plasmid had integrated at either 
the upstream or the downstream homologous regions. Colonies in which site-specific 
integration was detected were plated on 7HlO agar with 2% sucrose and kanamycin (no 
kanamycin used for pNIL/pGOAL-RD2) and incubated at 37°C for approximately 4 
weeks. When colonies were detected, individu al colonies were selected and grown in 
7H9 media. Colonies were screened for gene deletions by PCR as described above. 
Complementation of mpb64 and sigK. To complement mpb64, the mpb64 region was 
amplified from BCG Russia using the primers MPT64compF and MPT64compR (see 
Table 1). The amplified product was digested with HindIII and KpnI (Fermentas) and 
c10ned into the plasmid pKZ4 digested with the same restriction endonuc1eases. To 
complement sigK, the sigK region (inc1uding the complete gene and 288bp upstream), 
was amplified by PCR from M. tuberculosis H37Rv, BCG Russia, BCG Birkhaug and 
BCG Pasteur, using the primers Rv0445cL and sigKR (see Table 2.1). The amplified 
products were c10ned into the T -vector, pDRIVE (Qiagen). The sigK region was then 
removed by digestion with HindIII and KpnI and ligated to the integrative mycobacterial 
vector pMV306 (Stover et al., 1991) cut with the same restriction endonuc1eases. 
Integrity of the c10ned genes was confirmed by DNA sequencing. The resulting plasmids 
and the empty vectors were electroporated into BCG Denmark (mpb64) or BCG Pasteur 
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(sigK) , as described above for gene deletions. Transformants were grown at 37°C on 
Middlebrook 7HlO plates with hygromycin (50llglml) for mpb64 transformants or 
kanamycin (25 Ilg/mL) for sigK transformants. Complementation was PCR-confirmed 
by amplifying the cloned gene with vector-specific primers for the regions flanking the 
insert and these amplicons were sequence-confirmed for aIl transformants. 
DNA Extraction. Genomic DNA Extraction: Bacteria was grown to an OD600 of 0.3 to 
0.5, pelleted by centrifugation (3000rpm, 10 minutes), transferred to 2ml screw-cap tubes 
and re-pelleted. The pellet was re-suspended in 400111 fresh lysis buffer (Na-acetate 20 
mM, SDS 0.5%, EDTA ImM), after which Iml of acidified phenol:chloroform (5: 1, pH 
4.5; Ambion) and 0.8g of silica beads (Sigma) were added to the tube. Bacteria were 
lysed by agitation using a reciprocal shaker (FastPrep FP120, Savant Bio 101) set at a 
speed of 6.5 for 45s. The tubes were incubated on ice for 10 min and then centrifuged at 
4 oC. The aqueous phase was collected and mixed with an equal volume of chloroform-
isoamylalcohol (24:1), vortexed for 1 minute and centrifuged at maximum speed for 5 
minutes. The aqueous phase was collected, mixed with an equal volume of isopropanol 
and 1/10 volume of sodium acetate, and stored overnight at -70°C. DNA was pelleted by 
centrifugation, air dried and resuspended in nuclease-free water. 
High Molecular Weight DNA Extraction for Southern blotting: Bacteria were transferred 
to 2ml microcentrifuge tubes and heated at 80°C for 20 minutes. Tubes were centrifuged 
and the bacteria were resuspended in 500111 of TE buffer (lOOmM Tris/HCl - pH 8.0, 
lOmM EDTA). Lysozyme (lOmg/ml) was added and tubes were incubated at 37°C 
overnight. 70111 of 10% SDS and 10111 of proteinase K (lOmg/ml) were added and tubes 
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were incubated at 65°C for 20 minutes. 100~1 of NaCI (5M) and 100~ of CTABlNaCI 
were added, tubes were vortexed and incubated at 65°C for 10 minutes. 750~1 of 
chloroform-isoamylalcohol was added to each tube, tubes were vortexed and centrifuged. 
Aqueous phase was transferred to new tubes and mixed with 550~1 of isopropanol. 
Tubes were then incubated ovemight at -20°C. DNA was pelleted by centrifugation, 
washed with cold 70% ethanol and air-dried. The pellet was re-suspended in TE buffer. 
RNA extraction. Bacteria was grown to an OD600 of 0.3 to 0.5, pelleted by 
centrifugation (3000rpm, 10 minutes), resuspended in 1 ml of washing buffer (0.5% 
Tween 80, 0.8% sodium chloride) and transferred to 2ml screw-cap tubes. This 
suspension was centrifuged and the pellet was resuspended in 400~1 fresh lysis buffer 
(Na-acetate 20 mM, SDS 0.5%, EDTA ImM), after which lm! of acidified 
phenol:chloroform (5:1, pH 4.5; Ambion) and 0.8g of silica beads (Sigma) were added to 
the tube. Bacteria were lysed by agitation using a reciprocal shaker (FastPrep FP120, 
Savant Bio 101) set at a speed of 6.5 for 15s, followed by 4.5 for 15s. The tubes were 
incubated on ice for 10 min and then centrifuged at 4°e. The aqueous phase was 
transferred into a new tube and was replaced with 300~1 of lysis buffer. Cell lysis and 
collection of the aqueous phase was repeated three time. An equal volume of 
chloroform-isoamylalcohol (24:1) was added to the pooled aqueous phase (-800~1), 
tubes were mixed by inversion and centrifuged at 4°C. RNA was precipitated by adding 
an equal volume of isopropanol and 1110 volume of sodium acetate (Ambion) to the 
aqueous phase and stored ovemight at -20°e. RNA was pelleted by centrifugation at 
4 oC, washed with 70% ethanol and air dried for 10 minutes. The pellet was re-suspended 
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in RNase-free water (Ambion). Genomic DNA contamination was digested with DNase-
1 (Fermentas) and RNA was purified with RNeasy Purification Kit (Qiagen), following 
the manufacturer' s protocol. The quality of RNA was confirmed by denaturing gel 
electrophoresis (formaldehyde). 
Protein preparation and immunoblot analysis. 
Protein preparation BCG Complemented Strains: Cultures were grown in 7H9 media on 
a rolling platform for 7 days. The cultures were then centrifuged and the supernatant was 
filtered with a 0.22um membrane filter and concentrated with an Amicon Ultra-15 
CentrifugaI Filter Unit, 10 000 MWCO. Cell pellets were frozen and whole celllysates 
were prepared by resuspending the cell pellet in 100ul PBS and boiling for 20 minutes. If 
necessary, the culture filtrate proteins (CFP) were precipitated by the following protocol: 
1 volume of sample was mixed with 3 volumes of methanol, 1 volume of chloroform, 4 
volumes of water. Samples were centrifuged at max speed (-13200rpm) for 1 minute. 
The upper phase was removed and replaced with 4 volumes of methanol and mixed 
briefly. Protein was pelleted at max speed for 15 minutes (Wessel and Flugge, 1984). 
Protein was re-suspended in 100ul PBS and the final concentration was determined using 
Coomassie Plus Protein Determination Kit (Pierce) following standard protocol. 
Immunoblotting - MPB64: 5/l1 of the concentrated CFP for each strain was added to an 
equal volume of SDS-Ioading buffer, heated at 80°C for 5 minutes, and loaded into each 
lane. SDS-PAGE was performed under reducing conditions using the Mini-PROTEAN 3 
electrophoresis system (Biorad) with 10% polyacrylamide gels. Proteins were transferred 
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to a polyvinylidene difluoride membrane. Membranes were blocked in PBS containing 
2% BSA and 0.05% Tween 20, and then probed with primary antibodies for 1 hour at 
room temperature. Bound antibodies were recognized by horseradish peroxidase-Iabelled 
anti-mouse Ig. AIl antibodies were diluted in PBST with 1 % BSA. Mouse monoclonal 
antibody L24b4 (Oettinger and Andersen, 1994) was used at a dilution of 1/50 and the 
HRP-conjugated anti-mouse antibody was used at a dilution of 1110000. Protein bands 
were detected using ECL Plus™ Western Blotting Detection Reagents (Amersham). 
Immunoblotting - MPB70 and MPB83: A total of lOJ..Lg of CFP for each sample or 2ul of 
cell lysate was loaded in each lane. Samples were added to SDS-Ioading buffer and 
heated to 80°C for 5 minutes. SDS-PAGE was performed under reducing conditions 
using the Mini-PROTEAN 3 electrophoresis system (Biorad) with 12% polyacrylamide 
gels. Proteins were transferred to a polyvinylidene difluoride membrane. Membranes 
were blocked in PBS containing 2% BSA and 0.05% Tween 20, and then probed with 
primary antibodies for 1 hour at room temperature. Bound antibodies were recognized by 
horseradish peroxidase-Iabelled anti-mouse Ig. AlI antibodies were diluted in PBST with 
1 % BSA. Mouse monoclonal antibodies 1-5C (anti-MPB70) and MBS43 (anti-MPB83) 
(Wiker et al., 1998) were used at a dilution of 1/500 and the HRP-conjugated anti-mouse 
antibody was used at a dilution of 1/10000. Protein bands were detected using ECL 
Plus™ Western Blotting Detection Reagents (Amersham). 
BCG Strains Protein Preparation and Immunoblotting - MPB70 and MPB83: BCG 
strains were cultivated as surface pellicles on liquid synthetic Sauton medium for 3 weeks 
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at 37°C. The bacteria were washed and disrupted by a bead beater to yield a cellular 
extract and the culture medium was filtered to remove residual bacteria and concentrated 
by ammonium sulphate precipitation at 80% saturation. The antigens were separated 
under reducing conditions by horizontal sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) in precast 8-18% gradient Excel gel using a Multiphor II 
unit 2117 (Amersham Pharmacia). After separation, the proteins were transferred to a 
nitrocellulose membrane (pore size, 0.2 /lm) by diffusion blotting (Olsen and Wiker, 
1998) and the gel was stained with CBB. The membranes were blocked with PBS 
containing 2% bovine serum albumin (BSA) and 1 % gelatin and incubated with 
antibodies overnight. Bound antibodies were recognized by horseradish peroxidase-
labelled anti-rabbit or anti-mouse Ig. As substrate, 3,3-diaminobenzidine was added to 
visualize the bound antibodies. 
Southern blotting. 2/lg of DNA was digested with Pvull at 37°C for 1 hour. Digested 
DNA was run on a 0.8% agarose gel at 60V overnight. The gel was exposed to UV for 
10 minutes and then incubated in HCI (0.25M) for 10 minutes and twice with NaOH 
(O.4M) for 20 minutes. DNA was then transferred to a nylon membrane (Amersham) and 
the membrane was incubated with 4x SSC (0.6M NaCI, 60mM sodium citrate, pH7.0) for 
10 minutes. Probes were amplified by PCR using primers for the Rv 1986 gene of RD2 
and for the IS6110 sequence and labeled with an ECL-Iabeling kit (Amersham), 
following manufacturer's protocol. Membranes were pre-hybridized at 42°C for 1 hour 
and hybridized with the ECL-Iabeled probes at 42°C overnight. Membranes were 
washed once with 5x SSC (0.75M NaCI, 75mM sodium citrate, pH7.0) for 5 minutes, 
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twice with wash buffer (0.3x SSC, 0.4% SDS) for 15 minutes and twice with 2x SSC 
(O.3M NaCI, 30mM sodium citrate, pH7.0) for 5 minutes. Probes were detected using 
ECL Direct Nucleic Acid Detection System (Amersham). 
PCR amplification and sequencing across Rv0445c (sigK). The sequence of Rv0445c 
(sigK) was determined by amplifying the gene and flanking regions from isolates of M. 
canettii, M. tuberculasis H37Rv, M. tuberculasis H37Ra, M. africanum (n = 2), M. 
micrati (n = 2), M. caprae (n = 2), M. bavis (n = 2) and 13 members of the BCG family -
BCG Russia (ATCC 35740), BCG-Moreau, BCG-Japan, BCG-Sweden, BCG-Birkhaug 
(ATCC 35731), BCG-Prague, BCG-Glaxo (ATCC 35741), BCG-Denmark 1331 (ATCC 
35733), BCG-Tice (ATCC 35743), BCG-Frappier (ATCC 35735), BCG-Connaught, 
BCG-Phipps (ATCC 35744) and BCG-Pasteur 1173. The sequence was amplified using 
the primers sigKL (5'- agctcgagcagctcaaaatc -3') and sigKR (5'- acgcgtcaccccaactact -3') 
and amplicons were sequenced by di-deoxy terminal sequencing at the McGill University 
and Genome Quebec Innovation Center. To look for differences between the amplified 
sequence and the prototype genome sequences, results were compared by BLAST 
analysis to M. tuberculasis H37Rv using Tuberculist 
(http://genolist.pasteur.fr/TubercuListl), M. tuberculasis 210 and CDC1551 using the 
sequences provided at NCBI (http://www.ncbi.nlm.nih.gov/sutils/genom_table.cgi). M. 
bavis AF2122/97 using Bovilist (http://genolist.pasteur.frlBoviList/), and the assembly 
sequence of BCG Pasteur (http://www.sanger.ac.uk/cgi-binlblast/submitblast/m_bovis). 
Real-time quantitative RT -PCR. Targeted gene expression levels were determined 
using RT-PCR with molecular beacons or SYBR green, according to established 
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protocols (Manganelli et al., 1999;Mostowy et al., 2004). In brief, RNA was extracted 
from log-phase cultures and converted to cDNA using reverse transcriptase (Fermentas) 
and random hexamer primers, following the manufacturer's protocol. cDNA was 
amplified using a Roche LightCycler with the Roche LightCycler-FastStart DNA kit 
using fluorescent molecular beacons specifically designed for the genes of interest or 
with the LightCycler-FastStart DNA SYBR Green Kit. To provide a normalization 
standard for mRNA expression, expression of sigA was also determined, and the level of 
expression of the gene of interest was divided by that of sigA to normalize for differences 
in total rnRNA extracted (Manganelli et al., 1999). Sequences of the primers used for 
molecular beacon and SYBR green analysis and the sequences of the molecular beacons 
used are as listed in Table 2.1. 
Microarray Analysis. Microarray hybridization and analysis were done as previously 
described (Mostowy et al., 2004). In brief, rnRNA from BCG strains and complemented 
strains was extracted during log-phase in vitro growth and labeled with Cy3 or Cy5 dUTP 
by reverse-transcriptase (Amersham Biosciences). Labeled cDNA was hybridized to 
microarrays composed of oligonucleotide probes from the TB Array-Ready Oligo Set™ 
(Operon) that had been printed onto Sigmascreen ™ microarray slides (Sigma). 
Comparisons were performed between M. tuberculosis H37Rv and M. tuberculosis 
H37Rv8RD2, between BCG Russia and BCG Pasteur, between BCG Birkhaug and BCG 
Denmark, and between Pasteur::sigK and Pasteur::pMV306 (empty vector). In each case, 
duplicate hybridizations were performed for each dye combination (Cy3/Cy5 and 
Cy5/Cy3), resulting in four hybridizations per comparison. Hybridized arrays were 
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scanned with Scanarray 5000XL (PerkinElmer, Freemont, Calif.) and hybridization 
results were quantified with Scanalyze software (http://rana.Stanford.EDU/software/). 
Array analysis was performed as previously described (Mostowy et al., 2004) in order to 
determine a Z-score, indicative of how many standard deviations a data point lies from 
the population mean, for each gene. Z-scores for each gene were averaged across 
replicates within each experiment to minimize the probability of observing such variation 
by chance alone and genes with average Z-scores of 2 or greater are presented. 
Growth Curves. Stationary or rolling cultures of the selected strains were passaged with 
a 25-gauge needle to establish a single-celI suspension. The optical density at 600nm 
(OD600) was measured and the cultures were diluted to the desired initial density in 7H9 
media in triplicate. CelI density of each culture was measured daily by removing 0.8ml 
aliquot from each culture, passaging each aliquot through a 25-gauge needle to remove 
clumps and measuring the OD600. 
THP-l Infections. THP-l celIs were seeded in 24-welI tissue culture-treated plates 
(Falcon) at a density of 1.0 x 105 celIs per weIl in complete RPMI media with 100nM 
phorbol 12-myristate 13-acid (PMA; Sigma). CelIs were incubated at 3rC with 5% CO2 
for 48 hours, at which time celIs were washed and incubated in RPMI media with 
100U/ml recombinant human IFNy (BioDesign International) for 24 hours. For each 
infection, bacterial cultures were grown to mid-log phase, quantified by measuring the 
OD600, diluted in warm RPMI and added to each weIl at an MOI of 1, 10,25 or 50. CelIs 
were incubated at 37°C with 5% C02 for 4 hours, after which the celIs were washed three 
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times in warm RPMI. Complete RPMI was added to each well and cells were incubated 
at 37°C with 5% COz for 20 hours (total infection time 24 hours). Cytotoxicity was 
determined by measuring the metabolism of an oxidation-reduction dye (AlamarBlue; 
Biosource International). AlamarBlue was diluted in warm RPMI and added to each well 
for 6 hours, at which time the OD600 and OD570 of each sample were measured. 
Percentage of reduction of AlamarBlue was calculated according to the manufacturer' s 
instructions. 
Vaccination of mice. Bacterial cultures were grown to mid-log phase and re-suspended 
in PBS at a concentration of 107/ml. Inoculum doses were confirmed by serial dilution 
plating on 7HlO agar containing hygromycin (mpb64) or kanamycin (sigK). Mice were 
immunized by subcutaneous infection at the base of the tail with 106 bacteria in 100J..Ù of 
PBS using a 1.0-ml insulin syringe. 
Mouse Splenocytes and IFNy quantification. Four weeks after vaccination, mice (5 per 
group) were sacrificed by COz inhalation and the spleens were removed and placed in 
HBSS with 2% FBS. Spleens were passed through a nylon mesh filter and rinsed with 
HBSS with 2% FBS. Cells were pelleted and re-suspended in ACK buffer for 5 minutes 
to lyse red blood cells. Cells were washed three times with complete RPMI. Cells were 
plated in 96-well plates at a density of 5.0 x 105 cells per well in complete RPMI with 
various concentrations of antigens (RPMI alone, concanavalin A, MPB70 - MPB70 was 
provided by Harald Wiker). After 72 hours of culture, IFNy was quantified in seriaI 
77 
dilutions of supernatant by ELISA (BD Biosciences Pharmingen; San Jose, Ca) according 
to the manufacturer' s protocol. 
Intravenous infection of mice. For growth studies, naïve mice were infected with 106 
bacteria in 100J..lI of PBS intravenously. For challenge studies, mice were infected with 
106 bacteria in 100J..lI of PBS intravenously 10 weeks after vaccination. Bacterial cultures 
were grown to mid-log phase and re-suspended in PBS at a concentration of 107/ml. 
Inoculum doses were confirmed by seriai dilution plating on 7HlO agar. Mice were 
placed in a restraining cone and infected by injecting 100 J..lI in the caudal tail vein with a 
1.0-ml insulin syringe. On the indicated days, mice were sacrificed by CO2 inhalation. 
The lungs and spleen were removed and placed in 0.025% saponin-PBS on ice. Tissue 
homogenates were prepared with a Polytron PT 2100 bench-top homogenizer 
(Kinematica AG, Lucerne, Switzerland). The Polytron was washed sequentially in 
distilled H20-0.05% SDS-70% ethanol-PBS before the next organ was processed. 
Seriai dilutions of the organ homogenates were plated on 7H 1 0 agar containing 
hygromycin or kanamycin. For histopathologic evaluations, the renal vein was eut, and 
20 ml of PBS followed by 20 ml of 10% formalin was perfused via the left atrium with a 
30-ml syringe. Organs were embedded in paraffin, mounted, and stained with 
hematoxylin and eosin and for AFB. 
Statistical Methods. Data was analyzed by ANOVA and Kruskal-Wallis methods. For 
the ANOVA method, differences between means were assessed by Tukey's test. Ap 
value of <0.05 was considered significant. 
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TABLE 2.1 Sequences of Primers 
NAME OF PRIMER SEQUENCE 
RD2 Deletion 
RD2R5 
RD2L5 
RD2R3 
RD2L3 
NewRD2R5 
New RD2L5 pKO 
New RD2L5 p2NIL 
NewRD2F3 
NewRD2R3 
5' - caatgtcaccgatcgtcg - 3' 
5' - ccgatgatcttctgtttgacc - 3' 
5' - ggtggtcgccgtggagttg - 3' 
5' - tacaactgcgacaaagcgtc - 3' 
5' - ataaaagcttaacaaaatacatcatcgcgcc - 3' 
5' - ataagcatgcccgatgatcttctgtttgacc - 3' 
5' - ataacacgtgccgatgatcttctgtttgacc - 3' 
5' - ataaggatccggtggtcgccgtggagttg - 3' 
5' - ataaggtacctggcggagggagtgttcgt - 3' 
mpt64 Complementation 
MPT64compF 
MPT64compR 
5' - ataaaagcttcggtgctgcaaactactcc - 3' 
5' - ataaggtaccgtctaggccagcatcgagtc - 3' 
sigK Complementation 
Rv0445cL 
sigKR 
Molecular Beacons 
sigA 
sigK 
mpb70 
mpb83 
5' - agctcgagcagctcaaaatc - 3' 
5' - acgcgtcaccccaactact - 3' 
5' - cctcgcgtcgaagttgcgccatccgagcgagg - 3' 
5' - gcagcctgtcgaccgagtccgttggctgc - 3' 
5' - gcagccagctcaatccgcaagtaaacctgggctgc - 3' 
5' - gcagccagcatcctgacctaccacgtgaggctgc - 3' 
Beacon and SYBR green Primers 
sigA 
sigK 
mpb70 
mpb83 
dxr 
Rv2871 
Rv2872 
dipZ 
Rv2876 
Rv2877c 
mpb53 
Rv2879c 
Rv2880c 
cdsA 
Rv0441c 
PPEIO 
Rv0443 
Rv0444c 
Rv0446c 
ufaAl L 
Rv0448c 
Rv0449c 
mmpL4 
mmpS4 
Left Primer 
5' - tgcagtcggtgctggaca - 3' 
5' - agtttgactccgccaaaggt -3' 
5' - ctcgaacaatccggagttgaca - 3' 
5' - atcaactcaagactgacgccaaac - 3' 
5' - gggacttgaggtcatcgaaa - 3' 
5' - gtatcgatgacgagctgtacc - 3' 
5' - gactatcggggtttgcttga - 3' 
5' - tcggttggtatcaggcctac - 3' 
5' - agtgggagttcgacgtcagt - 3' 
5' - ggttccatgtatggctacgg - 3' 
5' - gttcggtctggccaatacac - 3' 
5' - gcgacgggtgtctattgagt - 3' 
5' - aacacggtctgcatttcctc - 3' 
5' - tggtcgttgtctgcatgatt - 3' 
5' - tgggtgccaaaaaggtagac - 3' 
5' - caattcggcactgatgtttg - 3' 
5' - cgggtgcaggatatacaggt - 3' 
5' - ggccgagcaagttctgac - 3' 
5' - tggcaactgtgggtattcaa - 3' 
5' - ccgacctttcgacctagttg - 3' 
5' - cttctacgtttcgccgtttc - 3' 
5' - cccacacccactatctggac - 3' 
5' - ctaaattcgcgaacgactcc - 3' 
5' - cctggaaaacagcaaaccat - 3' 
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Right Primer 
5' - cgcgcaggacctgtgagc - 3' 
5' - gcaccatagcgcacttcc - 3' 
5' - acaccgtgtactgaccgctgtt - 3' 
5' - caccttgcagggtctgatgg - 3' 
5' - tatggaaatcacaggcagca - 3' 
5' - ttggacgatagatcgacacc - 3' 
5' - tcaacatcggacgctaactg - 3' 
5' - ggtccaagtggcgtagttgt - 3' 
5' - acgtgatcaggaaccagtcc - 3' 
5' - agccagatagatcgctacgc - 3' 
5' - cgtccagaaccacaacacc - 3' 
5' - taccgtgcaggaaactcctt - 3' 
5' - cccatacccatgaacaccac - 3' 
5' - gagccattttccgggtagac - 3' 
5' - ccacaacagggtgacttcg - 3' 
5' - caggctaggtactgggttgc - 3' 
5' - tagtaccccgacagcaggtc - 3' 
5' - gcagccacatctgatacacg - 3' 
5' - cagcaggtaggtcatcagca - 3' 
5' - tgaacattgcgcacgaatac - 3' 
5' - tcatcgcgatctgtcttgtc - 3' 
5' - acatcgacatttccgactcc - 3' 
5' - cttccagtgacgggacaaat - 3' 
5' - ccacgatatttcccatcacc - 3' 
3. Results 
3.1. Characterizatian afthe RD2 regian 
BCG was derived from Mycabacterium bavis by continuous in vitra passaging 
during the years 1908-1921. Through genomic studies, it is now known that the RD1 
region, which is present in aIl virulent M. bavis isolates, is deleted from aIl strains of 
BCG and has been identified as the attenuating mutation leading ta the derivation of 
BCG. From 1921 to 1961, BCG were continually propagated in vitra, in numerous 
laboratories worldwide under a variety of conditions, until BCG Pasteur 1173 was 
lyophilized for storage and preservation after 1173 bi-weekly passages. Given that BCG 
arose from a mutation that occurred during in vitra growth, it has been speculated that 
subsequent mutations may have had an additional impact on characteristics such as 
growth, virulence and antigenicity - all of which may affect the ultimate phenotype upon 
which BCG is evaluated, its protective efficacy. RD2, encompassing Il ORFs and 
missing from BCG strains obtained from the Pasteur Institute after 1931, represents su ch 
a mutation. The significance of RD2, in terms of the ability of BCG strains to grow, 
persist, stimulate an immune response and protect against tuberculosis is presently 
unknown. The genes in the RD2 region include major antigenic proteins, a PE family 
protein and a probable transcriptional regulator, aIl of which can be proposed to play a 
significant role in the ability the of bacteria to interact with or adapt ta the hast 
environment, and thus upon their deletion, result in further attenuation. 
To evaluate any potential phenotype arising from the deletion of RD2, three 
approaches were pursued: 1) A late strain of BCG was complemented with the gene 
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mpb64 to evaluate the possibility that expressing MPB64 may increase its protective 
efficacy in a mouse challenge experiment; 2) aM. tuberculosis RD2-knockout strain, 
H37Rv~RD2, was created in the laboratory of David Sherman, at the University of 
Washington (Seattle, Washington), and evaluated for in vitro growth, cytotoxicity in a 
monocytic cell line and overall changes in gene expression; and 3) early and late 
strains of BCG were compared for differences in global gene expression, with an 
intent of revealing any potential phenotypes for subsequent targeted study. 
3.1.1. MP B64 Over-expression 
The loss of antigenic proteins from the later strains of BCG has been proposed 
to contribute to the lack of efficacy in sorne clinical trials (Behr, 2002) and the 
importance of extracellular proteins in developing a protective immune response has 
been demonstrated by successfully protecting guinea pigs against a M. tuberculosis 
challenge by vaccinating with extracellular antigens (Pal and Horwitz, 1992;Horwitz 
et al., 1995). In the RD2 region, the gene mpt64 encodes for the highly antigenic 
protein, MPT64, that has been previously identified as a candidate for new vaccines. 
To determine if the loss of this antigenic prote in has impacted on the degree of 
protective immunity generated by BCG, BCG Denmark was complemented with 
mpb64, expressed with the MOP promoter on an integrating plasmid, creating the 
strain BCG Denmark::mpb64. The mycobacterial optimal promoter, MOP, is an 
artificial promoter region derived from promoter sequences from the BCG heat shock 
protein gene, hsp70, and an Escherichia coli tac promo ter and is engineered to induce 
high gene expression from the plasmid. 
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First, expression of mpb64 in the complemented strains was assessed. Figure 
3.1 a shows the expression of mpb64 in three complemented strains, as weIl as BCG 
Russia (an early strain with an intact an RD2 region) and BCG Denmark (a late strain 
with deletion of the RD2 region). As expected, expression was detected in BCG 
Russia and no expression was found in BCG Denmark. Expression was detected in 
aIl three complemented strains examined and each strain showed greater expression 
than BCG Russia. To verify that gene expression correlated with protein production, 
the culture filtrate proteins from the complemented strains were analyzed qualitatively 
by immunoblotting for MPB64. As shown in Figure 3.1b, MPB64 could be detected 
in the culture filtrate proteins of the complemented strains, indicating that, similar to 
BCG Russia, these strains can produce and secrete the protein. Protein samples for 
immunoblotting were not prepared from the same cultures that were used to determine 
gene expression and thus the RNA expression values do not correlate with the 
quantity of protein detected in cultures. In related work, Horwitz and colleagues 
created recombinant strains of BCG that overexpress Ag85B. Although this antigen 
is present in all strains in BCG, vaccination with the recombinant strains displaying 
increased Ag85B production conferred enhanced protection against an M. 
tuberculosis challenge in guinea pigs and greater expression of the antigen correlated 
with better protection (Horwitz et al., 2000). Based on these results, the strain of 
BCG Denmark that expresses the highest level of mpb64 was selected for further 
studies as it presents the greatest potential to highlight any improvement in vaccine 
efficacy attributable to MPB64. 
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The ability of the BCG Denmark::mpb64 strain to induce a protective response 
was evaluated in C57BL/6 mice. Mice were vaccinated subcutaneously with either 
BCG Denmark::pKZ4 (empty vector control) or BCG Denmark::mpb64 and 
subsequently challenged by intravenous infection with BCG Russia. The latter strain 
was selected as a surrogate of a virulent strain in which the RD2 region is intact, 
because at the time of the experiment, construction of the level 3 laboratory was 
incomplete and experiments with M. tuberculosis were not permitted. Protection was 
determined by enumeration of colony forming units (CFU) of BCG Russia in the 
spleen and lungs of infected mice at four and eight weeks following the challenge. At 
both time points, protection induced by vaccination with either strain was greater in 
the lungs than in the spleen. The reduction of CFU in the spleens of mice vaccinated 
with either strain, compared to unvaccinated mice (sham-vaccinated with PBS), was 1 
log at four weeks and 0.5 log at eight weeks. In the lungs, at four weeks, vaccination 
with BCG Denmark::pKZ4 induced a 1.3 log reduction in CFU compared to 
unvaccinated mice. In mice vaccinated with BCG Denmark: :mpb64, however, CFU 
in the lungs were reduced an additional 0.3 log compared to BCG Denmark::pKZ4 
vaccinated mice (figure 3.2). This difference was no longer observed after eight 
weeks, at which time an equal 1 log reduction in CFU was seen in mice vaccinated 
with either vaccine. 
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3.1.2. Attempted deletion of RD2 in BCG and subsequent RD2 deletion in 
M. tuberculosis H37Rv 
In attempt to deI ete the RD2 region from early strains of BCG, three constructs 
were made using two plasmids, pKO and p2NILlpGOALI9. The first construct, 
pKO-RD2, contained a downstream homologous region of 953 bp and an upstream 
homologous region of 730 bp flanking a kanamycin resistance cassette, which would 
allow for the knockout strain to be marked with kanamycin resistance. In addition to 
the kanamycin resistance cassette, both plasmids also contained a hygromycin 
resistance cassette. BCG Russia, BCG Sweden and BCG Birkhaug were 
electroporated and plated on 7HlO with hygromycin for selection of integration of the 
plasmid. Site-specific integration at either the downstream or the upstream 
homologous region was screened for by PCR. Approximately 20% of the colonies 
screened had downstream site-specifie integration of the plasmid and no colonies with 
upstream site-specifie integration were identified. Colonies with site-specific 
integration were re-plated on 7HlO medium containing sucrose as a counter-selection 
method conferred by the presence of the sacB gene on the plasmid. Two outcomes 
arose upon plating of the site-specifie integrants on sucrose-containing plates, either 
very few colonies grew on the selective medium over the course of 4-6 weeks, or very 
high growth was seen with colonies forming within 1-2 weeks. The colonies 
appearing on the plates at 4-6 weeks were screened for each of the three expected 
outcomes: 1) deletion of the RD2 region; 2) reversion to wildtype by loss of the 
plasmid; or 3) growth on sucrose with maintenance of the plasmid by inactivation of 
the sacB gene. 
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Although the sacB gene may alIow for a high degree of selection, reduction of 
selective power, presumably by inactivation of sacB, has been reported (Pavelka, Jr. 
and Jacobs, Jr., 1999). AlI colonies appearing on these plates were screened for the 
loss of the RD2 region, as weIl as the presence of the plasmid. No strains having lost 
the RD2 region were identified and greater than 90% of the colonies screened had 
maintained the plasmid, as detected by PCR. 
The majority of the plates on which colonies appeared at 1-2 weeks could not 
be screened due to the high density of colonies. When isolated colonies could be 
selected, screening by PCR indicated maintenance of the plasmid. This suggested that 
a mutation in the sacB gene was acquired in the parent colony prior to plating on 
sucrose. For further experiments, such plates were not analyzed. 
A two-plasmid system was developed by Parish and Stoker (Parish and Stoker, 
2000), which consisted of a manipulation vector and a second vector containing 
various marker genes, in our case selected to inc1ude sacB for counter-selection. This 
allowed for the addition of the selection markers at a single restriction site in the 
manipulation vector subsequent to the c10ning of the homologous regions. The 
construct pNIL/pGOAL-RD2 was created using the same homologous regions as the 
pKO-RD2 construct. Approximately 70% of colonies screened from hygromycin 
selection were single cross-overs with downstream site-specifie integration of the 
plasmid. No upstream site-specifie integration was detected. AlI colonies that were 
positive for site-specific integration were plated on sucrose for selection of double 
cross-over transformants. Approximately 50% of colonies screened from sucrose 
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selection had maintained the plasmid while retaining the RD2 region. The vast 
majority of the remaining colonies screened were positive for detection of the RD2 
region and negative for the plasmid, suggesting a reversion to wild-type. 
Upstream site-specifie integration of the plasmid was detected in five colonies 
selected off sucrose plates, aIl of whieh arose from one parent colony. Since initial 
site-specifie integration in the parent colony was at the downstream region, this was 
suggestive of a double recombination event leading to the elimination of the RD2 
region. Both upstream and downstream site-specifie integration were confirmed by 
PCR in each of the five colonies. Further characterization of these colonies, however, 
also revealed the continued presence of mpt64, a gene in the RD2 region, and both the 
hyg and kan genes present on the plasmid. Examination of these cultures by PCR and 
Southern blotting for the possibility of these being mixed cultures containing an RD2-
knockout were inconc1usive and additional attempts to isolate the knockout were 
unsuccessful. 
A second pKO-based construct was designed with longer regions of homology 
flanking the kanamycin resistance cassette. Parish et al. demonstrated that in six of 
seven constructs used to knockout various genes involved in amino acid synthesis, 
recombination occurs preferentially on the side with the longer flanking region and 
although elimination of the gene of interest requires recombination at both flanking 
regions, a size greater than lkb was suggested to be beneficial (Parish et al., 1999). 
The upstream region in the second pKO-RD2 construct was 1290bp in length and the 
downstream region was 1472bp. Similar to the first pKO construct, aIl site-specifie 
integration of the plasmid in the colonies screened from the hygromycin selection was 
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downstream site-specific integration. No RD2-knockouts were identified from the 
colonies screened from the sucrose selection. 
In parallel, efforts were expended to also attempt to directly delete the RD2 
region from virulent M. tuberculosis H37Rv. Because the level 3 containment 
laboratory was not yet completed at McGill, this work, using the methodology 
outlined above, was performed in the laboratory of David Sherman, at the University 
of Washington. Deletion of the RD2 region was obtained in both M. tuberculosis 
H37Rv and M. tuberculosis H37Rv~RDl, and confirmed by Southern blot (Figure 
3.3). 
3.1.3. H37RvLfRD2 Growth Characterization 
To assess the impact of the loss of the RD2 region, we first examined the in 
vitro growth characteristics of the M. tuberculosis H37Rv~RD2 strain. The in vitro 
growth curve of H37Rv~RD2 was indistinguishable from that of H37Rv, as shown in 
Figure 3.4. The growth rates of the two strains in lag and log phases of growth were 
similar and the strains reached similar maximum densities. 
Cytotoxicity to THP-l cells caused by infection with M. tuberculosis can be 
observed as a decrease in cellular metabolism of an indicator dye, alamar blue. 
Infection of THP-l cells with M. tuberculosis H37Rv results in destruction of the cell 
mono layer over the course of the infection and a decrease in cell metabolism, 
resulting from cell death (Lewis et al., 2003). Contrary to H37Rv, infection with an 
attenuated strain of M. tuberculosis, as demonstrated by infection with M. 
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tuberculosis H37RvLlRDl (Lewis et al., 2003), does not result in either a decrease in 
metabolism or destruction of the monolayer. To assess what degree of attenuation, if 
any, resulted from the deletion of the RD2 region, THP-l cells were infected with 
H37Rv or H37RvLlRD2 and cell metabolism was determined four and seven days 
following infection. H37Rv and H37RvLlRD2 both induced a high degree of cell 
death, as determined by a significant decrease in metabolism of alamar blue (figure 
3.5) and destruction of the cell monolayer (data not shown). There was no difference 
between these strains suggesting that the loss of RD2 may not lead to any loss of 
virulence of M. tuberculosis, as measured by cytotoxicity to host macrophage-like 
cells. 
3.1.4. Microarray of Early BCG vs. Late BCG and Identification of 
mpb70/mpb83 
In an attempt to identify potential phenotypes arising from the loss of the RD2 
region, global gene expression of selected early strains of BCG was compared to that 
of late strains of BCG by whole genome microarray. The results summarizing the 
direct comparison of BCG Russia with BCG Pasteur and BCG Birkhaug with BCG 
Denmark are presented in Table 3.1. The genes that were consistently found to be 
differentially expressed between early BCG and late BCG were limited, many of 
which were annotated as conserved hypothetical proteins (open reading frames 
encoding conserved elements of unknown function). Of particular note, however, 
were the genes mpb70 and mpb83. MPB70 and MPB83 have been previously 
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identified as antigenic proteins that are highly produced in sorne strains of BCG, but 
almost undetectable in others. 
To confirm the microarray results, quantitative RT-PCR was used to compare 
the expression of these genes in the same strains of BCG that were used for the 
microarray comparisons. Expression of mpb70 and mpb83 was significantly higher in 
the early strains (BCG Russia and BCG Birkhaug) compared to the late strains (BCG 
Denmark and BCG Pasteur), with a ca1culated difference of greater than 50-fold 
(Figure 3.6). 
This difference was further confirmed by immunoblotting of culture filtrate 
proteins and whole-cell extracts from aIl BCG strains (Figure 3.7). MPB70 is a 
secreted protein, thus detectable in the CFP, and MPB83 is a membrane-bound 
protein and most often detectable in the cellular extracts, although can also be found 
in the CFP. MPB70 and MPB83 were both clearly detected in aIl early strains, while 
in late strains of BCG, MPB70 was undetectable and MPB83 was only faintly 
detectable. These results correlate with the subset of strains previously identified as 
being either high- or low-producers of MPB70 and MPB83. 
3.1.5. Microarray H37Rv vs. H37RvMD2 and Expression ofmpt70/mpt83 
From the previous results indicating a concurrence of the high-producing strains 
with the presence of the RD2 region and the low-producing strains with its absence, 
we hypothesized that the reduction in expression of mpb70 and mpb83 could be 
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consequential to the deletion of the RD2 region. To examine this possibility, whole 
genome microarray comparison of gene expression between H37Rv and H37Rvi1RD2 
was used. The only genes consistently observed to be down-regulated in the deletion 
mutant were genes of the RD2 region itself, suggesting that transcription of genes in 
the RD2 region does not significantly influence expression of genes outside of this 
region during standard laboratory in vitro growth (data not shown). Notably, neither 
mpt70, nor mpt83 were identified as differentially expressed as a function of RD2 
disruption. 
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3.2. Reduced expression of mpb70 and mpb83 is due to a start codon mutation in 
sigK 
The identification of antigenic proteins that induce a strong cellular immune 
response during M. tuberculosis infection has been a major focus in TB vaccine 
development. MPB70 was isolated from the culture filtrate of BCG Tokyo and was 
found to account for more than 10% of the secreted proteins (N agai, Matsumoto, and 
Nagasuga, 1981). The abundance of this protein in the culture filtrate and the high 
reactivity of BCG-sensitized animaIs to MPB70 instigated further characterization of 
this protein. Sensitization of guinea pigs with various strains of BCG and 
subsequently testing for DTH responsiveness to MPB70 revealed that not all strains 
of BCG induced reactivity to the protein (Miura et al., 1983;Haslov, Andersen, and 
Bentzon, 1987). A highly homologous protein, showing significant cross-reactivity 
with MPB70 and similar induction of DTH response in guinea pigs, was later 
identified and called MPB83 (Harboe et al., 1995). Further characterization of BCG 
strains resulted in the division of strains into high- and low-producers of these 
proteins (Abou-Zeid et al., 1986;Wiker et al., 1996). The sequence of mpb70 in the 
high- and low-producers is identical, but analysis of mRNA and Northern blots 
revealed significantly different levels of expression between high- and low-producers 
(Matsuo et al., 1995). Further studies provided evidence that mpt83 (Rv2873) and 
mpt70 (Rv2875) form part of the same transcription al unit (Juarez, Torres, and 
Espitia, 2001). Taken together, this information suggests that the difference in 
expression between high- and low-producing BCG strains could be due to a shared 
but unknown defect in transcription. 
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3.2.1. Identification and sequencing of sigK 
As the deletion of RD2 did not impact upon the expression of mpt70 and 
mpt83 as initially hypothesized, the initial microarray data examining the differences 
in gene expression between early and late strains of BCG were revisited. A second 
region, separate from the mpt70/mpt83 region, was also significantly down-regulated 
in late (low-producing) strains of BCG. This region includes a gene encoding a 
predicted regulatory protein, annotated as a probable alternate RNA polymerase 
sigma factor classified in the extracytoplasmic function (ECF) sigma factor subfamily 
(See Table 3.1). To explore the possibility that a mutation in sigK might be linked to 
the expression phenotype, we first compared the sequence of sigK from M. 
tuberculosis H37Rv to sequences generated by the genome sequencing projects for M. 
bovis 2122 and M. bovis BCG Pasteur. Alignment se arches predicted that BCG 
Pasteur had a mutation at the third basepair of sigK, prompting formaI sequencing and 
comparison across members of the M. tuberculosis complex, including different 
strains of BCG. 
Sequencing of sigK revealed a guanine to adenine mutation at the third 
nucleotide of the coding region in low-producing strains of BCG compared to high-
producing strains, resulting in a change from the typical AUG start codon to an AUA 
start codon in the corresponding strains. The AUG start codon was observed in aIl 
members of the M. tuberculosis complex except for the eight low-producing strains of 
BCG obtained after 1927 (table 3.2). While the codon AUA has been identified as a 
functional start codon in Escherichia coli, Bacillus subtilis and Salmonella spp, levels 
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of translation are substantially reduced with this codon compared to the convention al 
AUG start codon (Romero and Garcia, 1991;Sussman, Simons, and Simons, 1996). 
3.2.2. Complementation of sigK 
As the start codon mutation corresponded precisely with the low-producing 
strains, the functional consequences of this mutation were evaluated in a low-
producing strain, BCG Pasteur, by complementing this strain with sigK with an AUG 
start codon. Using an integrating vector, pMV306, BCG Pasteur was complemented 
with wild-type sigK from M. tuberculosis H37Rv, BCG Russia or BCG Birkhaug. In 
addition, this strain was complemented with a second copy of sigK from BCG Pasteur 
(mutant sigK) and with the empty vector to serve as controls. Complementation was 
confirmed by PCR using vector-specific primers (data not shown). 
3.2.3. Expression of sigK in complemented strains 
A common characteristic of ECF sigma factors, which has been confirmed for 
other M. tuberculosis ECF sigma factors (Helmann, 2002;Manganelli et al., 2004b), is 
that their expression is auto-regulated and as such, we first determined the effect of 
sigK complementation on its own expression using quantitative RT-PCR. As negative 
controls, complementation with the empty vector or with the mutant sigK resulted in 
no change of sigK expression, shown by BCG Pasteur::pMV306 and BCG 
Pasteur::sigKPasteur. The latter indicates that introducing a second copy of the 
mutant gene did not alter levels of transcription. In contrast, complementation with 
wild-type sigK, demonstrated with BCG Pasteur::sigKH37Rv, BCG 
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Pasteur::sigKRussia and BCG Pasteur::sigKBirkhaug, showed a marked increase in 
transcription of sigK (figure 3.8). Similar results were obtained with a second clone 
of each of the same strains (data not shown). Since the mutation in sigK is predicted 
to impair translation, not transcription, and complementation of wild-type, but not 
mutant-type, sigK served to markedly increase sigK expression, these results were 
consistent with auto-regulation of this gene, as is typically observed with ECF sigma 
factors. 
3.2.4. Transcription of mpb70lmpb83 and MPB70lMPB83 production in 
complemented strains 
Expression levels of mpb70 and mpb83 in the complemented strains were 
analyzed by quantitative RT-PCR. In BCG Pasteur::sigKPasteur and BCG 
Pasteur::pMV306, levels of mRNA were comparable to those previously 
demonstrated in low-producing strains of BCG, indicating the introduction of the 
empty vector, or a second mutant copy of the gene, had no effect on mpb70lmpb83 
expression. In contrast, the same strains in which an increase in sigK expression was 
observed (BCG Pasteur::sigKH37Rv, BCG Pasteur::sigKRussia and BCG 
Pasteur::sigKBirkhaug), manifested highly increased levels of transcription of mpb70 
and mpb83, comparable to the levels observed with high-producing strains of BCG 
(figure 3.9). The same results were obtained with a second clone of the same strains 
(data not shown). 
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To determine the effect of expression of wild-type sigK in BCG Pasteur on 
protein synthesis, culture filtrate proteins and whole cell lysates from the sigK-
complemented strains of BCG Pasteur were analyzed by SDS-P AGE and 
immunoblotting. MPB70 was detected in the culture filtrate proteins from BCG 
Pasteur::sigKH37Rv, BCG Pasteur::sigKRussia and BCG Pasteur::sigKBirkhaug, but 
could not be detected in Pasteur::sigKPasteur or BCG Pasteur::pMV306 (figure 
3.10a). Similarly, MPB83 was detected in the whole celllysates of the same clones in 
which MPB70 was abundantly detected in the culture filtrates (figure 3.10b). Upon 
complementation of wild-type sigK, BCG Pasteur was able to produce MPB70 and 
MPB83 in a pattern consistent with high-producing strains. 
3.2.5. Microarray of complemented strains, qRT-PCR confirmation 
Based on observed differences in expression of the genes neighbouring sigK 
and mpb70/mpb83 by microarray-based analysis of four BCG strains, we used 
quantitative RT-PCR to determine the effect of wild-type sigK complementation on 
transcription in these regions. As shown in figure 3.11a, expression of the genes 
Rv0443c-Rv0449c was increased over 2-fold with sigK complementation. 
Transcription of Rv2874, Rv2876 and Rv2877c was increased over lO-fold in the 
sigK-complemented strains compared to the control strain. Rv2878c (mpt53) was also 
increased, although to a lesser extent, with 4-fold increase seen in the sigK-
complemented strains. Contrary to expectations from a previous study indicating that 
Rv2871-Rv2874 are co-transcribed (Juarez, Torres, and Espitia, 2001), we did not 
detect any increased expression of either Rv2871 or Rv2872, suggesting that these two 
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genes are under separate transcriptional control. Based on the differences in 
transcription, this sigK-regulated gene region includes Rv2873 through Rv2878, but 
not Rv2872 or Rv2879. (figure 3.11b). 
To further examine the role that sigK plays in global gene expression, we analyzed 
global transcription in BCG Pasteur::sigKH37Rv, BCG Pasteur::sigKRussia and BCG 
Pasteur::sigKBirkhaug compared to BCG Pasteur::pMV306 by DNA microarray 
(table 3.3). Results revealed increased expression of the majority of genes presented 
in figure 3.11, with significant changes in expression as measured by both induction 
ratios and Z-scores. There were no genes outside of either the mpb70/mpb83 or the 
sigK regions that were found to be significantly up-regulated, suggesting a high 
degree of specificity of this system. Because of the stringency of the analysis 
performed, genes whose expression was induced in 3 of 4 arrays, but who se 
expression could not be optimally quantified on the fourth, were not included in the 
table (e.g. mpb83). Only four genes were repressed with introduction of wild-type 
sigK. 
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3.3. Characterization of BCG Pasteur::sigK 
The importance of MPB70 and MPB83 emerged as their immunological 
properties were studied. Both proteins can induce cellular and humoral responses in a 
variety of animaIs inc1uding mice, rab bits , guinea pigs and cows (Miura et al., 
1983;Haslov, Andersen, and Bentzon, 1987;Hewinson et al., 1996;Wiker et al., 
1998). Although MPB70 and MPB83 are c1assically considered to be antigens of M. 
bovis rather th an M. tuberculosis, the ability of MPB70 to stimulate lymphocyte 
proliferation in a significantly greater proportion of TB patients than BCG vaccinees 
points to production of this protein during natural infection by M. tuberculosis (Roche 
et al., 1994). In fact, while the in vitro production of MPT70 in M. tuberculosis is 
comparable to the low-producing BCG strains, a strong increase in expression of both 
mpt70 and mpt83 has been observed during intracellular infection by M. tuberculosis 
(Schnappinger et al., 2003). MBP70 has also been shown to be recognized by T-cells 
from donors with a wide variety of HLA backgrounds and was suggested as a good 
candidate for subunit vaccines due to its recognizability by a high proportion of the 
population (Al Attiyah et al., 2003). To determine the consequence of high 
production of these proteins, we compared our isogenic strains of BCG Pasteur that 
either fail to produce these proteins (BCG Pasteur::pMV306 - empty vector control) 
or produce them in high quantities (BCG Pasteur: :sigK) in in vitro and in vivo models. 
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3.3.1. In vitro Growth 
To characterize the impact of expression of the sigK regulon on growth, the in 
vitro growth rates of BCG Pasteur::pMV306 and BCG Pasteur::sigKRussia were 
compared (Figure 3.12). BCG Pasteur::sigKRussia consistently displayed a longer lag 
phase, but recovered to reach a similar maximum growth rate and maximum density 
as BCG Pasteur::pMV306. Similarly, when grown on solid media, Pasteur::pMV306 
colonies consistently appeared 2-5 days earlier than Pasteur: :sigKRussia colonies. 
3.3.2. THP-l Virulence Assay 
As previously described, the level of cytotoxicity induced by an infecting 
strain can be assessed using a THP-1 ceIl infection model. THP-1 cens were infected 
with BCG Pasteur::pMV306 and BCG Pasteur::sigKRussia with an MOI of 50:1, 
25: 1, 10: 1 and 1: 1 for 24 ho urs and metabolism of the indicator dye alamar blue was 
measured as an indication of cytotoxicity (Figure 3.13). At an MOI of 1:1, the cells 
infected with either strain appeared healthy and metabolism was comparable to 
uninfected ceIls. No difference in metabolism between infected ceIls was observed. 
Metabolism of the cens infected with an MOI of 10: 1 was lower th an that of 
uninfected ceIls and those infected with BCG Pasteur::sigKRussia consistently 
displayed significantly lower metabolism than those infected with BCG 
Pasteur::pMV306. At both 25:1 and 50:1, BCG Pasteur::sigKRussia displayed 
significantly greater cytotoxicity than BCG Pasteur: :pMV306. Metabolism of cells 
infected with either strain at these MOIs was significantly lower than that of 
uninfected cens and destruction of the ceIl mono layer was evident. 
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3.3.3. Infection of C57Bl/6 mice 
Characterization of the growth of potential vaccine strains in animal models 
highlights two important characteristics of live vaccines against tuberculosis: the 
persistence of the strain and the pathogenicity of the strain. To determine if the 
expression of mpb70 and mpb83 impacts on the growth and survival of BCG Pasteur 
in an animal model, C57BL/6 mice were infected with BCG Pasteur: :pMV306 and 
BCG Pasteur: :sigKRussia. The pattern of growth of each strain was similar in the two 
infections performed. Mice were infected with an average of 2.5 x 106 CFU in the 
first experiment and 5.7 x 106 CFU in the second experiment and the infection doses 
of the strains were not significantly different within each experiment. Despite the 
same inocula, BCG Pasteur::sigKRussia consistently showed higher CFUs in the 
lungs and spleen on day 1 (Figure 3.14), although this was not statistically significant 
in either infection. By day 21 in both experiments, the CFU in the lungs and spleen 
increased to the maximum levels observed and were almost identical between BCG 
Pasteur::sigKRussia and BCG Pasteur::pMV306. In the first experiment, the BCG 
Pasteur::sigKRussia CFU increased 3.6 and 4.6 times, in the spleen and lungs 
respectively, from day 1 to day 21, whereas the BCG Pasteur::pMV306 CFU 
increased 8.3 and 8.4 times, in the spleen and lungs respectively. Similarly, in the 
second experiment, BCG Pasteur::sigKRussia CFU increased 3.6 and 2.4 times from 
day 1 compared to 6.9 and 3.8 times, in the spleen and lungs respectively, for BCG 
Pasteur::pMV306. On days 42 and 84, the CFU declined for both strains in the spleen 
and lungs, however, in the two experiments, BCG Pasteur: :pMV306 declined to lower 
levels than BCG Pasteur::sigKRussia. 
99 
3.3.4. Splenocytes - IFNrELISA 
To determine if increased expression of mpb70 in BCG Pasteur::sigKRussia 
induced an antigen-specific immune response, splenocytes were isolated from 
vaccinated animaIs four weeks following vaccination and cultured with MPB70. 
Splenocytes from animaIs vaccinated with either BCG Pasteur: :pMV306 or BCG 
Pasteur::sigKRussia responded strongly when cultured with an unspecific mitogen 
concanavalin A, but only those cultured from animaIs vaccinated with BCG 
Pasteur::sigKRussia produced IFNy in response to stimulation with MPB70. As 
shown in figure 3.15, splenocytes from BCG Pasteur::sigKRussia vaccinated animaIs 
produced high Ievels of IFNy in response to purified MPB70, while Ievels of IFNy 
from splenocytes isolated from BCG Pasteur: :pMV306 vaccinated animaIs were 
almost undetectable. Both cultures responded to CFP purified from cultures of either 
strain (data not shown). 
3.3.5. Intravenous Challenge with BCG Russia in BCG Pasteur: :pMV306 
and BCG Pasteur: :sigKRussia vaccinated mice 
To evaluate the impact of the presentation of the antigenic proteins MPB70 and 
MPB83 to the immune system on the protective response induced by vaccination with 
BCG, a mouse challenge model was used. C57Bl/6 mice were vaccinated with BCG 
Pasteur::sigKRussia or BCG Pasteur::pMV306 (subcutaneous injection with 106 CFU) 
and challenged intravenously with BCG Russia ten weeks after vaccination. As 
construction of the Ievel 3 Iaboratory for the use of M. tuberculosis was incomplete, 
BCG Russia was used as a surrogate of a virulent strain expressing both MPB70 and 
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MPB83. Vaccination with either strain reduced the bacterial load in the lungs and 
spleen of challenged mice compared to unvaccinated mice (Figure 3.16). At week 4, 
vaccination with either strain resulted in a significant reduction in CFU as compared 
to unvaccinated mice, with a 1.5 log reduction in CFU observed in the lungs and a 1.0 
log reduction in the spleen. At week 8, the reduction in bacterial load in the 
Pasteur::sigKRussia vaccinated mice compared to unvaccinated mice was 0.7 log 
greater in the lungs and 0.4 log greater in the spleen than the reduction in the 
Pasteur::pMV306 vaccinated mice. The reduction in CFU in the Pasteur::pMV306 
vaccinated mice, however, was less than anticipated and the bacterial load in the 
spleen was not significantly different from that of the unvaccinated mice. 
3.3.6. Intravenous Challenge with M. tuberculosis H37Rv in BCG 
Pasteur::pMV306 and BCG Pasteur::sigKRussia vaccinated mice 
Upon completion of the level 3 laboratory, further challenge studies were 
pursued to better characterize the ability of BCG Pasteur::sigKRussia to induce a 
protective immune response compared to BCG Pasteur: :pMV306. As before, 
C57BL/6 mice were vaccinated subcutaneously with BCG Pasteur::sigKRussia or 
BCG Pasteur::pMV306, but were instead challenged with M. tuberculosis H37Rv by 
intravenous infection ten weeks after vaccination. The bacterial load in the lungs and 
spleen were determined at four and eight weeks after the M. tuberculosis challenge. 
In the first experiment (Figure 3.17), the average vaccination dose was 6.3 x 105 CFU 
of the designated strain of BCG and mice were challenged with 4.6 x 106 CFU of M. 
tuberculosis H37Rv. In the second experiment (Figure 3.18), mice were vaccinated 
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with an average of 2.7 x 106 CFU of BCG and challenged with 1.2 x 106 CFU of M. 
tuberculosis H37Rv. 
At four weeks post-challenge, significant levels of protection were observed 
with both vaccination strains compared to unvaccinated mice (figures 3.17a, 3.18a). 
The greatest levels of protection observed were III the lungs of the 
Pasteur::sigKRussia vaccinated mice in both experiments, in which a 1.3-1.4 log 
reduction in CFU compared to unvaccinated mice was observed. At eight weeks post-
challenge, a significant reduction in M. tuberculosis CFU was again observed in both 
vaccination groups compared to unvaccinated controls. In the first experiment, BCG 
Pasteur::pMV306 and BCG Pasteur::sigKRussia induced similar levels of protection. 
No difference in CFU reduction was observed between the groups vaccinated with 
BCG Pasteur: :pMV306 or BCG Pasteur: :sigKRussia (figure 3 .17b). In the second 
experiment, both strains induced a significant level of protection compared to 
unvaccinated mice and there was no difference between the two vaccinated groups in 
the reduction of M. tuberculosis CFU in the lungs. Reduction of CFU in the spleen in 
BCG Pasteur::sigKRussia vaccinated mice, however, was almost 0.5 log greater than 
the reduction observed in the BCG Pasteur::pMV306 vaccinated group (figure 3.18b). 
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FIGURE 3.1 - A. Expression of mpb64 upon complementation of BCG Denmark 
with mpb64 from BCG Russia. Values are expressed as a ratio of gene expression 
in complemented strains compared to BCG Denmark::pKZ4. AlI values were 
normalized to the levels of sigA mRNA and error bars represent the standard error 
of the mean. B. SDS-PAGE and immunoblorting of culture filtrate proteins from 
BCG Russia, BCG Denmark and complemented strains of BCG Denmark, using 
Mab L24b4. The strains used were as follows: R - BCG Russia, D - BCG Denmark, 
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FIGURE 3.3 - 80uthem blot analysis of Pvull-digested chromosomal 
DNA from M tubercu/osis H37Rv (lanes 5 and 6), M tubercu/osis 
H37Rv8RD2 (lanes 3 and 4) and Mtubercu/osis H37Rv8RDl8RD2 
(lanes 1 and 2), using probes for 186110 and Rv1986. 
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FIGURE 3.4 - In vitro growth of M. tuberculosis H37Rv and H37Rv~RD2. Growth 
was followed by measuring OD600 of cultures of M. tuberculosis H37Rv C+) and M. 
tuberculosis H37Rv~RD2 C.). Data for each time point is the mean and SEM ofthree 
cultures. 
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FIGURE 3.5 - Infection of human macrophage THP-l ceIlline with M. tuberculosis 
H37Rv (black) and H37Rv~RD2 (grey), with an MOI of 0.5 (0) or 1.0 (~). 
Cytotoxicity was determined as a function of cell metabolism and indicated as a percent 
of metabolism compared to day o. Metabolism by uninfected cells is represented by the 
dashed line. 
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Russia vs Pasteur 
TABLE 3.1-Predicted genes whose in vitro expression was significantly dysregulated between early versus late BCG. The Z-
score, indicative of how many standard deviations a data point lies from the population mean, is the average for that gene 
across replicate (n=2) rnicroarrays of Russia (early BCG) versus Pasteur (late BCG) and Birkhaug (early BCG) versus 
Denmark (late BCG). Genes with average Z-scores of 2 or greater for both early versus late BCG comparisons are presented 
and the fold change is calculated from a norrnalized log-ratio of that gene. The fold change in late BCG expression is 
expressed as a ratio, with early BCG expression for that gene providing the reference value of 1. Genes for which expression 
was decreased in late BCG are indicated by a negative sign, genes with increased expression in late BCG are reported by a 
positive sign. Open reading frame (ORF) and gene name are listed by Rv number as annotated for M. tuberculosis H37Rv 
(http://genolist.pasteur.fr/TubercuListl). Genes from the same region of the genome are grouped and presented in a darker 
shade. 
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FIGURE 3. 7 - SDS-PAGE and immunoblotting of culture filtrate proteins (A, C) 
and cell extracts (B, D) from BCG strains, using MAbs 1-5c for MPB70 (A, B) 
and MBS43 for MPB83 (C,D). The strains used were as follows; Ja-BCG Japan, 
Pa-BCG Pasteur, Ru-BCG Russia, Sw-BCG Sweden, Bi-BCG Birkhaug, Ph-BCG 
Phipps, GI-BCG Glaxo, Mo-BCG Moreau, Pr-BCG Prague, Fr-BCG Frappier, 
Co-BCG Connaught, Ti-BCG Tice, De-BCG Denmark. 
Strains 3bp of start codon 
M. canettii AUG 
M. tuberculosis H37Rv AUG 
M. tuberculosis H37Ra AUG 
M. africanum AUG 
M. microti AUG 
M. caprae AUG 
M. bovis AUG 
BCG Russia AUG 
BCG Moreau AUG 
BCG Japan AUG 
BCG Sweden AUG 
BCG Birkhaug AUG 
BCG Prague AUA 
BCG Glaxo AUA 
BCG Oenmark AUA 
BCG Tice AUA 
BCG Connaught AUA 
BCG Frappier AUA 
BCG Phipps AUA 
BCG Pasteur AUA 
TABLE 3.2 - Sequence analysis of sigK for two representative isolates of different M. 
tuberculosis complex members, with the exception of M. canettii where only one isolate 
was sequenced. 
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FIGURE 3.8 - Expression of sigK upon complementation of BCG Pasteur with sigK 
from 1 - M. tuberculosis H37Rv,2 - BCG Russia, 3 - BCG Birkhaug and 4 - BCG 
Pasteur. Values are expressed as a ratio of sigK expression in complemented strains 
compared to BCG Pasteur: :pMV306. AlI values were normalized to the levels of sigA 
mRNA and error bars represent the standard error of the mean. 
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FIGURE 3.9 - Expression of mpb70 (white) and mpb83 (grey) upon complementation of 
BCG Pasteur with sigK from 1 - M. tuberculosis H37Rv, 2 - BCG Russia, 3 - BCG 
Birkhaug and 4 - BCG Pasteur. Values are expressed as a ratio of gene expression in 
complemented strains compared to BCG Pasteur::pMV306. AlI values were normalized 
to the levels of sigA mRNA and error bars represent the standard error of the mean. 
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FIGURE 3.10 - SDS-PAGE and immunoblotting of culture filtrate proteins (top) 
and cell extracts (bottom) from complemented strains of BCG Pasteur, using 
MAbs 1-5c for MPB70 and MBS43 for MPB83. The strains used were as follows: 
1 - BCG Pasteur::sigKH37Rv, 2 - BCG Pasteur::sigKRussia, 
3 - BCG Pasteur::sigKBirkhaug, 4 - BCG Pasteur::sigKPasteur, 
5 - BCG Pasteur::pMV306. 
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FIGURE 3.11 - A. Expression analysis of the genes Rv0441c to Rv0450c. B. Expression 
analysis for the genes Rv2870c - Rv2881 c. Levels presented represent the ratio of gene 
expression in sigK complemented strains compared to the control strain BCG 
Pasteur: :pMV306. AlI values were normalized to the levels of sigA mRNA and the ratio 
presented represents the mean of results from different clones, specificalIy BCG 
Pasteur::sigKH37Rv, BCG Pasteur::sigKRussia and BCG Pasteur::sigKBirkhaug. 
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BCG Pasteur::sigKBirkhaug BCG Pasteur:: sigKH37Rv 
vs. vs. 
BCG Pasteur::pMV306 BCG Pasteur::pMV306 
Gene 
TABLE 3.3 - Predicted genes who se in vitro expression was significantly dysregulated between BCG Pasteur::pMV306 
(empty vector) and BCG Pasteur::sigK (wild type). The Z-score, indicative of how many standard deviations a data point lies 
from the population mean, is the average for that gene across replicate (n=2) microarrays of BCG Pasteur::sigKBirkhaug 
versus BCG Pasteur::pMV306 and BCG Pasteur::sigKH37Rv versus BCG Pasteur::pMV306. Genes with average Z-scores of 
2 or greater for both comparisons are presented and the fold change is calculated from a normalized log-ratio of that gene, with 
BCG Pasteur expression for that gene providing the reference value of 1. Open reading frame (ORF) and gene name are listed 
by Rv number as annotated for M. tuberculosis H37Rv (http://genolist.pasteur.frlTubercuListl). Genes from the same region of 
the genome are grouped and presented in a darker shade. 
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FIGURE 3.12 - In vitro growth of BCG Pasteur: :sigKRussia and BCG 
Pasteur: :pMV306. Growth was followed by measuring OD6oo of cultures of BCG 
Pasteur::sigKRussia (+) and BCG Pasteur::pMV306 (II). Data for each time point 
represents the mean of three experiments, each measured in duplicate and error bars 
represent the standard error of the mean. (*, p < 0.05) 
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FIGURE 3.13 - Infection ofhuman macrophage THP-l cellline with BCG 
Pasteur::sigKRussia C.) and BCG Pasteur::pMV306 C.). Cytotoxicity was determined 
as a function of cell metabolism and indicated as a percent age of metabolism compared to 
uninfected cells at 24hrs. Data is a representative sample of five experiments and is the 
mean of triplicate samples. Error bars represent the standard error of the mean. 
C*, p < 0.05) 
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FIGURE 3.14 - Bacterial growth in lungs (~) and spleens (0) after an intravenous 
infection of C57Bl/6 mice with BCG Pasteur: :sigKRussia (black) and BCG 
Pasteur::pMV306 (grey). Upper and lower panels represent two separate infections, data 
points are the mean of 4-5 mice per group and the error bars represent the standard error 
of the mean. (*, p < 0.05) 
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FIGURE 3.15 - IFNyproduction by splenocytes isolated from BCG Pasteur::pMV306 
(II) and BCG Pasteur: :sigKRussia (.) vaccinated mice and cultured with RPMI, 
conconavalin A or MPB70 for 72hrs. IFNy was measured by ELISA. Data represents 
the mean of triplicate samples and the error bars represent the standard error of the mean. 
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FIGURE 3.16 - Bacterial counts in the spleen and lungs of BCG Russia chaIlenged 
animaIs, at 4 and 8 weeks, following vaccination with PBS (0), BCG Pasteur::pMV306 
(II) or BCG Pasteur::sigKRussia (.). Results are expressed as the mean of 3-4 animaIs 
per group and error bars represent the standard error of the mean. (*, p < 0.05) 
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FIGURE 3.17 - M. tuberculosis H37Rv Challenge 1. Bacterial counts in the spleen and 
lungs of M. tuberculosis H37Rv challenged animaIs, at 4 and 8 weeks, following 
vaccination with PBS (0), BCG Pasteur::pMV306 (IID or BCG Pasteur::sigKRussia 
(.). Results are expressed as the mean of 5 animaIs per group and error bars represent 
the standard error of the mean. (*, p < 0.05) 
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FIGURE 3.18 - M. tuberculosis H37Rv Challenge 2. Bacterial counts in the spleen and 
lungs of M. tuberculosis H37Rv challenged animaIs, at 4 and 8 weeks, following 
vaccination with PBS (0), BCG Pasteur::pMV306 (.) or BCG Pasteur::sigKRussia 
(.). Results are expressed as the mean of 5-6 animaIs per group and error bars represent 
the standard error of the mean. (*, p < 0.05) 
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4. Discussion 
4.1. RD2 
Through the use of comparative genomics, it has been revealed that BCG has 
undergone significant in vitro evolution (Mostowy et al., 2003). Compared to 
virulent M. bovis, the average BCG strain has lost 18 890 bp, affecting 19.3 ORFs. 
Notably, the prolonged propagation of BCG in vitro has resulted in as much loss of 
genomic content as has been sustained by clinical isolates of M. tuberculosis. The 
selective pressures experienced in laboratory-controlled in vitro conditions will be 
different than those faced by c1inical isolates, and consequently, the loss of genomic 
content in laboratory-adapted strains likely indicates the selection of phenotypes that 
are better adapted for in vitro growth. A reduction in the diversity of response 
mechanisms, although potentially deleterious in vivo, may represent an adaptation to 
improve in vitro growth. Having become attenuated by a mutation acquired during in 
vitro growth and having subsequently sustained further substantial deletions, 
characterization of the resulting phenotypic changes in BCG strains is expected to 
provide insight into how these strains, in becoming adjusted to in vitro conditions, 
have changed in their ability to adapt to in vivo growth and to stimulate a protective 
immune response. 
After the time period between 1927 and 1931, there were reports describing a 
decrease in virulence in BCG (Oettinger et al., 1999). This time period coincides 
with the deletion of RD2, a region spanning 10.8 kB and Il ORFs, deleting among 
others a possible transcriptional regulator, a major antigenic protein (MPB64) and a 
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surface protein in the PE_PGRS family. The RD2 region was therefore hypothesized 
to have played a role in the decrease in virulence reported in BCG, however, direct 
comparisons between early and late strains of BCG to identify the effects of the RD2 
deletion would be confounded by the numerous other deletions accumulated in the 
various strains of BCG. The RD2-knockout strain of M. tuberculosis, created in the 
laboratory of David Sherman, provided us with the opportunity of studying the 
impacts of the loss of RD2 in isolation from other deletions. The loss of this region, 
however, did not obviously impact upon in vitro growth or virulence in THP-I cells. 
Growth curves measuring in vitro growth for wild-type M. tuberculosis H37Rv and 
M. tuberculosis H37Rv~RD2 were identical through lag, log and stationary phases, 
suggesting that the loss of RD2 did not contribute to an overt in vitro growth 
advantage. Infection of THP-I cells has previously been used as a model of 
virulence, in which an RD l-knockout strain was shown to be severely attenuated 
compared to wild-type M. tuberculosis (Lewis et al., 2003). This same model was 
used to compare virulence of the RD2-knockout strain to that of M. tuberculosis 
H37Rv. Both strains were found to cause a similar reduction in cell metabolism, 
indicating that any difference in virulence between these strains is, at most, minimal. 
Kato-Maeda et al. (Kato-Maeda et al., 2001) proposed that the accumulation of 
deletions among clinical isolates generally diminishes their virulence and similarly 
Behr et al. (Behr et al., 1999) speculated that further genomic deletion has led to the 
overattenuation of current BCG vaccines. The lack of a virulence phenotype in the 
RD2-knockout strain could be proposed to be a result of the strain in which the 
deletion was recreated. The effects of the deletion could in fact be negligible, as seen, 
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in a strain that has not suffered previous attenuating mutations, while the same 
deletion in BCG, an already attenuated strain relative to M. tuberculosis, could prove 
more debilitating as the ability of BCG strains to compensate for the deletion of RD2 
may be more limited than that of M. tuberculosis H37Rv. This is supported by the 
observation that although the deletion of RD1 in M. tuberculosis H37Rv severely 
attenuated this strain compared to wild-type M. tuberculosis, long-term animal studies 
revealed that M. tuberculosis H37RvÂRD1 remains more virulent than BCG Russia 
(Sherman et al., 2004). 
To characterize the potential impact of the loss of the antigenic protein MPB64 
through the loss of RD2 in late strains of BCG, BCG Denmark was complemented 
with mpb64. The complemented strains expressed mpb64 at a level 3-4 times greater 
than BCG Russia, and the secreted prote in was detectable by Western blotting of the 
CFP. Vaccination with extracellular proteins was demonstrated to effectively indu ce 
a protective immune response against M. tuberculosis in mice and guinea pigs (Pal 
and Horwitz, 1992;Andersen, 1994). Horwitz et al (Horwitz et al., 1995) proposed 
that extracellular proteins should play a key role in generating an immunoprotective 
response since the y are released into intracellular compartments making them 
available for proteolytic processing and MHC presentation, and vaccination with su ch 
proteins should thus induce a population of lymphocytes that is capable of 
recognizing and targeting infected cells. Since, however, vaccination with 
extracellular proteins induced an immune response that was less protective th an that 
induced by BCG, Horwitz et al. (Horwitz et al., 2000) attempted to enhance this 
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response by creating a strain of BCG that overexpresses a major secretory protein, 
Ag85B. This strain of BCG effectively protected against an M. tuberculosis challenge 
in guinea pigs, with levels of protection greater th an that induce by BCG. Although 
not as abundant as Ag85B, MPT64 is an effectively secreted prote in and does induce 
a significant immune response in animal models and in TB patients (Haga et al., 
1995;Oettinger et al., 1995;Roche, Feng, and Britton, 1996;Mustafa et al., 
1998;Lightbody et al., 1998). From the consistency of the responses induced and 
given that MPT64 is an M. tuberculosis complex-specific antigen (Harboe et al., 
1986;Abe, Hirano, and Tomiyama, 1999), MPT64 has been included in diagnostic 
tests for tuberculosis, which have shown a high degree of specificity and sensitivity 
(Nakamura et al., 1998;Hirano et al., 2004). The Ag85 complex, however, has 
homologues in many mycobacterial species (Wiker and Harboe, 1992) and Ag85-
specific responses are detected in non-tuberculosis patients more frequently than are 
MPT64-specific responses. This suggests that protection dependent on a strong 
response to Ag85-complex antigens may be limited in the degree of protective 
response that can be generated above the immunity stimulated by previous exposure 
to mycobacteria. However, as MPT64 is a strong immunostimulatory secreted protein 
with limited distribution in other mycobacterial species, inclusion of this protein in a 
vaccine may have greater potential to induce a protective response than Ag85-
complex antigens in populations determined to have high levels of exposure to 
environmental mycobacteria. Also of interest, Ag85B is produced by all strains of 
BCG and increasing the expression by 2-6 fold significantly increased the protection 
afforded by vaccination with the recombinant strain. Of the rBCG30 strains tested, 
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the strain expressing higher levels of Ag85B was found to induce the greatest 
protective response (Horwitz and Harth, 2003). MPB64 is not produced in eight BCG 
strains, therefore it was hypothesized that restoring the expression of mpb64 in a 
strain that otherwise lacks this gene would increase the protective immunity over that 
generated by vaccination with the parental strain. In addition, the expression level in 
BCG Denmark::mpb64 was higher than that in BCG Russia, which, similar to 
overexpressing Ag85B, would in theory emphasize any benefit derived from 
expressing this protein. At four weeks post-challenge, expression of mpb64 appeared 
to be beneficial, as vaccination with BCG Denmark: :mpb64 induced a 1.6 log 
reduction in CFU in the lungs, while BCG Denmark reduced CFU in the lungs by 1.3 
log compared to unvaccinated animaIs. Although this difference was no longer 
observed at eight weeks, nor was it observed in the spleen, further testing in an 
aerosol M. tuberculosis challenge model or in a model with environmental 
mycobacteria pre-sensitization may be informative. In unpublished data, a 
recombinant strain of BCG expressing mpt64 was found to be more protective against 
an M. tuberculosis challenge than the parental strain of BCG, and although the level 
of protection was stated to be less than that induced by rBCG30, no details regarding 
the recombinant strain expressing mpt64 were provided (Horwitz, 2005). 
Although no phenotypic changes have yet been identified in M. tuberculosis 
H37Rv~RD2, changes in gene expression may reveal potential phenotypes. To this 
end, we compared the global gene expression of two early strains versus two late 
strains of BCG and found limited, but striking differences. Only two regions were 
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significantly dysregulated, however, one of these regions inc1udes genes encoding two 
highly antigenic proteins, MPB70 and MPB83. These proteins are of particular 
interest because of their high production in sorne strains of BCG and because previous 
attempts to identify the cause of the differential expression were unsuccessful. As the 
RD2 region encompasses a potential transcriptional regulator and the difference in 
expression and protein production is c1early a division between early and late strains 
of BCG, the deletion of this region was proposed as a likely cause of the loss of 
expression of these genes in late strains of BCG. Further investigations into the 
second region in which expression differs between early and late strains of BCG, 
however, revealed that a mutation in this region, and not the deletion of RD2, was 
responsible for the decreased expression of mpb70 and mpb83 in late strains of BCG. 
This will be explored further in section 4.2. 
To date, no c1ear phenotype has been associated with the loss of the RD2 
region in M. tuberculosis H37Rv. However, this does not prec1ude the possibility of 
any detrimental or beneficial effects arising from the loss of this region in BCG. 
Although the region itself does not cause significant attenuation in a virulent strain of 
M. tuberculosis, the possibility that the loss of this region may have contributed to a 
further attenuation of BCG must still be examined. The accumulation of deletions has 
been proposed to lead to the attenuation of clinical isolates of M. tuberculosis, and 
thus the accumulation of deletions in BCG may also be a pathway by which BCG has 
become more attenuated with continued passaging. To fully understand the effects of 
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subsequent deletions in BCG, isogenic strains with accumulated mutations continue to 
be required. 
4.2. Expression of mpb70 and mpb83 as a function of sigK and the potential raie 
ofsigK 
Comparative genomic studies have demonstrated the substantial genome decay 
experienced by BCG strains during a half-century of in vitro passage (Mostowy et al., 
2003). While DNA microarray-based comparisons have efficiently uncovered 
genomic deletions as an evident form of evolution, these tools overlook other forms 
of genomic v ariability, such as duplications and single nuc1eotide polymorphisms 
(SNPs). With the targeted study of specifie genes, there has come the recognition of 
numerous 10ss-of-function SNPs during BCG evolution, inc1uding a SNP that impairs 
synthesis of methoxymycolic acids (Behr et al., 2000), a SNP predicted to decrease 
the DNA-binding ability of a CRP homologue (Spreadbury et al., 2005) and the start 
codon mutation described here. Remarkably, along with the loss of the RD2 region 
(Mahairas et al., 1996), these three SNPs aIl coincide with the interval of 1927-1931, 
suggesting either a period of considerable in vitro evolution or the replacement of one 
BCG stock with another at the Pasteur Institute in the late 1920's. 
Our data indicate that a SNP in the start codon of the ECF sigma factor, sigK, 
occurred between 1927-1931 at the Pasteur Institute and resulted, either directly or 
indirectly, in a major drop in production of the antigenic proteins MPB70 and 
MPB83. Previous attempts to identify the cause of the differential production of these 
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proteins between high- and low-producing strains were inconc1usive and attributed the 
differences in gene expression to differential transcriptional efficiencies (Matsuo et 
al., 1995), suggesting that a difference in transcription initiation may be the cause. 
The mutation in the start codon of sigK effectively results in a difference in 
transcription al efficiencies between high- and low-producing strains as transcription 
in the Iow-producing strains can only be initiated by the Iow levels of SigK that are 
produced from the AUA start codon, whereas the greater efficiency of translation of 
sigK mRNA in high-producing strains increases the transcription of the sigK-
regulated genes. The most common naturally occurring initiation codons are AUG 
and GUG (61 % and 35% respectively in M. tuberculosis ), however AUA has been 
documented to be a functional start codon in bacteria (Romero and Garcia, 
1991;Sussman, Simons, and Simons, 1996;SchoenhaIs, Kihara, and Macnab, 1998), as 
well as in S. cerevisiae, Caenorhabditis elegens and humans cells (Zitomer et al., 
1984;Peabody, 1989;Hernandez et al., 2002;Ko and Chow, 2003). The efficiency of 
AUA as a start codon is significantly lower than that of the predominant AUG start 
codon and has been demonstrated to have less th an 10% of the activity of the AUG 
initiation codon in E. coli (Romero and Garcia, 1991;Sussman, Simons, and Simons, 
1996). The AUG to AUA mutation in sigK may have been selected for by conferring 
a growth advantage in vitro, as shown by the faster growth of BCG Pasteur: :pMV306 
compared to BCG Pasteur: :sigKRussia. Although the role of sigK and the sigK-
regulon in infection are unknown, the growth advantage conferred by losing the 
expression of this regulon may have been of greater benefit in vitro to a continually 
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passaged laboratory culture than the potential benefit of retaining the normal in vivo 
function of this regulon. 
SigK is one of ten extracytoplasmic function (ECF) sigma factors annotated in 
the M. tuberculosis H37Rv genome. As the name suggests, these regulatory elements 
mediate responses to changing external conditions (Manganelli et al., 2001 ;Ando et 
al., 2003;Hu et al., 2004;Manganelli et al., 2004a). As an indicator of the possible 
role the sigK-regulon may play in adapting to extracellular conditions, mpb70 and 
mpb83 are among the most highly up-regulated genes at 4, 24 and 48 hours in in vivo 
macrophage infection as determined by Schnappinger et al (Schnappinger et al., 
2003). Infection of unactivated and activated bone marrow- derived macrophages 
from both NOS2+/+ and NOS2-/- mice induced similar up-regulation of mpb70 and 
mpb83 , suggesting that induction of expression of these genes, and likely their 
function, is independent of the activation state of the macrophages and of the 
generation of RNI. A common feature of ECF sigma factors is their control over 
relatively small regulons (Bashyam and Hasnain, 2004). For instance, by microarray 
analysis, the regulon of sigC has been estimated to contain 13, 14, and 18 genes, in 
exponential, early stationary and late stationary growth phases respectively (Sun et 
al., 2004). This is consistent with our observations of 13 genes being consistently up.,. 
regulated in wild-type sigK-complemented strains. Four genes were observed to be 
consistently down-regulated in the sigK-complemented strains, however, the role of 
sigK in the expression of these genes is undetermined. A decrease in gene expression 
could be attributable to an increased expression of a repressor or to the sequestration 
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of a transcription al activator, however, these possibilities were not further 
investigated. The striking feature of the sigK regulon is not its size, however, it is its 
specificity. AU 13 genes that are up-regulated comprise only two regions, one 
containing sigK itself and the second containing mpb70 and mpb83. This indicates 
the large degree of specificity of this system. No other M. tuberculosis ECF sigma 
factor for which a regulon has been determined, has demonstrated a similar degree of 
specificity. 
MPB70 and MPB83 exhibit striking amino acid sequence homology 
(Hewinson et al., 1996) and both are exported, but the two proteins localize 
differently. MPB70 has been confirmed to be a secreted protein, with a high 
localization index indicating a highly efficient secretion process, while MPB83 has 
been localized mainly to the cell surface (Fifis et al., 1991 ;Hewinson et al., 
1996;Harboe et al., 1998). The structure of MPB70 has recently been solved and 
superimposition of MPB83 on the MPB70 structure confirmed the overall homology 
of the antigens (Carr et al., 2003). Based on the conserved residues, which are both 
solvent exposed and in the core regions, Carr et al. suggested that these proteins 
interact with host ceU proteins either to modulate signaling pathways in ho st cells or 
to act as attachment proteins. MPB70 displays both sequence and structural 
homology to the FAS1 domains of fasciclin, periostin and ~ig-h3 (Ulstrup et al., 
1995;Matsumoto et al., 1995;Carr et al., 2003), aU of which have been characterized 
as cell adhesion molecules. ~ig-h3 has been found to bind to several integrins via the 
FASI domains (Kim et al., 2000;Kim et al., 2002) and, although the binding domains 
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were not identified, periostin has also been found to bind various integrins (Gillan et 
al., 2002). A possible function of MPB70 and MPB83 could be to interact with 
selected integrins to increase the uptake of M. tuberculosis, a step required for 
pathogenesis, or to alter signaling in the macrophage. A sigK-knockout strain in M. 
tuberculosis H37Rv has recently been created (Said-Salim et al., 2006) and this 
should allow for further elucidation of the function of the sigK-regulon. Studies of 
growth of the BCG Pasteur: :sigK strain in mice have, however, provided sorne initial 
insight into the possible importance of this system. As shown in Figure 3.14, C57BI/6 
mice infected with Pasteur::sigKRussia have higher CFU in the spleen and lungs at 
day 1 compared to mice infected with Pasteur::pMV306, des pite equal or slightly 
higher Pasteur: :pMV306 infection inoculums, suggesting that increased expression of 
MPB70 and MPB83 conferred sorne advantage to BCG Pasteur early in infection. 
Similar to the in vitro growth curves, growth of Pasteur::pMV306 was faster th an that 
of Pasteur::sigKRussia over the first three weeks of infection, at which point both 
strains reached their maximum CFU detected and the infection was brought under 
control. Interestingly, over the later time points, Pasteur::pMV306 decreased more 
rapidly and to lower levels in both the lungs and the spleen than Pasteur: :sigKRussia. 
Long term studies would be required to determine if and to what extent 
Pasteur::sigKRussia persists longer than Pasteur::pMV306, but this early data again 
suggests that expression of a functional sigK-regulon may be advantageous during 
infection. As persistence of BCG is crucial for an effective protective response, 
expression of the sigK-regulon could be a beneficial characteristic of a BCG-based 
vaccme. 
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From immunologie studies, it is known that both MPB70 and MPB83 induce 
cellular and humoral responses in experimental infections of model hosts and in 
natural infections of humans (Miura et al., 1983;Haslov, Andersen, and Bentzon, 
1987;Roche et al., 1994;Fifis et al., 1994;Harboe et al., 1995;Wiker et al., 
1996;Vordermeier et al., 2000;Lyashchenko et al., 2001). Based on these 
observations, both MBP70 and MPB83 have been developed as candidates for novel 
TB vaccine development (Chambers et al., 2000;Morris et al., 2000;AI Attiyah et al., 
2003;Tollefsen et al., 2003;Xue et al., 2004). Vaccination of cattle with both mpb70 
and mpb83 DNA vaccines successfully induced strong cellular and humoral antigen-
specifie responses, although vaccination with mpb83 was noted to produce a superior, 
more reliable response (Vordermeier et al., 2000). Subcutaneous vaccination of 
C57BI/6 mice with both BCG Pasteur::pMV306 and BCG Pasteur::sigKRussia 
induced a cellular immune response towards BCG, but only BCG Pasteur::sigKRussia 
induced a strong, specifie response to MPB70. These results were encouraging as 
they indicate that the proteins are indeed produced in vivo and importantly, that these 
proteins stimulate an immune response. 
Results of protection from mpb83-based vaccines, which have been more 
commonly tested than mpb70:'based vaccines, have not been consistent between 
models. Protection against an intravenous M. bavis challenge in Balb/c mice 
vaccinated with an mpb83 DNA vaccine was equivalent to that induced by BCG, with 
significant levels of protection in lungs and spleen being observed (Chambers et al., 
2000). In another study using an mpb83 DNA vaccine, protection against a M. 
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tuberculasis aerosol challenge in C57Bl/6 mice revealed only moderate protection, 
measured as a reduction of CFU (only significant in lungs), that was not comparable 
to BCG (Morris et al., 2000). Protection in guinea pigs was more ambiguous with no 
reduction in CFU being observed in the mpb83-DNA vaccinated animaIs, but an 
improvement of lung histopathology intermediate to the non-vaccinated and the BCG 
vaccinated animaIs was observed. This improvement was reported as a decrease in 
the number of lesions in the lungs and a reduction in the extent of granulomatous 
inflammation and caseation (Chambers et al., 2002). A time to death experiment was 
not performed, but would have been informative as to whether the apparent 
histopathological improvement correlated with a decrease in disease severity and 
adverse outcomes. Vaccination of cattle with any of an mpb83 DNA vaccine, an 
mpb70 DNA vaccine or an mpb70 DNA prime, MPB70 protein boost strategy did not 
effectively protect against an intratracheal challenge with M. bavis. Only BCG 
vaccination in this model reduced the number of animaIs with lung and lymph node 
lesions, the mean score of these lesions and the bacterial load in the lymph nodes 
(Wedlock et al., 2003). Although this may be indicative that MPB70 and MPB83 
may not be capable of solely inducing a strong protective immune response equivalent 
to or better than BCG, it does not suggest that either or both of these proteins cannot 
be an effective and beneficial component of strongly protective vaccine. There is no 
single M. tuberculasis antigen yet identified that, when used alone as a DNA or 
subunit vaccine, has been shown to have the capability of equaling the protective 
capacity of BCG vaccination in animal models. The vaccines that have shown an 
effective level of protection have either been combinations of antigens or BCG-based 
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vaccines. Since a moderate level of protection was induced by MPB70 and MPB83 in 
these previous challenge models, the inclusion of these genes in the strains of BCG 
used for vaccination may improve the amplitude and the range of the immune 
response induced by BCG. As extracellular antigens have consistently been 
implicated in the induction of a protective immune response against M. tuberculosis, 
it is remarkable that aIl BCG strains are unable to pro duce the antigenic proteins 
ESAT-6 and CFP-lO (1ost with the RDI deletion of 1908-1921), while strains 
obtained after 1927-31 are also deficient in the proteins MPB64 (Harboe et al., 
1986;Li et al., 1993) and CFP-21 (Mahairas et al., 1996;Weldingh et al., 
1998;Weldingh and Andersen, 1999) and are functionally deficient in production of 
MPB70 and MPB83 via the sigK mutation described here. Two challenge models 
were used to evaluate the efficacy of BCG Pasteur::sigKRussia compared to BCG 
Pasteur::pMV306. In both infection models, in which vaccinated mice were 
challenged with BCG Russia or M. tuberculosis H37Rv, equal protection was induced 
by BCG Pasteur: :pMV306 and BCG Pasteur: :sigKRussia at four weeks following 
infection. At eight weeks, however, the protective efficacy of BCG 
Pasteur::sigKRussia was slightly greater than BCG Pasteur::pMV306 in two of the 
three challenge studies. Although the overall differences between the vaccination 
strains were not significant, the trend shows that BCG Pasteur: :sigKRussia confers 
slightly enhanced protection over that induced by BCG Pasteur: :pMV306 and 
suggests that sigK, MPB70 and MPB83 should be considered beneficial elements of a 
BCG vaccine and of the protective immune response induced by such a vaccine. The 
ability of BCG Pasteur::sigKRussia to protect against an aerosol M. tuberculosis 
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challenge in guinea pigs was examined by collaborating researchers at Colorado State 
University. Although BCG Pasteur::sigKRussia did induce a significant level of 
protection against a M. tuberculosis challenge in this model, the level of protection 
observed was equivalent to that induced by BCG Pasteur::pMV306, as measured by 
histopathological determination of tissue damage in the lungs and by CFU 
enumeration in thelungs and the spleen of challenged animaIs (A. Izzo, personal 
communication). To further evaluate the protective ability of BCG 
Pasteur::sigKRussia vaccination, aM. bovis challenge experiment in cattle is currently 
in progress. MPB70 and MPB83 are constitutively expressed at high levels in M. 
bovis and as such, are classically considered as M. bovis antigens. Enhancing the 
protection against M. bovis infection in cattle would have enormous economic 
benefits to the cattle industry worldwide. 
Comparison of BCG Pasteur::sigKRussia with BCG Pasteur in mice pre-
sensitized to environmental mycobacteria may elucidate any potential benefit of a 
strain that persists longer and that expresses two immunodominant antigens that are 
not expressed in mycobacteria outside of the M. tuberculosis complex. From studies 
in Malawi, the species of environmental mycobacteria to which there is a higher 
prevalence of responsiveness than to M. tuberculosis include M. avium, M. 
intracellulare and M. scrofulaceum. Similarly, in England, the same species had the 
highest prevalence of responsiveness, albeit with a much lower prevalence than in 
Malawi. These strains, as with almost aIl environmental mycobacteria, do not express 
mpb70 or mpb83. Animal studies looking at the effects of pre-sensitization by 
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environmental mycobacteria on a BCG-induced immune response and BCG 
proliferation have used two of these strains (M. avium, M. scrofulaceum,), as weIl as 
M. fortuitum, M. vaccae and M. kansasii. Proliferation of BCG in mice pre-
sensitized to environmental bacteria is hampered to varying degrees depending on the 
sensitizing strain, with the greatest inhibition being induced by M. avium (Demangel 
et al., 2005). Inhibition of BCG growth was either reduced or not significant, 
depending on the pre-sensitizing strain, when the BCG strain used was BCG: :RD 1. 
The ability of the BCG: :RD 1 strain to grow in pre-sensitized mice was attributed to 
two factors: first, BCG::RDI persists longer in immunocompetant mice and second, 
infection with BCG::RDI generates a strong ESAT-6 response (Demangel et al., 
2005). These same two factors may be applicable to BCG Pasteur: :sigK. Our sigK-
complemented strain appears to have increased persistence (to be further examined in 
a long term infection model) and expresses two strongly immunogenic antigens that 
are unique to the M. tuberculosis complex. Vaccination with strains expressing 
mpb70 and mpb83, like BCG::RD1, may be able to overcome the inhibition of BCG 
induced by environ mental mycobacteria. In countries where there is a high 
prevalence of immune responses to environmental mycobacteria, vaccination with 
antigen expressing recombinant BCG, such as BCG::sigK, may prove to be highly 
advantageous. 
The data presented here explain the difference in expression between high-
producing and low-producing BCG strains. However, MPB70 and MPB83 are also 
differentially produced by M. tuberculosis and M. bovis. Although these organisms 
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have identical, wild type AUG sigK start codons, in vitro expression is low (albeit 
inducible) in M. tuberculosis and constitutively high in M. bovis (Wiker et al., 1996). 
The constitutive in vitro production of MBP70 and MPB83 observed in M. bovis may 
therefore stem from unregulated activity of SigK. Activity of an ECF sigma factor 
can be mediated by a second protein, the anti-sigma factor, that functions post-
translationally as a negative regulator to prevent constitutive expression of the target 
regulon (Helmann, 2002;Manganelli et al., 2004b). The sigma/anti-sigma pair are 
usually adjacent and co-transcribed genes. For instance, in M. tuberculosis, RshA 
(Rv3221A) is the anti-sigma factor for SigH (Rv3223c) , UsfX (Rv3287c) is the anti-
sigma factor for SigF (Rv3286c) (Beaucher et al., 2002;Song et al., 2003) and RsIA 
(Rv0736) has been demonstrated to act as an anti-sigma factor for sigL (Rv0735) 
(Hanh 2005, Dainese 2006). Consistent with this pattern, recent investigations, based 
on the presence of two non-synonymous SNPs in Rv0444c restricted to M. 
tuberculosis complex species presenting constitutively high MPB70 production, have 
demonstrated that Rv0444c is the anti-sigma factor of SigK (Rv0445c) (Said-Salim et 
al., 2006). 
As BCG vaccines are given to an estimated 2 million infants per week, there 
are important practical implications of these findings. The sigK mutation described 
here impairs the production of two immunodominant antigens, MPB70 and MPB83, 
as weIl as transcription of mpb53. The importance of this deficit for TB 
immunization is unknown because strains of BCG that produce these antigens have 
never been utilized in a randomized clinical trial, although results from sorne 
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observational studies have suggested a greater potency to sorne of the high-producing 
strains (Kroger et al., 1994;Vitkova et al., 1995). Based on the number of 
documented differences between BCG strains obtained before 1927 and those 
obtained after 1931, there is a compelling rationale to perform a human trial 
comparing BCG strains from these two groups. Furthermore, these results are also 
applicable towards efforts to develop improved vaccines against TB. Recent 
advances have demonstrated that recombinant strains of BCG expressing M. 
tuberculosis antigens provide an important avenue towards more effective vaccines 
(Horwitz et al., 2000;Pym et al., 2003). These constructs may benefit from the 
inherent MPB70 and MPB83 expression of the high-producing strains obtained before 
1931, or alternatively, by correcting the sigK mutation in later strains to achieve the 
same result. 
4.3. General Discussion 
Although the use of BCG as a vaccine for tuberculosis is often criticized for 
the lack of reproducible protective efficacy, two facts remain true: first, BCG is given 
to millions of individuals every year and is beneficial in certain populations and 
second, perhaps more importantly, tuberculosis continues to kill millions of people 
every year, indicating that a vaccine that induces a greater immune response is not 
necessarily what is required, but a vaccine that provides a more reliable and 
ubiquitous protective response is what is necessary. 
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It has been c1early and extensively demonstrated that BCG is not one uniform 
vaccine. This has been further demonstrated here with the characterization of a single 
nuc1eotide polymorphism in the start codon of an ECF sigma factor that profoundly 
affects the expression of two immunodominant antigens. However, even though it 
may be conceptually simple to rationalize that the loss of both regulatory and 
antigenic proteins from various strains of BCG could impact upon how each strain 
interacts with its environ ment and its ho st during infection, demonstrating this 
potential impact in vivo and particularly in terms of vaccine efficacy has been 
challenging. Comparison of the protective efficacy of BCG strains in animal models 
has identified varying abilities of the strains to prote ct against an M. tuberculosis 
challenge, however, no c1ear trend has been established and variations between 
experiments makes direct comparisons difficult (Lagranderie et al., 1996;Castillo-
RodaI et al., 2006). In addition, comparison of protection induced by vaccination 
with the same strains of BCG, but in different animal models, failed to produce a 
consensus regarding the ranking of the protective efficacy of the strains tested, even 
within the same testing laboratory (Smith, Wiegeshaus, and Balasubramanian, 2000). 
Consequently, this confusion has contributed to the impression that strain selection is 
insignificant and to date, there was perhaps not sufficient evidence to warrant the 
selection of one particular strain over another. As our knowledge of the differences 
between the strains increases, however, we should be able to tailor our choice of 
strain to maximize the protection induced by vaccination. For example, persistence of 
BCG is necessary for the induction of a protective immune response. Selecting a 
strain of BCG that persists longer or whose replication is not inhibited by 
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environmental mycobacteria, may prove to be more protective. As an example, the 
recombinant strain of BCG expressing the RDI region was shown to persist longer, 
both in unsensitized animaIs and in animaIs previously sensitized with environmental 
mycobacteria, and was capable of surpassing the level of protection induced by BCG 
(Pym et al., 2002;Pym et al., 2003;Demangel et al., 2005). As suggested by the in 
vivo growth data presented here, BCG Pasteur: :sigK may persist longer in both the 
lungs and spleen of infected C57BL/6 mice than BCG Pasteur not expressing the sigK 
regulon, and although this needs further examination, it is a potentially beneficial 
characteristic that needs to be considered when selecting a BCG strain for use in 
vaccination programs. 
Similarly to selecting a strain that is not growth inhibited by environmental 
mycobacteria, selection of a strain with limited antigenic crossreactivity to 
environmental mycobacteria may produce a broader response by inducing an immune 
response to antigens to which the vaccinated individual has not been previously 
exposed. This would in effect use the environmental mycobacteria to increase the 
breadth of the immune response, given that there will be less similarity between the 
response stimulated by this exposure and the immune response induced by the 
vaccme. As previously described, vaccination of animaIs pre-sensitized with 
environmental mycobacteria was most effective when there was the least 
crossreactivity between the sensitizing and the vaccinating strains (Orme and Collins, 
1984). Given that exposure to environmental mycobacteria will likely remain a 
persistent factor, the strain of BCG used for vaccination should be selected such that 
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it induces the maximum immune response that would not be acquired by sensitization 
to environmental mycobacteria. This would not only enhance the level of protection 
attributable to BCG, but it would take advantage of the immunity stimulated by 
natural exposure to mycobacteria. BCG Pasteur::sigK is a promising candidate to 
fulfill such a role, as it expresses two immunodominant antigens that are not present 
in mycobacteria species outside of the M. tuberculosis complex. Alternatively, using 
a strain of BCG that naturally expresses the sigK regulon (ie. early strains of BCG) 
also has the advantage of having the expression of MPT64, another M. tuberculosis 
complex specific antigen. 
The continued use of BCG has been debated both in countries with low 
prevalence of tuberculosis and in countries where there is a high burden of disease. In 
man y countries with low prevalence, the widespread use of BCG has been 
discontinued, with selective vaccination of high risk individuals being favoured. In 
countries with high prevalence of tuberculosis, widespread use generally continues to 
be supported due to the effectiveness of the vaccine in the prevention of morbidity 
and mortality from disseminated disease in children and has recently been reported to 
be a highly co st effective intervention for control of tuberculosis in children (Trunz, 
Fine, and Dye, 2006). However, the protection observed in children has very little 
effect on the prevention of propagation of the disease, as tuberculosis in young 
children is rarely a significant source of transmission. It is for these two reasons that 
it is argued that BCG vaccination is both effective and ineffective; it protects children 
against the most serious forms of the disease, but it is minimally effective at 
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combating disease in adults and reducing the propagation of the disease. It is this 
latter aspect on which a large portion of future vaccine development should focus. 
The use of a prime-boost strategy has promising potential to be an effective 
mechanism to induce and maintain a protective response. Encouraging results were 
obtained in a Phase 1 clinical trial conducted by McShane et al. (McShane et al., 
2004) examining the safety and immunogenicity of a modified vaccinia virus 
expressing Ag85A (MV A85A). Testing MV A85A as a booster in individuals 
previously vaccinated with BCG (mean of 18y prior) produced an immune response 
with greater magnitude and of longer duration than that observed by vaccination with 
either BCG or MV A85A alone. Although these results are encouraging that a prime-
boost strategy using BCG as the prime could be effective, it is difficult to assess the 
efficacy of any tuberculosis vaccine strategy without undertaking the long term study 
looking at disease incidence. Immune correlates of protection have not been weIl 
established and this poor understanding of what responses are predictive of a 
protective vaccine induced immune response has made the evaluation of new vaccines 
difficult. 
The selection of which strain of BCG to use will be an important aspect of a 
prime-boost strategy that includes BCG. Testing of new vaccines as boosters to a 
BCG prime has the advantage of having millions of individu aIs who have already 
been vaccinated with BCG, however, to sorne extent, this is may also work as a 
disadvantage, as the choice of which strain of BCG to use is eliminated. Designing a 
combination of a BCG prime and a boosting vaccine will maximize the individual 
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benefits of both vaccines. Both DNA and subunit vaccines incorporating MPT70 and 
MPT83 have been shown to have the capacity to stimulate a certain degree of 
protection in animal models and should be tested as booster vaccines to a strain of 
BCG expressing these antigens. 
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4.4. Conclusions and Summary 
The strains of BCG currently in use have previously been shown to be 
genotypically distinct from each other, however, how those genetic differences have 
impacted on the phenotypes of each of those strains has received little attention. 
Deletion of the RD2 region in late strains of BCG, which resulted in the loss of 
antigenic and regulatory proteins, was hypothesized to have contributed to further 
attenuation of these strains. The deletion of this region in a virulent strain of M. 
tuberculosis did not lead to an obvious attenuation in the models in which it was 
examined, however, studying this deletion in combination with other deletions and 
mutations that contribute to the attenuation of BCG strains (such as RDI), may reveal 
a degree of attenuation not observed in this study. 
Comparison of global gene expression between early and late strains of BCG, 
however, led to the identification of the cause of the decreased expression of the 
antigenic proteins MPB70 and MPB83 in late strains of BCG. Two regions were 
identified as consistently down-regulated in late strains of BCG compared to early 
strains, one of which contained the gene encoding the ECF sigma factor, sigK, and the 
second of which contained the genes encoding MPB70 and MPB83. Sequencing of 
the sigK gene revealed a single nucleotide polymorphism at the third base pair of the 
start codon, which was hypothesized to limit the translation of sigK mRNA and thus 
decrease the expression of SigK-controlled genes. Through complementation of sigK 
from strains of BCG that pro duce high amounts of MPB70 and MPB83 to a low-
producing strain, we revealed that SigK controls a strikingly small regulon, consisting 
of the sigK region itself and the mpb70/mpb83 region. 
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Characterization of BCG Pasteur::sigK revealed both in vitro and in vivo 
differences compared to control strains of BCG Pasteur. The control strains 
demonstrated an in vitro growth advantage over the complemented strains, suggesting 
that an in vitro advantage was gained by the loss of expression of the sigK and 
mpb70/mpb83 regions. In vivo studies, however, suggested that expression of MPB70 
and MPB83 is beneficial to in vivo conditions. Specific characteristics of BCG 
Pasteur: :sigK that would be advantageous to BCG as a vaccine include stimulation of 
a strong antigen-specific immune response, increased deposition in organs following 
infection and prolonged persistence. In the challenge studies completed here, 
protection induced by vaccination with BCG Pasteur::sigK was equal or greater than 
that induced by vaccination with BCG Pasteur::pMV306. Taken together, these 
results suggest that expression of MPB70 and MPB83 is a beneficial characteristic of 
a BCG-based vaccine. Further use of BCG strains as vaccines for TB should take into 
consideration the characteristics of the BCG strain used, as it has been demonstrated 
here that the deletions and mutations that BCG strains have sustained through in vitro 
propagation have impacted upon the characteristics that are important for BCG as a 
vaccine. 
148 
5. Appendices 
5.1. Approval Formsfor Animal Use Protocols 
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Summary 
Mycobacterium bovis Bacille Calmette-Guérin (BCG) 
strains are genetically and phenotypically heteroge-
neous. Expression of the antigenic proteins MPB70 
and MPB83 is known to vary considerably across 
BCG strainsj however, the reason for this phenotypic 
difference has remained unknown. By immunoblot, 
we separated BCG into high- and low-producing 
strains. By quantitative reverse transcription poly-
merase chain reaction (RT-PCR), we determined that 
transcription of the antigen-encoding genes, mpb70 
and mpb83, follows the same strain pattern with 
mRNA levels reduced over 50-fold in low-producing 
strains. Transcriptome comparison of the same BCG 
strains by DNA microarray revealed two gene regions 
consistently downregulated in low-producing strains 
compared with high-producing strains, one including 
mpb70 (Rv2875) and mpb83 (Rv2873) and a second 
that includes the predicted sigma factor, sigK. DNA 
sequence analysis revealed a point mutation in the 
start codon of sigK in ail low-producing BCG strains. 
Complementation of a low-producing strain, BCG 
Pasteur, with wild-type sigKfully restored MPB70 and 
MPB83 production. Microarray-based analysis and 
confirmatory RT-PCR of the complemented strains 
revealed an upregulation in gene transcription limited 
to the sigK and the mpb83/mpb70 gene regions. 
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These data demonstrate that a mutation of sigK is 
responsible for decreased expression of MPB70 and 
MPB83 in low-producing BCG strains and provide 
clues into the role of Mycobacterium tuberculosis 
SigK. 
Introduction 
Mycobacterium bovis Bacille Calmette-Guérin (BCG) 
strains have been given to billions of people as vaccines 
against tuberculosis (TB) since their derivation at the Pas-
teur Institute between 1908 and 1921. While BCG immu-
nization reliably provides protection in animal models, 
their protection in human clinical trials has been inconsis-
tent, leading to a number of hypotheses to explain these 
variable findings (Fine, 1995; Agger and Andersen, 2002). 
One theory that has been the subject of recent investiga-
tion pertains to the heterogeneity of BCG preparations 
used in an era before standardized vaccines. With the 
advent of comparative genomic tools has come the rec-
ognition that BCG strains are distinct from each other and 
different from the vaccines first provided in the early 20th 
century (Mostowy et al., 2003). Moreover, analysis of the 
elements implicated in BCG evolution indicates that genes 
encoding regulatory elements and antigenic proteins are 
over-represented in the genomic deletions incurred by 
BCG strains (Behr, 2002). 
The importance of antigenic proteins in TB pathogene-
sis and vaccine development has been weil established 
through their use in generating immunity to TB and the 
demonstration that disruption of the ESAT-6 region con-
tributed to the derivation of BCG (Andersen, 1994; Harboe 
et al., 1996; Mahairas et al., 1996; Pym et al., 2002; Lewis 
et al., 2003; Brodin et al., 2004; Doherty et al., 2004). 
Therefore, the observation that BCG strains have suffered 
loss of antigenic proteins du ring in vitro passage is con-
sistent with a potential impairment in their capacity to 
serve as immunizing agents. Of the described antigenic 
proteins of the Mycobacterium tuberculosis complex, the 
M. bovis antigens MPB70 and MPB83 (also known as 
MPT70 and MPT83 when studied in M. tuberculosis) fig-
ure prominently as candidates for vaccine development 
(Fifis et al., 1994; Mustafa et al., 1998; Chambers et al., 
2002; 2004). Although the genes encoding these proteins 
2 D. Charlet et al. 
have not been deleted in BCG evolution, production of 
these proteins by BCG vaccines during in vitro growth 
varies considerably. In certain BCG strains, such as BCG 
Tokyo, MPB70 represents the most abundant protein in 
the culture filtrate (Nagai et al., 1981). In other BCG 
strains, su ch as BCG Pasteur, production of MPB70 is 
markedly reduced, leading to the division of BCG strains 
into high-producers or low-producers (Miura et al., 1983; 
Harboe and Nagai, 1984). The same pattern of antigen 
production across BCG strains has also been observed 
for MPB83, although the differences have generally not 
been as dichotomous (Wiker et al., 1996). 
To explore the reasons underlying these differences in 
production, sequence-based analysis has been per-
formed, but no mutations in the encoding genes or their 
upstream promoter regions have been detected (Hewin-
son et al., 1996; Vosloo et al., 1997). Complementation of 
BCG Pasteur with mpb70 from BCG Tokyo did not restore 
levels of MPB70 to those observed with BCG Tokyo, sug-
gesting differences in expression inherent to the parent 
BCG strain (Matsumoto et al., 1995). By targeted expres-
sion analysis, using reverse transcription polymerase 
chain reaction (RT-PCR) and Northern blots, an obvious 
difference in mpb70 transcription was observed between 
BCG Tokyo (high-producer) and BCG Pasteur (Iow-pro-
ducer) (Matsuo et al., 1995). However, the reason for this 
difference has remained unknown. 
Because the history of BCG strain dissemination has 
been recorded, it has been possible to precisely deter-
mine the chronology of specifie genetic changes in BCG 
strains (Behr and Small, 1999). A number of these muta-
tions affect putative regulatory genes (Behr et al., 1999; 
Brosch et al., 2000; Spreadbury et al., 2005), so we 
hypothesized that a mutation in a regulatory gene was 
likely responsible for the variable production of MPB70 
and MPB83. We have therefore determined the produc-
tion of MPB70 and MPB83 across a panel of BCG strains, 
in order to assign the chronology of this phenotypic 
change and thereby guide studies towards identifying the 
responsible mutation. Our data implicate a start codon 
mutation in the M. tuberculosis sigma factor K (Rv0445c 
or sigl<) and point to a highly specifie link between sigK 
and expression of MPB70 and MPB83. 
Results 
Immunoblotting M. bovis BCG culture fiftrate proteins and 
whole-cefl extracts 
To determine the production of MPB70 and MPB83 across 
BCG strains, we analysed culture filtrate proteins and 
whole-cell extracts blinded to strain identity. Upon decod-
ing the samples, MPB70 was detected in substantial 
amounts in the culture filtrates of BCG Russia, Birkhaug, 
Sweden, Japan and Moreau and not in the remalnlng 
strains (Fig. 1A). In the whole-cell extracts, MPB70 was 
not detectable in any strain (Fig. 1 B). MPB83 was 
detected in both the culture filtrate proteins and the whole-
cell extracts of BCG Russia, Birkhaug, Sweden, Japan 
and Moreau (Fig. 1C). In the remaining strains of BCG, 
MPB83 could be detected in low amounts in the whole-
cell extracts (Fig. 1 D). These results are in agreement with 
previous results from a subset of these strains (Miura 
et al., 1983; Harboe and Nagai, 1984; Wiker et al., 1996) 
and indicate a clear delineation between strains obtained 
from the Pasteur Institute until1927 (high-producers) ver-
sus strains obtained, either directly or indirectly, in 1931 
or later (Iow-producers). 
Transcription of mpb70 and mpb83 in BCG strains 
To determine whether transcriptional differences might 
correlate with variations in protein production, we 
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Fig. 1. SDS-PAGE and immunoblotting 01 culture liltrate proteins (A 
and C) and cell extracts (B and D) from BCG strains, using mono-
clonal antibodies 1-5c for MPB70 (A and B) and MBS43 for MPB83 
(C and D). The strains used were as lollows: Ja, BCG Japan; Pa, 
BCG Pasteur; Ru, BCG Russia; Sw, BCG Sweden; Bi, BCG Birkhaug; 
Ph, BCG Phipps; GI, BCG Glaxo; Mo, BCG Moreau; Pr, BCG Prague; 
Fr, BCG Frappier; Co, BCG Connaught; Ti, BCG Tice; De, BCG 
Denmark. 
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Expression of mpb70 and mpb83 in BCG strains 
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Fig. 2. Expression 01 mpb70 (white) and mpb83 (grey) in M. bovis 
BCG strains. Ratio 01 expression is to that 01 BCG Pasteur. Ali values 
were normalized to the levels of sigA mRNA. 
employed quantitative RT-PCR with molecular beacons to 
estimate relative mRNA levels for mpb70 and mpb83. As 
immunoblotting results pointed to distinctions between 
strains obtained before or after the interval 1927-1931, 
we selected the first and last strain obtained from each 
group (BCG Russia and BCG Birkhaug for the earlierl 
high-producing group and BCG Danish and BCG Pasteur 
for the later/low-producing group). Consistent with previ-
ous reports indicating different mRNA expression (Matsuo 
et al., 1995), measured levels of mpb70 and mpb83 
mRNA were profoundly lower in BCG Danish and BCG 
Pasteur as compared with BCG Birkhaug and BCG Rus-
sia with a calculated difference greater than 50-fold 
(Fig. 2). 
Table 1. Microarray analysis 01 Mycobacterium bovis BCG strains. 
MPB70183 in BCG strains 3 
Microarray analysis of BCG strains 
To look for other differences in gene expression that might 
coincide with transcription of mpb70 and mpb83, we stud-
ied the same four BCG strains by whole genome microar-
ray, directly comparing BCG Russia with BCG Pasteur 
and BCG Birkhaug with BCG Danish (Table 1). Consistent 
with the RT-PCR data, levels of mpb70 and mpb83 were 
significantly lower in BCG Pasteur and BCG Danish, as 
compared with BCG Russia and BCG Birkhaug. Aiso in 
this region, Rv2876 and Rv2878c showed decreased 
expression in late/low-producing strains compared with 
early/high-producing strains. A second region that showed 
consistent downregulation in the low-producing strains 
was Rv0445o-Rv0449c. Of these genes, the only putative 
transcriptional regulator is Rv0445c (sigK), which is pre-
dicted to encode an alternate sigma factor, prompting 
further analysis. 
Sequence analysis of sigK 
Comparison of sigK across sequenced genomes indi-
cated two polymorphisms in BCG Pasteur compared with 
M. tuberculosis H37Rv. First, located at nucleotide -31 
upstream from the sigK start codon, the adenine residue 
is replaced by a thymidine residue in BCG Pasteur. 
Sequencing this region across members of the M. tuber-
culosis complex and 13 BCG strains revealed that this 
mutation represents an M. tuberculosis polymorphism; 
Mycobacterium canettii, Mycobacterium microti, Myco-
bacterium caprae, M. bovis and ail BCG strains have the 
thymidine residue at the -31 upstream position while 
Russia versus Pasteur Birkhaug versus Denmark 
ORF Fold change 
~~~~~~~~ 
Gene name 
Rv3681c whiB4 2.73 
z-score 
2.08 
Fold change z-score Gene product 
3.06 2.22 Transcriptional regulatory protein 
Predicted genes whose in vitro expression was signilicantly dysregulated between early versus late BCG. The z-score, indicative 01 how many 
standard deviations a data point lies trom the population mean, is the average lor that gene across replicate (n = 2) microarrays 01 Russia (early 
BCG) versus Pasteur (Iate BCG) and Birkhaug (early BCG) versus Denmark (Iate BCG). Genes with average z-scores 01 2 or greater lor both 
early versus late BCG comparisons are presented and the lold change is calculated Irom a normalized log ratio of that gene. The lold change in 
late BCG expression is expressed as a ratio, with early BCG expression lor that gene providing the reference value of 1. Genes for which 
expression was decreased in late BCG are indicated by a negative sign; genes with increased expression in late BCG are reported by a positive 
sign. Open reading frame (ORF) and gene name are listed by Rv number as annotated for M. tubercu/osis H37Rv (http://genolist.pasteur.lr/ 
TubercuListl). Genes Irom the same region 01 the genome are grouped and presented in a darker shade. 
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$equenced M. tuberculosis strains (H37Rv, 210 and 
COC1551) have the adenine residue. Second, in M. tuber-
culosis H37Rv, the start codon of sigK is the predominant 
start codon sequence AUG, while in BCG Pasteur there 
is a G ~ A mutation at the third nucleotide, resulting in 
an altered AUA start codon. The AUG was observed in ail 
members of the M. tuberculosis complex except for the 
eight low-producing BCG strains obtained after 1927 in 
which the altered AUA start codon was observed 
(Table 2). While the codon AUA has been identified as a 
functional start codon in Escherichia coli, Bacillus subtilis 
and Salmonella spp., levels of translation are substantially 
reduced with this codon compared with the conventional 
start codon AUG (Romero and Garcia, 1991; Sussman 
et al., 1996). Because the start codon mutation correlated 
precisely with the BCG strains having decreased sigK and 
mpb83/mpb70 expression, we proceeded to examine the 
functional consequence of the sigK mutation. 
Effect of sigK complementation on transcription 
in BCG Pasteur 
We first determined the effect of sigK complementation 
on its own expression by quantitative RT-PCR. Comple-
mentation with the empty vector or with the mutant sigK 
resulted in no change of sigK expression, as seen with 
BCG Pasteur::pMV306 (empty vector) and BCG Pas-
teur::pPAST. This latter result indicated that a second 
copy of the mutant gene did not alter levels of transcrip-
tion. In contrast, complementation with wild-type sigK, 
Table 2. Sequence Analysis 01 sigK. 
31 bp belore 3 bp 01 
Strains start codon start codon 
M. canettii T G 
M. tubercu/osis H37Rv A G 
M. tubercu/osis H37Ra A G 
M. africanum T G 
M. microti T G 
M. caprae T G 
M. bovis T G 
BCG Russia T G 
BCG Moreau T G 
BCG Japan T G 
BCG Sweden T G 
BCG Birkhaug T G 
BCG Prague T A 
BCG Glaxo T A 
BCG Denmark T A 
BCG Tice T A 
BCG Connaught T A 
BCG Frappier T A 
BCG Phipps T A 
BCG Pasteur T A 
Sequence analysis 01 sigKlor two representative isolates 01 different 
M. tubercu/osis complex members, with the exception 01 M. canettii 
where only one isolate was sequenced. The only polymorphisms 
detected are presented. 
demonstrated with BCG Pasteur::pH37Rv, BCG Pas-
teur::pRUSS and BCG Pasteur::pBIRK, showed a 
marked increase in transcription of sigK (Fig. 3A). Similar 
results were obtained with a second clone of each of the 
same strains (data not shown). As the mutation in sigKis 
predicted to impair translation, not transcription, and com-
plementation of wild-type, but not mutant-type, sigK 
served to markedly increase sigK expression, these 
results sig nif y that expression of this gene appears to be 
autoregulated, as has been described for other M. tuber-
culosis sigma factors (Helmann, 2002; Manganelli et al., 
2004a). 
Next, we determined the effect of sigK complementa-
tion on mpb70 and mpb83 levels, using the same clones 
and mRNA preparations. In BCG Pasteur::pPAST and 
BCG Pasteur::pMV306, levels of mRNA were comparable 
to those previously demonstrated in low-producing strains 
of BCG. The same strains in which we observed 
increased sigK expression, BCG Pasteur::pH37Rv, BCG 
Pasteur::pRUSS and BCG Pasteur::pBIRK, manifested 
highly increased transcription levels for mpb70 and 
mpb83, comparable to the levels observed with high-pro-
ducing strains of BCG (Fig. 3B). The same results were 
obtained with a second clone of the same strains (data 
not shown). 
Effect of sigK complementation on MPB70 and 
MPB83 production 
To determine the effect of expression of wild-type sigK in 
BCG Pasteur on protein synthesis, culture filtrate proteins 
and whole-cell Iysates from the sigK-complemented 
strains of BCG Pasteur were analysed by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SOS-PAGE) 
and immunoblotting. MPB70 was detected in the culture 
filtrate proteins in BCG Pasteur::pH37Rv, BCG Pas-
teur::pRUSS and BCG Pasteur::pBIRK, but could not be 
detected in Pasteur::pPAST or BCG Pasteur::pMV306 
(Fig. 3C). Similarly, MPB83 was detected in the whole-cell 
Iysates of the same clones where MPB70 was abundantly 
detected in the culture filtrates (Fig. 3D). Upon comple-
mentation of wild-type sigK, BCG Pasteur was able to 
produce MPB70 and MPB83 in a pattern consistent with 
high-producing strains. 
Further expression analysis of genes neighbouring 
mpb70/mpb83 and sigK 
Based on observed differences in expression of the genes 
neighbouring sigK and mpb70/mpb83 by microarray-
based analysis of four BCG strains, we used quantitative 
RT-PCR to determine the effect of wild-type sigK comple-
mentation on transcription in these regions. As shown in 
Fig. 4A, expression of Rv0443c-Rv0449c was increased 
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Fig. 3. A and B. Expression of sigK (A) and mpb70 (white) and mpb83 (grey) (B) upon complementation of BCG Pasteur with sigK from M. 
tubercu/osis H37Rv, BCG Russia, BCG Birkhaug and BCG Pasteur. Values are expressed as a ratio of mRNA copies in complemented strains 
compared with BCG Pasteur::pMV306. Ali values were normalized to the levels of sigA mRNA and error bars represent the standard error of the 
mean. 
C and O. SOS· PAGE and immunoblotting of culture filtrate proteins (C) and cell extracts (0) !rom complemented BCG Pasteur, using monoclonal 
antibodies 1-5c for MPB70 (C) and MBS43 for MPB83 (0). The strains used were as follows: 1, BCG Pasteur::pH37Rv; 2, BCG Pasteur::pRUSS; 
3, BCG Pasteur::pBIRK; 4, BCG Pasteur::pPAST; 5, BCG Pasteur::pMV306. 
over twofold with sigK complementation. Transcription of 
Rv2874, Rv2876and Rv2877cwas increased over 10-fold 
in the sigK-complemented strains compared with the con-
trol strain. Rv2878c (mpt53) was also increased, although 
to a lesser extent, with fourfold increase seen in the sigK-
complemented strains. Contrary to expectations from pre-
vious study indicating that Rv2871-Rv2874 are cotrans-
cribed (Juarez et al., 2001), we did not detect any 
increased expression of either Rv2871 or Rv2872, sug-
gesting that these two genes are under separate tran-
scriptional control. Based on the differences in 
transcription, this sigK-regulated gene region includes 
Rv2873 through Rv2878, but not Rv2872 or Rv2879 
(Fig.4B). 
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Microarray-based analysis of sigK complementation 
To further examine the role that sigK plays in global gene 
expression, we analysed global transcription in BCG Pas-
teur::pH37Rv, BCG Pasteur::pRUSS and BCG Pas-
teur::pBIRK compared with BCG Pasteur::pMV306 by 
DNA microarray. Results revealed increased expression 
of the majority of genes presented in Fig. 4, with signifi-
cant changes in expression as measured by both induc-
tion ratios and z-scores. Because of the stringency of the 
analysis performed, genes whose expression was 
induced in three of four arrays, but whose expression 
could not be optimally quantified on the fourth, were not 
included in the table (e.g. mpb83). Only four genes were 
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Fig. 4. A. Expression analysis 01 the genes Rv0441c to Rv0450c. 
B. Expression analysis for the genes Rv2870c to Rv2881c. Levels presented represent the ratio 01 mRNA copies in sigK-complemented strain 
to the control strain BCG Pasteur::pMV306 (empty vector). Ali values were normalized to the levels 01 sigA mRNA and the ratio presented 
represents the mean 01 results lrom different clones, specilicaliy BCG Pasteur::pH37Rv, BCG Pasteur::pRUSS and BCG Pasteur::pBIRK. 
repressed with introduction of wild-type sigK; genes 
whose expression was increased were restricted to the 
sigK and the mpb70lB3 regions (Table 3). 
Discussion 
Comparative genomic studies have demonstrated the 
substantial genome decay experienced by BCG strains 
during a half-century of in vitro passage (Mostowy et al" 
2003). While DNA microarray-based comparisons have 
efficiently uncovered genomic deletions as the most evi-
dent form of evolution, these tools overlook other forms of 
genomic variability, su ch as duplications and single nucle-
otide polymorphisms (SNPs). With targeted study of spe-
cifie genes has come the recognition of numerous loss-
of-function SNPs during BCG evolution, including a SNP 
that impairs synthesis of methoxymycolic acids (Behr 
et al., 2000), a SNP predicted to decrease the DNA bind-
ing ability of a cAMP receptor protein (CRP) homologue 
(Spreadbury et al., 2005) and the start codon mutation 
described in this report. Remarkably, along with the loss 
of the RD2 region (Mahairas et al., 1996), these three 
SNPs ail coincide with the interva11927-1931 , suggesting 
either a period of considerable in vitro evolution or the 
replacement of one BCG stock with another at the Pasteur 
Institute in the late 1920s. 
Our data indicate that the sigK SNP occurred between 
1927 and 1931 at the Pasteur Institute and resulted, either 
directly or indirectly, in a major drop in production of the 
antigenic proteins MPB70 and MPB83. These two pro-
Table 3. Genes whose expression was changed upon complementation 01 BCG Pasteur with wild-type sigK. 
ORF 
Rv3681c 
Gene 
name 
rpte 
tbpB 
whiB4 
BCG Pasteur::pBIRK versus 
BCG Pasteur::pMV306 
Fold change z-score 
-2.2 2.1 
BCG Pasteur:: pH37Rv versus 
BCG Pasteur::pMV306 
Fold change z-score 
-2.2 2.0 
Gene product 
Probable resuscitation-promoting factor C 
Secreted antigen 85-B 
Heat shock protein X 
Transcriptional regulator protein 
Predicted genes whose in vitro expression was significantly dysregulated between BCG Pasteur::pMV306 (empty vector) and BCG Pasteur::sigK 
(wild type). The z-score, indicative 01 how many standard deviations a data point lies Irom the population mean, is the average lor that gene 
across replicate (n=2) microarrays of BCG Pasteur::pBIRK versus BCG Pasteur::pMV306 and BCG Pasteur::pH37Rv versus BCG Pas-
teur::pMV306. Genes with average z-scores of 2 or greater lor both comparisons are presented and the lold change is calculated from a normalized 
log ratio 01 tha! gene, with BCG Pasteur expression for that gene providing the reference value 01 1. Open reading Irame (ORF) and gene name 
are listed by Rv number as annotated for M. tubercu/osis H37Rv (http://genolist.pasteur.lrlTubercuLisV). Genes from the same region of the 
genome are grouped and presented in a darker shade. 
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teins exhibit striking amino acid sequence homology 
(Hewinson et al., 1996) and both are exported, but local-
ize differently. The single form of MPB70 is secreted into 
culture media while MPB83 is present in two forms, a 
26 kDa lipoprotein which remains associated with the 
mycobacterial cell wall and a 23 kDa form which is found 
in the culture media (Harboe et al., 1998). The structure 
of MPB70 has recently been solved and superimposition 
of MPB83 on the MPB70 structure confirmed the overall 
homology of the antigens (Carr et al., 2003). From immu-
nologic studies, it is known that both proteins induce cel-
lular and humoral responses in experimental infection of 
model hosts and natural infection of humans (Miura et al., 
1983; Haslov etai., 1987; Fifis etai., 1994; Roche etai., 
1994; Harboe et al., 1995; Wiker et al., 1996; Vordermeier 
et al., 2000; Lyashchenko et al., 2001). Based on these 
observations, both MBP70 and MPB83 have been devel-
oped as candidates for novel TB vaccine development 
(Chambers et al., 2000; Morris et al., 2000; AI Attiyah 
et al., 2003; Tollefsen et al., 2003; Xue et al., 2004). As 
extracellular antigens have consistently been implicated 
in the induction of a protective immune response against 
M. tuberculosis, it is remarkable that ail BCG strains are 
unable to produce the antigenic proteins ESAT-6 and 
CFP-10 (Iost with the RD1 deletion of 1908-1921), while 
strains obtained after 1927-1931 are also deficient 
(through the deletion of RD2) in the proteins MPB64 (Har-
boe et al., 1986; Li et al., 1993) and CFP-21 (Mahairas 
et al., 1996; Weldingh et al., 1998; Weldingh and Ander-
sen, 1999) and functionally deficient in production of 
MPB70 and MPB83 via the sigKmutation described here. 
SigK is one of 10 extracytoplasmic function (ECF) 
sigma factors annotated in the M. tuberculosis H37Rv 
genome. As the name suggests, these regulatory ele-
ments mediate responses to changing external conditions 
(Manganelli et al., 2001; 2004b; Ando et al., 2003; Hu 
et al., 2004), with a common feature being their control 
over relatively small regulons (Bashyam and Hasnain, 
2004). For instance, by microarray analysis, the regulon 
of sigC has been estimated to contain 13, 14 and 18 
genes, in exponential, early and late stationary phase 
growth, respectively (Sun et al., 2004), consistent with our 
observations of two regions, comprising 13 genes, being 
consistently upregulated in wild-type sigK-complemented 
strains. Mutants of sigC, sigD, sigE and sigH ail exhibit 
reduced virulence in animal models (Kaushal et al., 2002; 
Calamita et al., 2005; Raman et al., 2004; Sun et al., 
2004), but to date, there have been no published papers 
looking specifically at M. tuberculosis sigK ln transposon 
site hybridization studies, neither sigK nor any of the other 
genes in the regulon we have identified was observed to 
be essential for in vivo growth in a murine model (Sassetti 
and Rubin, 2003). However, these experiments averaged 
the results for M. tuberculosis H37Rv and BCG Pasteur, 
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and BCG Pasteur is now shown to be functionally deficient 
in this regulon, therefore the impact of mutations in these 
genes may have been minimized. An epidemiologic study 
of M. tuberculosis isolates in San Francisco used genomic 
hybridization studies to determine deletions in strains that 
had successfully caused TB, thereby generating a list of 
genes that are apparently nonessential for disease (Tso-
laki et al., 2004). Of 224 genes disrupted in at least one 
clinical isolate, none of the genes implicated in the sigK 
nor the mpb83/70 regions is featured, suggesting that loss 
of these genes may be detrimental to disease causation. 
The relevance of sigK-regulated genes is supported by 
transcriptome analysis of M. tuberculosis during intracel-
lular conditions, where mpb70 and mpb83 figure among 
the most highly induced genes, across time points and in 
both activated and non-activated macrophages (Schnap-
pinger et al., 2003). Additionally, in a microarray-based 
study of M. tuberculosis expression during murine infec-
tion, sigK and mpt53 were among those genes noted as 
significantly dysregulated in vivo (Talaat et al., 2004). 
Together, these results point to a potential role of the sigK 
regulon in the pathogenesis of TB that merits further 
attention. 
The data presented here explain the difference in 
expression between high-producing and low-producing 
BCG strains. However, MPB70 and MPB83 are also dif-
ferentially produced by M. tuberculosis and M. bovis. 
Although these organisms have identical, wild-type AUG 
sigK start codons, in vitro expression is low (although 
inducible) in M. tuberculosis and constitutively high in M. 
bovis (Wiker et al., 1996). The constitutive in vitro produc-
tion of MBP70 and MPB83 observed in M. bovis may 
therefore stem from unregulated activity of SigK. Activity 
of an ECF sigma can be mediated by a second protein, 
the anti-sigma factor, that functions post-translationally as 
a negative regulator to prevent constitutive expression of 
the target regulon (Helmann, 2002; Manganelli et al., 
2004a). The sigma/anti-sigma pair are usually adjacent 
and co-transcribed genes; for instance, in M. tuberculosis, 
RshA (Rv3221A) is the anti-sigma factor for SigH 
(Rv3223c) while UsfX (Rv3287c) is the anti-sigma factor 
for SigF (Rv3286c) (Beaucher et al., 2002; Song et al., 
2003). Consistent with this pattern, Rv0444c may encode 
the anti-sigma factor for sigK (Rv0445c), and by exten-
sion, mutations in Rv0444c might result in unregulated 
expression of sigK Ongoing investigations are pursuing 
this possibility, based on the presence of two non-syno-
myous SNPs in Rv0444c restricted to M. tuberculosis 
complex species presenting constitutively high MPB70 
production (data not shown). 
As BCG vaccines are given to an estimated 2 million 
infants per week, there are important practical implica-
tions of these findings. The sigK mutation described here 
impairs the production of two immunodominant antigens, 
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MPB70 and MPB83, as weil as transcription of mpb53. 
The importance of this deficit for TB immunization is 
unknown because strains of BCG that produce these anti-
gens have never been utilized in a randomized clinical 
trial, although results from some observational studies 
have suggested a greater potency to some of the high-
producer strains (Kroger et al., 1994; Vitkova et al., 1995). 
Based on the number of documented differences between 
BCG strains obtained before 1927 and those obtained 
after 1931, these is compelling rationale to perform a 
human trial comparing BCG strains from these two 
groups. Furthermore, these results are also applicable 
towards efforts to develop improved vaccines against TB. 
Recent advances have demonstrated that recombinant 
strains of BCG expressing M. tuberculosis antigens pro-
vide an important avenue towards more effective vaccines 
(Horwitz et al., 2000; Pym et al., 2003). These constructs 
may benefit from the inherent MPB70 and MPB83 expres-
sion of the high-producing strains obtained before 1931, 
or alternatively, by correcting the sigK mutation in later 
strains to achieve the same result. 
Experimental procedures 
8acterial cultures 
Unless otherwise stated, BCG strains were grown at 3rC in 
Middlebrook 7H9 medium (Difco Laboratories, Detroit, MI) 
containing 0.05% Tween 80 (Sigma-Aldrich, St. Louis, MO) 
and 10% albumin-dextrose-catalase (Becton Dickinson 
and Co., Sparks, MD) supplement on a rotating platform 
(Wheaton). Transformed BCG strains were resuspended in 
7H9 containing 15% glycerol and frozen in 1 ml aliquots at -
80°C until needed. Frozen bacteria were thawed and diluted 
in fresh 7H9 medium containing 10% albumin-dextrose-cat-
alase and grown with rotation at 37°C. 
PCR amplification and sequencing across Rv0445c (sigK) 
The sequence of Rv0445c (sigK) was determined by 
amplifying the gene and flanking regions from isolates of M. 
canettii, M. tuberculosis H37Rv, M. tuberculosis H37Ra, 
Mycobacterium africanum (n = 2), M. microti (n = 2), M. 
caprae (n = 2), M. bovis (n = 2) and 13 members of the BCG 
family - BCG Russia (ATCC 35740), BCG Moreau, BCG 
Japan, BCG Sweden, BCG Birkhaug (ATCC 35731), BCG 
Prague, BCG Glaxo (ATCC 35741), BCG Denmark 1331 
(ATCC 35733), BCG Tice (ATCC 35743), BCG Frappier 
(ATCC 35735), BCG Connaught, BCG Phipps (ATCC 35744) 
and BCG Pasteur 1173. The sequence was amplified using 
left primer: 5'-agctcgagcagctcaaaatc-3'; and right primer: 5'-
acgcgtcaccccaactact-3' and amplicons were sequenced by 
di-deoxy terminal sequencing at the McGili University and 
Genome Quebec Innovation Center. To look for differences 
between the amplified sequence and the prototype 
genome sequences, results were compared by BLAST 
analysis to M. tuberculosis H37Rv using Tuberculist (http:// 
genolist.pasteur.frrrubercuListl), M. tuberculosis 210 and 
CDC1551 using the sequences provided at NCBI (http:// 
www.ncbLnlm.nih.gov/sutiis/genom_table.cgi). M. bovis 
AF2122/97 using Bovilist (http://genolist.pasteur.fr/BoviListl), 
and the assembly sequence of BCG Pasteur (http:// 
www.sanger.ac.uklcgi-bin/blastlsubmitblastfm_bovis). 
RNA extraction 
BCG strains grown to an ODsoo of 0.3-0.5 were pelleted by 
centrifugation, resuspended in 1 ml of wash buffer (0.5% 
Tween 80, 0.8% sodium chloride) and transferred to 1.5 ml 
screw-cap cryovials. RNA was extracted by a modified phe-
nol-chloroform extraction protocol as previously described 
(Belley et al., 2004). Genomic DNA contamination was 
removed by RNAeasy on-column digestion, following the 
manufacturer's protocol (Qiagen, Mississauga, Canada). The 
quality of RNA was confirmed by denaturing gel electro-
phoresis (formaldehyde). 
Real-time quantitative RT-PCR 
Targeted gene expression levels were determined using RT-
PCR with molecular beacons or SYBR green, according to 
established protocols (Manganelli et al., 1999; Mostowy 
et al., 2004). To provide a normalization standard for mRNA 
expression, expression of sigA was also determined, and the 
level of expression of a gene of interest divided by that of 
sigA to normalize for differences in total mRNA extracted 
(Manganelli et al., 1999). Sequences of the primers used for 
molecular beacon and sybr green analysis and the 
sequences of the molecular beacons used are as listed in 
Table 4. 
Microarray analysis 
Microarray hybridization and analysis were performed as pre-
viously described (Mostowy et al., 2004). ln brief, mRNA from 
BCG strains and complemented strains was extracted during 
log-phase in vitro growth and labelled with Cy3 or Cy5 dUTP 
by reverse-transcriptase (Amersham Biosciences). Labelled 
cDNA was hybridized to microarrays composed of oligonu-
cleotide probes from the TB Array-Ready Oligo Set™ 
(Operon) that had been printed ante Sigmascreen ™ microar-
ray si ides (Sigma). Initial comparisons were BCG Russia 
versus BCG Pasteur, and BCG Birkhaug versus Denmark. 
After complenting BCG Pasteur with wild-type sigK, compar-
isons of Pasteur::sigK versus Pasteur::pMV306 (empty 
vector) were also performed. In each case, duplicate hybrid-
izations were performed for each dye combination (Cy3/Cy5 
and Cy5/Cy3), resulting in four hybridizations per compari-
son. Hybridized arrays were scanned with Scanarray 5000XL 
(PerkinElmer, Freemont, CA) and hybridization results 
were quantified with Scanalyze software (http://rana.lbl.gov/ 
EisenSoftware.htm/). 
Array analysis was performed as previously described 
(Mostowy et al., 2004) in order to determine a z-score, indic-
ative of how many standard deviations a data point lies from 
the population mean, for each gene. z-scores for each gene 
were averaged across replicates within each experiment to 
minimize the probability of observing such variation by 
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Table 4. Sequences of primers and molecular beacons for quantitative RT-peR. 
Gene Lelt primer (5' ta 3') Right primer (5' ta 3') Beacon 
sigA 
sigK 
mpb70 
mpb83 
dxr 
Rv2871 
Rv2872 
dipZ 
Rv2876 
Rv2877c 
mpb53 
Rv2879c 
Rv2880c 
cdsA 
Rv0441c 
PPE10 
Rv0443 
Rv0444c 
Rv0446c 
ufaA1 
Rv0448c 
Rv0449c 
mmpL4 
mmpS4 
tgcagtcggtgctggaca 
agtttgactccgccaaaggt 
ctcgaacaatccggagttgaca 
atcaactcaagactgacgccaaac 
gggacttgaggtcatcgaaa 
gtatcgatgacgagctgtacc 
gactatcggggtttgcttga 
tcggttggtatcaggcctac 
agtgggagttcgacgtcagt 
ggttccatgtatggctacgg 
gttcggtctggccaatacac 
gcgacgggtgtctattgagt 
aacacggtctgcatttcctc 
tggtcgttgtctgcatgatt 
tgggtgccaaaaaggtagac 
caattcggcactgatgtttg 
cgggtgcaggatatacaggt 
ggccgagcaagttctgac 
tggcaactgtgggtattcaa 
ccgacctttcgacctagttg 
cttctacgtttcgccgtttc 
cccacacccactatctggac 
ctaaattcgcgaacgactcc 
cctggaaaacagcaaaccat 
cgcgcaggacctgtgagc 
gcaccatagcgcacttcc 
acaccgtgtactgaccgctgtt 
caccttgcagggtctgatgg 
tatggaaatcacaggcagca 
ttggacgatagatcgacacc 
tcaacatcggacgctaactg 
ggtccaagtggcgtagttgt 
acgtgatcaggaaccagtcc 
agccagatagatcgctacgc 
cgtccagaaccacaacacc 
taccgtgcaggaaactcctt 
cccatacccatgaacaccac 
gagccattttccgggtagac 
ccacaacagggtgacttcg 
caggctaggtactgggttgc 
tagtaccccgacagcaggtc 
gcagccacatctgatacacg 
cagcaggtaggtcatcagca 
tgaacattgcgcacgaatac 
tcatcgcgatctgtcttgtc 
acatcgacatttccgactcc 
cttccagtgacgggacaaat 
ccacgatatttcccatcacc 
cctcgcgtcgaagttgcgccatccgagcgagg 
gcagcctgtcgaccgagtccgttggctgc 
gcagccagctcaatccgcaagtaaacctgggctgc 
gcagccagcatcctgacctaccacgtgaggctgc 
chance alone and genes with average z-scores of 2 or 
greater are presented. 
Complementation of sigK 
To complement BCG strain Pasteur, the sigK region (includ-
ing the complete gene and 288 bp upstream) was amplified 
via PCR from M. tuberculosis H37Rv, and BCG strains Rus-
sia and Birkhaug. As a control, the sigK from BCG Pasteur 
was also complemented to determine the effect of having a 
second copy of the mutated gene. To complement, PCR was 
performed using the following primers Rv0445cL and sigKR 
(Ieft primer: 5'-agctcgagcagctcaaaatc-3'; right primer: 5'-
acgcgtcaccccaactact-3') and amplified products were cloned 
into the T-vector, pDRIVE (Qiagen). The sigK region was th en 
removed by digestion with Hindlll and Kpnl and ligated to the 
integrative mycobacterial vector pMV306 (Stover et al., 1991) 
cut with the same restriction endonucleases. Integrity of the 
cloned genes was confirmed by DNA sequencing, then the 
resulting plasmids (pH37Rv, pRUSS, pBIRK and pPAST) 
were electroporated into M. bovis BCG Pasteur cells, using 
previously described methods (Belley et al., 2004). The 
empty pMV306 vector was also included as a control. Trans-
formants were grown at 37°C on Middlebrook 7H10 agar 
supplemented with 10% ADC [albumin (bovine fraction V), 
dextrose and catalase; BD/BBL media] and kanamycin 
(25 /-lg ml-1j. Complementation was PCR-confirmed by 
amplifying the sigK gene with primers specific for the regions 
of pMV306 flan king the sigKinsert and these amplicons were 
sequence-confirmed for ail transformants. 
Protein preparation and immunoblot analysis 
BCG strains. BCG strains were cultivated as surface pelli-
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cles on liquid synthetic Sauton medium for 3 weeks at 37"C. 
The bacteria were washed and disrupted by a bead beater 
to yield a cellular extract and the culture medium was filtered 
to remove residual bacteria and concentrated by ammonium 
sulphate precipitation at 80% saturation. The antigens were 
separated under reducing conditions by horizontal SDS-
PAGE in precast 8-18% gradient Excel gel using a Multiphor 
Il unit 2117 (Amersham Pharmacia). After separation, the 
proteins were transferred to a nitrocellulose membrane (pore 
size, 0.2 mm) by diffusion blotting (Olsen and Wiker, 1998) 
and the gel was stained with CBB. Th.e membranes were 
blocked with PBS containing 2% bovine serum albumin 
(BSA) and 1 % gelatin and incubated with antibodies over-
night. Bound antibodies were recognized by horseradish per-
oxidase (HRP)-Iabelled anti-rabbit or anti-mouse Ig. As 
substrate, 3,3-diaminobenzidine was added to visualize the 
bound antibodies. 
BCG Pasteur complemented strains. Cultures were grown 
at 37°C in 7H9 with 10% ADC, supplemented with kanamycin 
(25 /-lg ml-1) for 7 days. The cultures were the centrifuged and 
the supernatant was filtered with a 0.22 J.lm membrane filter 
and concentrated with an Amicon Ultra-15 Centrifugai Filter 
Unit, 10000 MWCO. Cell pellets were frozen and whole-cell 
Iysates were prepared by resuspending the cell pellet in 
100 J.l1 of PBS and boiling for 20 min. The culture filtrate 
proteins (CFP) were precipitated by the following protocol: 1 
volume of sam pie was mixed with 3 volumes of methanol, 1 
volume of chloroform, 4 volumes of water. Samples were 
centrifuged at max speed (-13200 rpm) for 1 min. The upper 
phase was removed and replaced with 4 volumes of metha-
nol and mixed briefly. Protein was pelleted at max speed for 
15 min (Wessel and Flugge, 1984). Protein was resuspended 
in 100 /-lI of PBS and the final concentration was determined 
using Coomassie Plus Protein Determination Kit (Pierce) fol-
lowing standard protocol. 
1 0 D. Charlet et al. 
A total of 10 Ilg of CFP for each sam pie or 2 III of ceillysate 
was loaded in each lane. Samples were added to SDS-
loading buffer and heated to 80c C for 5 min. SDS-PAGE was 
performed under reducing conditions using the Mini-PRO-
TEAN 3 electrophoresis system (Bio-Rad) with 12% 
polyacrylamide gels. Proteins were translerred to a 
polyvinylidene difluoride membrane. Membranes were 
blocked in PBS containing 2% BSA and 0.05% Tween 20, 
then probed with primary antibodies for 1 h at room temper-
ature. Bound antibodies were recognized by HRP-Iabelled 
anti-mouse Ig. Ali antibodies were diluted in PBST with 1% 
BSA. Mouse monoclonal antibodies 1-5C (anti-MPB70) and 
MBS43 (anti-MPB83) (Wiker et al., 1998) were used at a 
dilution of 1/500 and the HRP-conjugated anti-mouse anti-
body was used at a dilution of 1/10000. Protein bands were 
detected using ECL PIUS™ Western Blotting Detection 
Reagents (Amersham). 
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